WO2023001069A1 - 大环酰胺类化合物及其应用 - Google Patents
大环酰胺类化合物及其应用 Download PDFInfo
- Publication number
- WO2023001069A1 WO2023001069A1 PCT/CN2022/105959 CN2022105959W WO2023001069A1 WO 2023001069 A1 WO2023001069 A1 WO 2023001069A1 CN 2022105959 W CN2022105959 W CN 2022105959W WO 2023001069 A1 WO2023001069 A1 WO 2023001069A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- add
- pharmaceutically acceptable
- synthesis
- acceptable salt
- Prior art date
Links
- -1 amide compounds Chemical class 0.000 title claims abstract description 91
- 150000001875 compounds Chemical class 0.000 claims abstract description 374
- 150000003839 salts Chemical class 0.000 claims abstract description 42
- 229910052757 nitrogen Inorganic materials 0.000 claims description 83
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 72
- 125000000217 alkyl group Chemical group 0.000 claims description 47
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims description 19
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 17
- 229910052736 halogen Inorganic materials 0.000 claims description 15
- 150000002367 halogens Chemical class 0.000 claims description 15
- 125000001072 heteroaryl group Chemical group 0.000 claims description 13
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 11
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 125000003386 piperidinyl group Chemical group 0.000 claims description 8
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims description 7
- 229910052794 bromium Inorganic materials 0.000 claims description 7
- 229910052801 chlorine Inorganic materials 0.000 claims description 7
- 229910052731 fluorine Inorganic materials 0.000 claims description 7
- 229910052740 iodine Inorganic materials 0.000 claims description 6
- 125000004193 piperazinyl group Chemical group 0.000 claims description 6
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 5
- 125000006580 bicyclic heterocycloalkyl group Chemical group 0.000 claims description 5
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 5
- 125000002757 morpholinyl group Chemical group 0.000 claims description 5
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 5
- 125000002393 azetidinyl group Chemical group 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 claims description 4
- 125000003566 oxetanyl group Chemical group 0.000 claims description 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N dichloromethane Natural products ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 230
- 239000000243 solution Substances 0.000 description 180
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 150
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 132
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 118
- 238000003786 synthesis reaction Methods 0.000 description 117
- 230000015572 biosynthetic process Effects 0.000 description 116
- 238000006243 chemical reaction Methods 0.000 description 116
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 102
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Substances CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 87
- 239000012043 crude product Substances 0.000 description 86
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 80
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 65
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 60
- 238000010898 silica gel chromatography Methods 0.000 description 59
- 210000004027 cell Anatomy 0.000 description 55
- 239000012074 organic phase Substances 0.000 description 47
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 45
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 44
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 44
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 44
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 43
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 43
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 42
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 42
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 42
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 38
- 125000004429 atom Chemical group 0.000 description 37
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 36
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 36
- 239000012141 concentrate Substances 0.000 description 36
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 35
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 34
- 238000003756 stirring Methods 0.000 description 34
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 28
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 27
- 239000012071 phase Substances 0.000 description 25
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 24
- 239000004305 biphenyl Substances 0.000 description 22
- 230000002401 inhibitory effect Effects 0.000 description 22
- 206010028980 Neoplasm Diseases 0.000 description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 235000010290 biphenyl Nutrition 0.000 description 21
- 239000000706 filtrate Substances 0.000 description 21
- 238000002953 preparative HPLC Methods 0.000 description 21
- 238000012360 testing method Methods 0.000 description 21
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 18
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 18
- 238000000034 method Methods 0.000 description 18
- 230000005764 inhibitory process Effects 0.000 description 17
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 16
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 15
- 125000004432 carbon atom Chemical group C* 0.000 description 15
- 238000000605 extraction Methods 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- 125000006413 ring segment Chemical group 0.000 description 15
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- 108091000080 Phosphotransferase Proteins 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 125000005842 heteroatom Chemical group 0.000 description 14
- 239000012528 membrane Substances 0.000 description 14
- 230000035772 mutation Effects 0.000 description 14
- 102000020233 phosphotransferase Human genes 0.000 description 14
- 229920006395 saturated elastomer Polymers 0.000 description 14
- 239000005695 Ammonium acetate Substances 0.000 description 13
- 235000019257 ammonium acetate Nutrition 0.000 description 13
- 229940043376 ammonium acetate Drugs 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- 239000011259 mixed solution Substances 0.000 description 13
- 238000010791 quenching Methods 0.000 description 13
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- DORMTBIPKNPJPY-UHFFFAOYSA-N acetic acid;iodobenzene Chemical compound CC(O)=O.IC1=CC=CC=C1 DORMTBIPKNPJPY-UHFFFAOYSA-N 0.000 description 11
- 238000012054 celltiter-glo Methods 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 10
- 230000000875 corresponding effect Effects 0.000 description 10
- 125000004122 cyclic group Chemical group 0.000 description 10
- 238000010828 elution Methods 0.000 description 10
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 10
- 239000012065 filter cake Substances 0.000 description 10
- 229910052760 oxygen Inorganic materials 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 229910052717 sulfur Inorganic materials 0.000 description 10
- 239000002033 PVDF binder Substances 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 125000004433 nitrogen atom Chemical group N* 0.000 description 9
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 9
- 235000017557 sodium bicarbonate Nutrition 0.000 description 9
- 239000012224 working solution Substances 0.000 description 9
- 108010044467 Isoenzymes Proteins 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 8
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 8
- 238000001962 electrophoresis Methods 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 238000000926 separation method Methods 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 125000001424 substituent group Chemical group 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 7
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 7
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 229960001456 adenosine triphosphate Drugs 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 125000002950 monocyclic group Chemical group 0.000 description 7
- 239000003208 petroleum Substances 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 238000012546 transfer Methods 0.000 description 7
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 6
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 6
- 230000004663 cell proliferation Effects 0.000 description 6
- 239000000460 chlorine Substances 0.000 description 6
- 229940121647 egfr inhibitor Drugs 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 6
- 238000010253 intravenous injection Methods 0.000 description 6
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 6
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 239000006143 cell culture medium Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000003292 glue Substances 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 230000026731 phosphorylation Effects 0.000 description 5
- 238000006366 phosphorylation reaction Methods 0.000 description 5
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 5
- 125000003003 spiro group Chemical group 0.000 description 5
- IBXMKLPFLZYRQZ-UHFFFAOYSA-N 1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1C=CC(=O)C=CC1=CC=CC=C1 IBXMKLPFLZYRQZ-UHFFFAOYSA-N 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 235000011114 ammonium hydroxide Nutrition 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 229910002091 carbon monoxide Inorganic materials 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 239000012295 chemical reaction liquid Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 4
- 229940044631 ferric chloride hexahydrate Drugs 0.000 description 4
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 4
- 125000002632 imidazolidinyl group Chemical group 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- NQXWGWZJXJUMQB-UHFFFAOYSA-K iron trichloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].Cl[Fe+]Cl NQXWGWZJXJUMQB-UHFFFAOYSA-K 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 125000005647 linker group Chemical group 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 description 4
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 4
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 3
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 description 3
- 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 description 3
- 108010026925 Cytochrome P-450 CYP2C19 Proteins 0.000 description 3
- 108010000543 Cytochrome P-450 CYP2C9 Proteins 0.000 description 3
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 3
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 3
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 3
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 3
- 102100026533 Cytochrome P450 1A2 Human genes 0.000 description 3
- 102100029363 Cytochrome P450 2C19 Human genes 0.000 description 3
- 102100029358 Cytochrome P450 2C9 Human genes 0.000 description 3
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 description 3
- 102100039205 Cytochrome P450 3A4 Human genes 0.000 description 3
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 3
- 239000005909 Kieselgur Substances 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- 239000006180 TBST buffer Substances 0.000 description 3
- 230000003698 anagen phase Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 3
- 125000000532 dioxanyl group Chemical group 0.000 description 3
- 125000005883 dithianyl group Chemical group 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 3
- 239000012280 lithium aluminium hydride Substances 0.000 description 3
- 210000001853 liver microsome Anatomy 0.000 description 3
- 238000004020 luminiscence type Methods 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 description 3
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 3
- 229960003278 osimertinib Drugs 0.000 description 3
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 description 3
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 3
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 3
- 238000007747 plating Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- RSIJVJUOQBWMIM-UHFFFAOYSA-L sodium sulfate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]S([O-])(=O)=O RSIJVJUOQBWMIM-UHFFFAOYSA-L 0.000 description 3
- 229940079101 sodium sulfide Drugs 0.000 description 3
- 229910052979 sodium sulfide Inorganic materials 0.000 description 3
- ZGHLCBJZQLNUAZ-UHFFFAOYSA-N sodium sulfide nonahydrate Chemical compound O.O.O.O.O.O.O.O.O.[Na+].[Na+].[S-2] ZGHLCBJZQLNUAZ-UHFFFAOYSA-N 0.000 description 3
- 229940048181 sodium sulfide nonahydrate Drugs 0.000 description 3
- WMDLZMCDBSJMTM-UHFFFAOYSA-M sodium;sulfanide;nonahydrate Chemical compound O.O.O.O.O.O.O.O.O.[Na+].[SH-] WMDLZMCDBSJMTM-UHFFFAOYSA-M 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- QWUWMCYKGHVNAV-UHFFFAOYSA-N 1,2-dihydrostilbene Chemical group C=1C=CC=CC=1CCC1=CC=CC=C1 QWUWMCYKGHVNAV-UHFFFAOYSA-N 0.000 description 2
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 101000652482 Homo sapiens TBC1 domain family member 8 Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 102100030302 TBC1 domain family member 8 Human genes 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 description 2
- JFBZPFYRPYOZCQ-UHFFFAOYSA-N [Li].[Al] Chemical compound [Li].[Al] JFBZPFYRPYOZCQ-UHFFFAOYSA-N 0.000 description 2
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethanethiol Chemical compound CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 2
- ZIUSEGSNTOUIPT-UHFFFAOYSA-N ethyl 2-cyanoacetate Chemical compound CCOC(=O)CC#N ZIUSEGSNTOUIPT-UHFFFAOYSA-N 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 150000004675 formic acid derivatives Chemical class 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000006317 isomerization reaction Methods 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000004467 single crystal X-ray diffraction Methods 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000003419 tautomerization reaction Methods 0.000 description 2
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 2
- 125000002053 thietanyl group Chemical group 0.000 description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- DIPJMSNYGIUYII-UHFFFAOYSA-N 1-bromo-2-chloro-5-fluoro-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC(Cl)=C(Br)C=C1F DIPJMSNYGIUYII-UHFFFAOYSA-N 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- NNWFSRBWMOZDAK-UHFFFAOYSA-N 2-[2-(carboxymethyl)-3-iodophenyl]acetic acid Chemical compound OC(=O)CC1=CC=CC(I)=C1CC(O)=O NNWFSRBWMOZDAK-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- MZSAMHOCTRNOIZ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylaniline Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(NC2=CC=CC=C2)C=CC=1 MZSAMHOCTRNOIZ-UHFFFAOYSA-N 0.000 description 1
- SKJCWIFHLDWPEO-UHFFFAOYSA-N 3-benzyl-4-phenylbutan-2-one Chemical compound C=1C=CC=CC=1CC(C(=O)C)CC1=CC=CC=C1 SKJCWIFHLDWPEO-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- ROADCYAOHVSOLQ-UHFFFAOYSA-N 3-oxetanone Chemical compound O=C1COC1 ROADCYAOHVSOLQ-UHFFFAOYSA-N 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- VQCWSOYHHXXWSP-UHFFFAOYSA-N 4-bromo-2-fluoro-1-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(Br)C=C1F VQCWSOYHHXXWSP-UHFFFAOYSA-N 0.000 description 1
- POILWHVDKZOXJZ-UHFFFAOYSA-N 4-hydroxypent-3-en-2-one Chemical compound CC(O)=CC(C)=O POILWHVDKZOXJZ-UHFFFAOYSA-N 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- MNCFZWFXTUZLEI-UHFFFAOYSA-N CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.NC(N)COCCO Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.NC(N)COCCO MNCFZWFXTUZLEI-UHFFFAOYSA-N 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 239000012425 OXONE® Substances 0.000 description 1
- XZRUNZCMOCXTDJ-UHFFFAOYSA-N P.CC1(C)c2ccccc2Oc2ccccc12 Chemical compound P.CC1(C)c2ccccc2Oc2ccccc12 XZRUNZCMOCXTDJ-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 229940122907 Phosphatase inhibitor Drugs 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- QTENRWWVYAAPBI-YZTFXSNBSA-N Streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O QTENRWWVYAAPBI-YZTFXSNBSA-N 0.000 description 1
- 238000010154 Tamhane test Methods 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 1
- ZEEBGORNQSEQBE-UHFFFAOYSA-N [2-(3-phenylphenoxy)-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound C1(=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)C1=CC=CC=C1 ZEEBGORNQSEQBE-UHFFFAOYSA-N 0.000 description 1
- REAYFGLASQTHKB-UHFFFAOYSA-N [2-[3-(1H-pyrazol-4-yl)phenoxy]-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound N1N=CC(=C1)C=1C=C(OC2=NC(=CC(=C2)CN)C(F)(F)F)C=CC=1 REAYFGLASQTHKB-UHFFFAOYSA-N 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229960001686 afatinib Drugs 0.000 description 1
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229940125808 covalent inhibitor Drugs 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229950002205 dacomitinib Drugs 0.000 description 1
- LVXJQMNHJWSHET-AATRIKPKSA-N dacomitinib Chemical compound C=12C=C(NC(=O)\C=C\CN3CCCCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 LVXJQMNHJWSHET-AATRIKPKSA-N 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LDCRTTXIJACKKU-ARJAWSKDSA-N dimethyl maleate Chemical compound COC(=O)\C=C/C(=O)OC LDCRTTXIJACKKU-ARJAWSKDSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 238000004146 energy storage Methods 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- YEIKGFFXYDKWAJ-UHFFFAOYSA-N ethyl hydrogen sulfate;2-piperazin-1-ylethanol Chemical compound CCOS(O)(=O)=O.OCCN1CCNCC1 YEIKGFFXYDKWAJ-UHFFFAOYSA-N 0.000 description 1
- PAVZHTXVORCEHP-UHFFFAOYSA-N ethylboronic acid Chemical compound CCB(O)O PAVZHTXVORCEHP-UHFFFAOYSA-N 0.000 description 1
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- OCVXZQOKBHXGRU-UHFFFAOYSA-N iodine(1+) Chemical group [I+] OCVXZQOKBHXGRU-UHFFFAOYSA-N 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 229960001632 labetalol Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- VFZXMEQGIIWBFJ-UHFFFAOYSA-M magnesium;cyclopropane;bromide Chemical compound [Mg+2].[Br-].C1C[CH-]1 VFZXMEQGIIWBFJ-UHFFFAOYSA-M 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 229940050176 methyl chloride Drugs 0.000 description 1
- KTMKRRPZPWUYKK-UHFFFAOYSA-N methylboronic acid Chemical compound CB(O)O KTMKRRPZPWUYKK-UHFFFAOYSA-N 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000010413 mother solution Substances 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- HJKYXKSLRZKNSI-UHFFFAOYSA-I pentapotassium;hydrogen sulfate;oxido sulfate;sulfuric acid Chemical compound [K+].[K+].[K+].[K+].[K+].OS([O-])(=O)=O.[O-]S([O-])(=O)=O.OS(=O)(=O)O[O-].OS(=O)(=O)O[O-] HJKYXKSLRZKNSI-UHFFFAOYSA-I 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- SSOLNOMRVKKSON-UHFFFAOYSA-N proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- CMZUMMUJMWNLFH-UHFFFAOYSA-N sodium metavanadate Chemical compound [Na+].[O-][V](=O)=O CMZUMMUJMWNLFH-UHFFFAOYSA-N 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000001875 tumorinhibitory effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 229910000166 zirconium phosphate Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Definitions
- the present invention relates to a series of macrocyclic amide compounds and applications thereof, in particular to compounds represented by formula (V) and pharmaceutically acceptable salts thereof.
- Epidermal growth factor receptor is a receptor tyrosine kinase that transduces mitotic signals and is widely expressed in normal tissues. Meanwhile, aberrant activating mutations of EGFR are present in 10-15% of Caucasians and up to 50% of East Asian NSCLC patients. These activating mutations promote tumor cell survival, proliferation and metastasis. Among them, exon 19 deletion (del 19) and exon 21 L858R point mutation are the most common mutations.
- TKI tyrosine kinase inhibitor
- BI-4020 is a non-covalent macrocyclic TKI, which not only inhibits EGFR del19/T790M/C797S triple mutant, but also inhibits double mutant EGFR del19/T790M and single mutant EGFR del19, and has good selectivity for EGFR wild type .
- BI-4020 also showed good inhibitory activity against EGFR mutant cells, superior kinase selectivity and pharmacokinetic properties in vivo.
- PC-9 EGFR del19/T790M/C797S
- BI-4020 also showed good anti-tumor efficacy, but BI-4020 did not enter clinical research.
- the present invention provides a compound represented by formula (V) or a pharmaceutically acceptable salt thereof,
- T 1 and T 2 are independently selected from N and CH;
- L 1 is selected from -O- and -NH-;
- L 5 selected from -C 3-5 cycloalkyl-, -4-5 membered heterocycloalkyl-, -CH 2 -C 5-6 cycloalkyl-, -CH 2 -C 5-6 cycloalkyl-CH 2 -, -CH 2 -5-6 membered heterocycloalkyl- and -CH 2 -5-6 membered heterocycloalkyl-CH 2 -;
- R 3 is selected from C 1-3 alkyl, C 3-5 cycloalkyl and -piperazinyl-methyl;
- R 4 is selected from C 1-3 alkyl, said C 1-3 alkyl is optionally substituted by 1, 2 or 3 R d ;
- R 6 is selected from H and CH 3 optionally substituted by 1, 2 or 3 halogens
- R 5 and R 6 form cyclopropyl with the connected atoms
- R a is selected from C 1-3 alkyl and C 3-5 cycloalkyl
- R c is selected from H and C 1-3 alkyl
- Re is selected from H, F, Cl, Br, I and CN;
- R g is selected from CH 3 and 4-6 membered heterocycloalkyl, and the 4-6 membered heterocycloalkyl is optionally substituted by 1 or 2 CH 3 ;
- said T 1 is selected from N, and other variables are as defined in the present invention.
- said T 1 is selected from CH, and other variables are as defined in the present invention.
- the T 2 is selected from N, and other variables are as defined in the present invention.
- the R a is selected from CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 and cyclopropyl, and other variables are as defined in the present invention.
- the R 3 is selected from CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , cyclopropyl and Other variables are as defined herein.
- the R 4 is selected from CH 3 , CH 2 CH 2 N(CH 3 ) 2 and CH 2 CH 2 NHCH(CH 3 ) 2 , and other variables are as defined in the present invention.
- the structural unit -L 4 -R 3 is selected from Other variables are as defined herein.
- the structural unit selected from The "#" end is connected to pyrazolyl, and other variables are as defined in the present invention.
- T 3 is selected from N and CR e ;
- T 4 is selected from N and CR f ;
- L 1 is selected from -O- and -NH-;
- L 3 is selected from -O-, -NH- and -CH 2 -;
- L 5 selected from C 3-5 cycloalkyl and 4-5 membered heterocycloalkyl
- R 1 does not exist
- R 2 is selected from CH 3 ;
- R and R form a five - membered heteroaryl group with the connected atoms;
- R 3 is selected from C 1-3 alkyl, C 3-5 cycloalkyl and -piperazinyl-methyl;
- R 4 is selected from C 1-3 alkyl, said C 1-3 alkyl is optionally substituted by 1, 2 or 3 R d ;
- R 5 is selected from CH 3 optionally substituted by 1, 2 or 3 halogens
- R 6 is selected from H and CH 3 optionally substituted by 1, 2 or 3 halogens
- R 7 is selected from H and CH 3 , said CH 3 is optionally substituted by 1, 2 or 3 halogens; or R 5 and R 6 form a cyclopropyl group with the connected atoms;
- R b is selected from C 1-3 alkyl
- R c is selected from H and C 1-3 alkyl
- Re is selected from H, F, Cl, Br, I and CN;
- the R b is selected from CH 3 , CH 2 CH 3 and CH(CH 3 ) 2 , and other variables are as defined in the present invention.
- the structural unit -L 4 -R 3 is selected from Other variables are as defined herein.
- the structural unit selected from The "#" end is connected to pyrazolyl, and other variables are as defined in the present invention.
- the present invention provides a compound represented by formula (IV) or a pharmaceutically acceptable salt thereof,
- T 1 and T 2 are independently selected from N and CH;
- R 2 is selected from CH 3 ;
- R 3 is selected from C 1-3 alkyl, C 3-5 cycloalkyl and -piperazinyl-methyl;
- the R a is selected from CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 and cyclopropyl, and other variables are as defined in the present invention.
- R and R form a five - membered heteroaryl group with the connected atoms;
- the compound or a pharmaceutically acceptable salt thereof is selected from,
- L 3 is selected from -O-, -NH- and -CH 2 -;
- R 1 does not exist
- R and R form a five - membered heteroaryl group with the connected atoms;
- R 3 is selected from C 1-3 alkyl, C 3-5 cycloalkyl and -piperazinyl-methyl;
- R a is selected from C 1-3 alkyl and C 3-5 cycloalkyl
- R a and R 3 form a 5-6 membered heterocycloalkyl group with the connected atoms, and the 5-6 membered heterocycloalkyl group is optionally substituted by 1 CH 3 ;
- T 1 and T 2 are independently selected from N and CH;
- L 1 is selected from -O- and -NH-;
- L 3 is selected from -O-, -NH- and -CH 2 -;
- R 1 does not exist
- R 2 is selected from CH 3 ;
- R and R form a five - membered heteroaryl group with the connected atoms;
- R 3 is selected from C 1-3 alkyl, C 3-5 cycloalkyl and -piperazinyl-methyl;
- R a is selected from C 1-3 alkyl and C 3-5 cycloalkyl
- R b is selected from C 1-3 alkyl
- the compound or a pharmaceutically acceptable salt thereof is selected from,
- T 1 , T 2 , L 1 , L 2 , L 3 , L 4 , R 1 , R 2 and R 3 are as defined in the present invention.
- the R a is selected from CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 and cyclopropyl, and other variables are as defined in the present invention.
- the R b is selected from CH 3 , CH 2 CH 3 and CH(CH 3 ) 2 , and other variables are as defined in the present invention.
- the R 3 is selected from CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , cyclopropyl and -piperazinyl-methyl, and other variables are as defined in the present invention.
- the structural unit -L 4 -R 3 is selected from Other variables are as defined herein.
- the compound or a pharmaceutically acceptable salt thereof is selected from
- T 3 , L 5 , R 2 , R 3 , R 4 , R b and R f are as defined in the present invention.
- the present invention also provides the following compounds or pharmaceutically acceptable salts thereof,
- pharmaceutically acceptable refers to those compounds, materials, compositions and/or dosage forms, which are suitable for use in contact with human and animal tissues within the scope of sound medical judgment , without undue toxicity, irritation, allergic reaction or other problems or complications, commensurate with a reasonable benefit/risk ratio.
- pharmaceutically acceptable salt refers to a salt of a compound of the present invention, which is prepared from a compound having a specific substituent found in the present invention and a relatively non-toxic acid or base.
- base addition salts can be obtained by contacting such compounds with a sufficient amount of base, either neat or in a suitable inert solvent.
- acid addition salts can be obtained by contacting such compounds with a sufficient amount of the acid, either neat solution or in a suitable inert solvent.
- Certain specific compounds of the present invention contain basic and acidic functional groups and can thus be converted into either base or acid addition salts.
- the pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound containing acid groups or bases by conventional chemical methods.
- such salts are prepared by reacting the free acid or base form of these compounds with a stoichiometric amount of the appropriate base or acid in water or an organic solvent or a mixture of both.
- the compounds of the invention may exist in particular geometric or stereoisomeric forms.
- the present invention contemplates all such compounds, including cis and trans isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereoisomers isomers, (D)-isomers, (L)-isomers, and their racemic and other mixtures, such as enantiomerically or diastereomerically enriched mixtures, all of which are subject to the present within the scope of the invention.
- Additional asymmetric carbon atoms may be present in substituents such as alkyl groups. All such isomers, as well as mixtures thereof, are included within the scope of the present invention.
- enantiomer or “optical isomer” refer to stereoisomers that are mirror images of each other.
- cis-trans isomers or “geometric isomers” arise from the inability to rotate freely due to the double bond or the single bond of the carbon atoms forming the ring.
- diastereoisomer refers to stereoisomers whose molecules have two or more chiral centers and which are not mirror images of the molecules.
- keys with wedge-shaped solid lines and dotted wedge keys Indicates the absolute configuration of a stereocenter, with a straight solid-line bond and straight dashed keys Indicates the relative configuration of the stereocenter, with a wavy line Indicates wedge-shaped solid-line bond or dotted wedge key or with tilde Indicates a straight solid line key and straight dashed keys
- tautomer or “tautomeric form” means that isomers with different functional groups are in dynamic equilibrium at room temperature and are rapidly interconvertible. If tautomerism is possible (eg, in solution), then chemical equilibrium of the tautomers can be achieved.
- proton tautomers also called prototropic tautomers
- Valence isomers include interconversions by recombination of some bonding electrons.
- keto-enol tautomerization is the interconversion between two tautomers of pentane-2,4-dione and 4-hydroxypent-3-en-2-one. For tautomers.
- the terms “enriched in an isomer”, “enriched in an isomer”, “enriched in an enantiomer” or “enantiomerically enriched” refer to one of the isomers or enantiomers
- the content of the enantiomer is less than 100%, and the content of the isomer or enantiomer is greater than or equal to 60%, or greater than or equal to 70%, or greater than or equal to 80%, or greater than or equal to 90%, or greater than or equal to 95%, or Greater than or equal to 96%, or greater than or equal to 97%, or greater than or equal to 98%, or greater than or equal to 99%, or greater than or equal to 99.5%, or greater than or equal to 99.6%, or greater than or equal to 99.7%, or greater than or equal to 99.8%, or greater than or equal to 99.9%.
- the terms “isomer excess” or “enantiomeric excess” refer to the difference between the relative percentages of two isomers or two enantiomers. For example, if the content of one isomer or enantiomer is 90% and the other isomer or enantiomer is 10%, then the isomer or enantiomeric excess (ee value) is 80% .
- the compounds of the present invention may contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute the compounds.
- compounds may be labeled with radioactive isotopes such as tritium ( 3 H), iodine-125 ( 125 I) or C-14 ( 14 C).
- radioactive isotopes such as tritium ( 3 H), iodine-125 ( 125 I) or C-14 ( 14 C).
- heavy hydrogen can be used to replace hydrogen to form deuterated drugs.
- the bond formed by deuterium and carbon is stronger than the bond formed by ordinary hydrogen and carbon.
- deuterated drugs can reduce toxic side effects and increase drug stability. , enhance the efficacy, prolong the biological half-life of drugs and other advantages. All changes in isotopic composition of the compounds of the invention, whether radioactive or not, are included within the scope of the invention.
- substituted means that any one or more hydrogen atoms on a specified atom are replaced by a substituent, which may include deuterium and hydrogen variants, as long as the valence of the specified atom is normal and the substituted compound is stable.
- any variable eg, R
- its definition is independent at each occurrence.
- said group may optionally be substituted with up to two R, with independent options for each occurrence of R.
- substituents and/or variations thereof are permissible only if such combinations result in stable compounds.
- linking group When the number of a linking group is 0, such as -(CRR) 0 -, it means that the linking group is a single bond.
- linking group listed does not indicate its linking direction
- its linking direction is arbitrary, for example,
- the connecting group L in the middle is -MW-, at this time -MW- can connect ring A and ring B in the same direction as the reading order from left to right to form It can also be formed by connecting loop A and loop B in the opposite direction to the reading order from left to right
- any one or more sites of the group can be linked to other groups through chemical bonds.
- connection method of the chemical bond is not positioned, and there is an H atom at the connectable site, when the chemical bond is connected, the number of H atoms at the site will decrease correspondingly with the number of chemical bonds connected to become the corresponding valence group.
- the chemical bonds that the site connects with other groups can use straight solid line bonds Straight dotted key or tilde express.
- the straight-shaped solid-line bond in -OCH3 indicates that it is connected to other groups through the oxygen atom in the group;
- the straight dotted line bond indicates that the two ends of the nitrogen atom in the group are connected to other groups;
- the wavy lines in indicate that the 1 and 2 carbon atoms in the phenyl group are connected to other groups;
- halogen or halogen by itself or as part of another substituent means a fluorine (F), chlorine (Cl), bromine (Br) or iodine (I) atom.
- C 1-3 alkyl is used to denote a straight or branched chain saturated hydrocarbon group consisting of 1 to 3 carbon atoms.
- the C 1-3 alkyl group includes C 1-2 and C 2-3 alkyl groups, etc.; it can be monovalent (such as methyl), divalent (such as methylene) or multivalent (such as methine) .
- Examples of C 1-3 alkyl include, but are not limited to, methyl (Me), ethyl (Et), propyl (including n-propyl and isopropyl), and the like.
- C 1-3 alkylamino denotes those alkyl groups containing 1 to 3 carbon atoms attached to the rest of the molecule through an amino group.
- the C 1-3 alkylamino group includes C 1-2 , C 3 and C 2 alkylamino groups and the like.
- Examples of C 1-3 alkylamino include, but are not limited to, -NHCH 3 , -N(CH 3 ) 2 , -NHCH 2 CH 3 , -N(CH 3 )CH 2 CH 3 , -NHCH 2 CH 2 CH 3 , -NHCH 2 CH 2 CH 3 , -NHCH 2 (CH 3 ) 2 etc.
- C 3-5 cycloalkyl means a saturated cyclic hydrocarbon group composed of 3 to 5 carbon atoms, which is a monocyclic ring system, and the C 3-5 cycloalkyl includes C 3 -4 and C 4-5 cycloalkyl, etc.; it can be monovalent, divalent or multivalent.
- Examples of C 3-5 cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and the like.
- C 5-6 cycloalkyl means a saturated cyclic hydrocarbon group composed of 5 to 6 carbon atoms, which is a monocyclic and bicyclic ring system, and the C 5-6 cycloalkyl includes C 5 and C 6 cycloalkyl, etc.; it may be monovalent, divalent or multivalent.
- Examples of C 5-6 cycloalkyl include, but are not limited to, cyclopentyl, cyclohexyl, and the like.
- the terms "5-membered heteroaryl ring” and “5-membered heteroaryl” in the present invention can be used interchangeably.
- the nitrogen and sulfur heteroatoms may be optionally oxidized (ie, NO and S(O) p , where p is 1 or 2).
- a 5-membered heteroaryl can be attached to the rest of the molecule through a heteroatom or a carbon atom.
- Examples of the 5-membered heteroaryl group include, but are not limited to, pyrrolyl (including N-pyrrolyl, 2-pyrrolyl and 3-pyrrolyl, etc.), pyrazolyl (including 2-pyrazolyl and 3-pyrazolyl, etc.
- imidazolyl including N-imidazolyl, 2-imidazolyl, 4-imidazolyl and 5-imidazolyl, etc.
- oxazolyl including 2-oxazolyl, 4-oxazolyl and 5-oxazolyl etc.
- triazolyl (1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, 1H-1,2,4-triazolyl and 4H-1,2,4 -triazolyl, etc.
- tetrazolyl isoxazolyl (3-isoxazolyl, 4-isoxazolyl and 5-isoxazolyl, etc.)
- thiazolyl including 2-thiazolyl, 4- thiazolyl and 5-thiazolyl, etc.
- furyl including 2-furyl and 3-furyl, etc.
- thienyl including 2-thienyl and 3-thienyl, etc.
- the term "4-5 membered heterocycloalkyl” by itself or in combination with other terms means a saturated monocyclic group consisting of 4 to 5 ring atoms, respectively, whose 1, 2, 3 or 4 ring atoms is a heteroatom independently selected from O, S, and N, and the remainder is carbon atoms, wherein the nitrogen atom is optionally quaternized, and the nitrogen and sulfur heteroatoms may be optionally oxidized (i.e., NO and S(O) p , p is 1 or 2).
- a heteroatom may occupy the attachment position of the heterocycloalkyl to the rest of the molecule.
- the 4-5 membered heterocycloalkyl group includes 4-membered and 5-membered heterocycloalkyl groups.
- Examples of 4-5 membered heterocycloalkyl groups include, but are not limited to, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrothiophenyl (including tetrahydrothiophen-2-yl and tetrahydrothiophen-3-yl, etc.) or tetrahydrofuranyl (including tetrahydrofuran-2-yl, etc.) and the like.
- 4-6 membered heterocycloalkyl by itself or in combination with other terms means a saturated cyclic group consisting of 4 to 6 ring atoms, respectively, whose 1, 2, 3 or 4 ring atoms is a heteroatom independently selected from O, S, and N, and the remainder is carbon atoms, wherein the nitrogen atom is optionally quaternized, and the nitrogen and sulfur heteroatoms may be optionally oxidized (i.e., NO and S(O) p , p is 1 or 2). It includes monocyclic and bicyclic ring systems, wherein bicyclic ring systems include spiro, fused and bridged rings.
- a heteroatom may occupy the attachment position of the heterocycloalkyl to the rest of the molecule.
- the 4-6-membered heterocycloalkyl group includes 5-6-membered, 4-membered, 5-membered and 6-membered heterocycloalkyl groups and the like.
- 4-6 membered heterocycloalkyl groups include, but are not limited to, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrothiophenyl ( Including tetrahydrothiophen-2-yl and tetrahydrothiophen-3-yl, etc.), tetrahydrofuranyl (including tetrahydrofuran-2-yl, etc.), tetrahydropyranyl, piperidinyl (including 1-piperidinyl, 2- piperidinyl and 3-piperidinyl, etc.), piperazinyl (including 1-piperazinyl and 2-piperazinyl, etc.), morpholinyl (including 3-morpholinyl and 4-morpholinyl, etc.), Dioxanyl, dithianyl, isoxazolidinyl, isothiazolidin,
- the term "5-6 membered heterocycloalkyl" by itself or in combination with other terms represents a saturated or partially unsaturated cyclic group consisting of 5 to 6 ring atoms, whose 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from O, S, and N, and the rest are carbon atoms, wherein the nitrogen atom is optionally quaternized, and the nitrogen and sulfur heteroatoms can be optionally oxidized (i.e., NO and S(O ) p , p is 1 or 2). It includes monocyclic and bicyclic ring systems, wherein bicyclic ring systems include spiro, fused and bridged rings.
- a heteroatom may occupy the attachment position of the heterocycloalkyl to the rest of the molecule.
- the 5-6 membered heterocycloalkyl group includes 5-membered and 6-membered heterocycloalkyl groups.
- 5-6 membered heterocycloalkyl groups include, but are not limited to, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrothiophenyl (including tetrahydrothiophen-2-yl and tetrahydrothiophen-3-yl, etc.) , tetrahydrofuranyl (including tetrahydrofuran-2-yl, etc.), tetrahydropyranyl, piperidinyl (including 1-piperidinyl, 2-piperidinyl and 3-piperidinyl, etc.), piperazinyl (including 1 -piperazinyl and 2-piperazinyl, etc.), morpholinyl (including 3-morpholinyl and 4-morpholinyl, etc.), dioxanyl, dithianyl, isoxazolidinyl, isothiazole Alkyl, 1,2-oxazinyl, 1,2-thiazinyl, etc.
- the term "5-6 membered monocyclic heterocycloalkyl” by itself or in combination with other terms represents a saturated or partially unsaturated cyclic group consisting of 5 to 6 ring atoms, of which 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from O, S, and N, and the remainder are carbon atoms, wherein the nitrogen atom is optionally quaternized, and the nitrogen and sulfur heteroatoms can be optionally oxidized (i.e., NO and S (O) p , p is 1 or 2), which is only a single ring.
- the term "7-11 membered heterocycloalkyl" by itself or in combination with other terms denotes a saturated cyclic group consisting of 7 to 11 ring atoms, respectively, whose 1, 2, 3 or 4 ring atoms is a heteroatom independently selected from O, S, and N, and the remainder is carbon atoms, wherein the nitrogen atom is optionally quaternized, and the nitrogen and sulfur heteroatoms may be optionally oxidized (i.e., NO and S(O) p , p is 1 or 2).
- a heteroatom may occupy the attachment position of the heterocycloalkyl group to the rest of the molecule.
- the 7-11 membered heterocycloalkyl group includes 7-membered, 8-membered, 9-membered, 10-membered and 11-membered heterocycloalkyl groups and the like.
- Examples of 7-11 membered heterocycloalkyl include, but are not limited to, homopiperazinyl, homopiperidinyl, dioxepanyl, and the like.
- the term "7-11 membered bicyclic heterocycloalkyl" by itself or in combination with other terms means a saturated cyclic group consisting of 7 to 11 ring atoms, whose 1, 2, 3 or 4 ring Atoms are heteroatoms independently selected from O, S, and N, and the remainder are carbon atoms, wherein the nitrogen atom is optionally quaternized, and the nitrogen and sulfur heteroatoms may be optionally oxidized (i.e., NO and S(O) p , p is 1 or 2), said bicyclic ring system includes spiro ring, fused ring and bridged ring.
- the term "5-11 membered heterocycloalkyl" by itself or in combination with other terms denotes a saturated cyclic group consisting of 5 to 11 ring atoms, respectively, whose 1, 2, 3 or 4 ring atoms is a heteroatom independently selected from O, S, and N, and the remainder is carbon atoms, wherein the nitrogen atom is optionally quaternized, and the nitrogen and sulfur heteroatoms may be optionally oxidized (i.e., NO and S(O) p , p is 1 or 2).
- a heteroatom may occupy the attachment position of the heterocycloalkyl to the rest of the molecule.
- the 5-11 membered heterocycloalkyl group includes 5-10, 5-9, 5-8, 5-7, 5-6, 5, 6, 7, 8, 9 , 10 and 11 membered heterocycloalkyl groups, etc.
- Examples of 5-11 membered heterocycloalkyl groups include, but are not limited to, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrothiophene (including tetrahydrothiophen-2-yl and tetrahydrothiophen-3-yl, etc.) , tetrahydrofuranyl (including tetrahydrofuran-2-yl, etc.), tetrahydropyranyl, piperidinyl (including 1-piperidinyl, 2-piperidinyl and 3-piperidinyl, etc.), piperazinyl (including 1 -piperazinyl and 2-piperazinyl, etc.), morpholinyl (including 3-morpholinyl and 4-morpholinyl, etc.), dioxanyl, dithianyl, isoxazolidinyl, isothiazole Alkyl, 1,2-oxazinyl, 1,2-thiazinyl,
- C n-n+m or C n -C n+m includes any specific instance of n to n+m carbons, for example C 1-12 includes C 1 , C 2 , C 3 , C 4 , C 5 , C 6 , C 7 , C 8 , C 9 , C 10 , C 11 , and C 12 , also including any range from n to n+m, for example, C 1-12 includes C 1- 3 , C 1-6 , C 1-9 , C 3-6 , C 3-9 , C 3-12 , C 6-9 , C 6-12 , and C 9-12 etc.; similarly, n to n +m means that the number of atoms on the ring is from n to n+m, for example, a 3-12-membered ring includes a 3-membered ring, a 4-membered ring, a 5-membered ring, a 6-membered ring, a 7-membered ring, an 8-member
- the compounds of the present invention can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments listed below, the embodiments formed by combining them with other chemical synthesis methods, and the methods well known to those skilled in the art Equivalent alternatives, preferred embodiments include but are not limited to the examples of the present invention.
- the structure of the compounds of the present invention can be confirmed by conventional methods known to those skilled in the art. If the present invention involves the absolute configuration of the compound, the absolute configuration can be confirmed by conventional technical means in the art. For example, single crystal X-ray diffraction (SXRD), the cultured single crystal is collected with a Bruker D8 venture diffractometer to collect diffraction intensity data, the light source is CuK ⁇ radiation, and the scanning method is ⁇ / ⁇ scanning. After collecting relevant data, the direct method is further adopted (Shelxs97) By analyzing the crystal structure, the absolute configuration can be confirmed.
- SXRD single crystal X-ray diffraction
- the solvent used in the present invention is commercially available.
- the compound of the present invention exhibits higher inhibitory activity to kinases carrying triple mutations of EGFR (L858R/T790M/C797S) and EGFR (del19-E746-A750/T790M/C797S); (del19-E746-A750/T790M/C797S) triple mutant cell lines exhibited strong cell proliferation inhibitory activity against EGFR (L858R/T790M), EGFR (del19-E746-A750/T790M), EGFR (del19- E746-A750/C797S) and EGFR (L858R/C797S) dual mutation cell lines also exhibited higher cell proliferation inhibitory activity; The EGFR phosphorylation of the mutant cell line has a good inhibitory effect.
- the compound of the present invention has weak inhibition on EGFR (WT) kinase and cell lines, and has good selectivity.
- the compound of the present invention has weak inhibitory effect on P450 isozyme.
- the compound of the present invention also has excellent pharmacokinetic properties and excellent tumor inhibitory effect.
- A-1-1 (2.11g, 21.55mmol, 2eq), sodium bicarbonate (3.43g, 32.33mmol, 3eq) and [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride
- Dichloromethane complex (8.80g, 10.78mmol, 1eq) was added into anisole (40mL), and the reaction solution was stirred at 130°C for 16 hours. After the reaction, the reaction solution was filtered through diatomaceous earth to obtain a filtrate, and the filter cake was washed three times with toluene (30 mL), and combined to obtain a black filtrate.
- B-1-1 (1.38g, 10.00mmol, 1.29mL, 1eq) was dissolved in THF (30mL), cooled to -70°C, and a THF solution of isopropylmagnesium chloride (2M, 3.09g, 30mmol, 15mL, 3eq) stirred for 2 hours, then slowly warmed up to 25°C and stirred for 3 hours. Then cool to 0°C, add 0.5M hydrochloric acid aqueous solution (40mL) to quench the reaction, extract 3 times with ethyl acetate 30mL, combine the organic phases, wash once with saturated sodium chloride solution (20mL), dry over anhydrous sodium sulfate, filter, Concentrate under reduced pressure.
- Dissolve B-1-1 (1.38g, 10.00mmol, 1.29mL, 1eq) in THF (30mL), cool to -70°C, add cyclopropylmagnesium bromide in THF (0.5M, 3.09g, 30mmol) dropwise , 60mL, 3eq) stirred for 2 hours, then slowly warmed up to 25°C and stirred for 3 hours.
- the reaction solution was concentrated under reduced pressure to obtain a crude product.
- the crude product was separated by preparative HPLC, chromatographic column: Welch Xtimate C18 100*40mm*3 ⁇ m; mobile phase: [water (trifluoroacetic acid)-acetonitrile]; gradient: acetonitrile%: 16%-46%, 8 minutes, to get WX-007 of trifluoroacetate.
- reaction solution was separated by preparative HPLC, chromatographic column: Welch Xtimate C18 100*40mm*3 ⁇ m; mobile phase: [water (trifluoroacetic acid)-acetonitrile]; acetonitrile %: 12%-42%, purified in 8 minutes. Then 30 mL of dichloromethane was added, washed once with saturated sodium bicarbonate solution and once with saturated sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated to obtain compound WX-016.
- reaction solution was separated by preparative HPLC, chromatographic column: Welch Xtimate C18 100*40mm*3 ⁇ m; mobile phase: [water (trifluoroacetic acid)-acetonitrile]; acetonitrile%: 18%-48%, purified in 8 minutes. Then 30 mL of dichloromethane was added, washed once with saturated sodium bicarbonate solution and once with saturated sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated to obtain compound WX-017.
- reaction solution was separated by preparative HPLC, chromatographic column: Welch Xtimate C18 100*40mm*3 ⁇ m; mobile phase: [water (trifluoroacetic acid)-acetonitrile]; acetonitrile%: 17%-47%, purified in 8 minutes. Then 30 mL of dichloromethane was added, washed once with saturated sodium bicarbonate solution and once with saturated sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated to obtain compound WX-020.
- reaction solution was separated by preparative HPLC, chromatographic column: Welch Xtimate C18 100*40mm*3 ⁇ m; mobile phase: [water (trifluoroacetic acid)-acetonitrile]; acetonitrile%: 17%-47%, purified in 8 minutes. Then 30 mL of dichloromethane was added, washed once with saturated sodium bicarbonate solution and once with saturated sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated to obtain compound WX-021.
- Compound 23-2 (30mg, 47.56 ⁇ mol, 1eq) was dissolved in a mixed solution of methanol (2mL) and acetic acid (0.065mL), and aqueous formaldehyde (7.14mg, 95.12 ⁇ mol, 2eq), sodium cyanoborohydride (7.47mg , 118.90 ⁇ mol, 2.5eq), stirred at 25°C for 12 hours.
- the reaction solution was separated by preparative HPLC, chromatographic column: Welch Xtimate C18 100*40mm*3 ⁇ m; mobile phase: [water (trifluoroacetic acid)-acetonitrile]; acetonitrile%: 3%-33%, purified in 8 minutes.
- reaction solution was separated by preparative HPLC, chromatographic column: Welch Xtimate C18 100*40mm*3 ⁇ m; mobile phase: [water (trifluoroacetic acid)-acetonitrile]; gradient: acetonitrile%: 2%-32%, purified in 8 minutes, then added 30 mL of dichloromethane, washed once with saturated sodium bicarbonate solution, washed once with saturated sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated compound 24-2.
- LCMS m/z 589.1 [M+1] + .
- Step 8 Synthesis of Compounds WX-027A and WX-027B
- N-1 (56.76mg, 323.91 ⁇ mol, 1.5eq) in 1,4-dioxane (2.5mL) and dichloromethane (1mL) solution was added 2-(Di-tert-butylphosphine)biphenyl (19.33mg, 64.78 ⁇ mol, 0.3eq), sodium tert-butoxide solution in tetrahydrofuran (2M, 647.8 ⁇ mol, 323.91 ⁇ l, 3eq), after nitrogen replacement, add tri(dibenzyl Dipalladium (29.66mg, 32.39 ⁇ mol, 0.15eq), stirred at 80°C for 14 hours under nitrogen protection.
- EGFR L858R/T790M/C797S
- EGFR del19-E746-A750/T790M/C797S
- WT EGFR
- reaction buffer (20mM hydroxyethylpiperazine ethylsulfuric acid (Hepes) (pH7.5), 10mM magnesium chloride (MgCl 2 ), 1mM ethylene glycol bisaminoethyl ether tetraacetic acid (EGTA), 0.02% polyoxyethylene Lauryl ether (Brij35), 0.02mg/ml BSA, 0.1mM sodium vanadate (Na 3 VO 4 ), 2mM dithiothreitol (DTT), 1% DMSO) were sequentially added a certain concentration of substrate, coenzyme Factors, kinases, and test compounds (10 doses, 3-fold serial dilutions, 2% DMSO final concentration) were mixed well, the mixture was incubated at room temperature for 20 minutes, and a certain concentration of 33 P-ATP was added to the reaction mixture to start The reaction was followed by incubation at room temperature for 120 minutes.
- Hepes hydroxyethylpiperazine eth
- the radioactivity of the reactants is detected by the filter-binding method.
- the final kinase activity is expressed as the ratio of the kinase activity remaining in the test sample to the kinase activity of the DMSO control.
- the dose-effect relationship curve was fitted by GraphPad software and IC 50 was calculated. The results are shown in Table 1 and Table 2:
- the compound of the present invention exhibits higher inhibitory activity to kinases carrying EGFR (L858R/T790M/C797S) and EGFR (del19-E746-A750/T790M/C797S) triple mutations, and has higher inhibitory activity on EGFR (WT) kinases low, showing good selectivity.
- Adenosine Tri-Phosphate is a common energy carrier in various life activities in nature, and is the smallest unit of energy storage and transfer.
- CellTiter-Glo TM Live Cell Detection Kit uses luciferase as the detection substance, and luciferase needs the participation of ATP in the process of luminescence.
- Add CellTiter-Glo TM reagent to the cell culture medium measure the luminescence value, the light signal is directly proportional to the amount of ATP in the system, and ATP is positively correlated with the number of living cells. Therefore, by using the CellTiter-Glo kit to detect the ATP content, the cell proliferation can be detected.
- the cell lines are Ba/F3-FL-EGFR(L858R/T790M/C797S), Ba/F3-FL-EGFR(WT), Ba/F3-FL-EGFR(L858R), Ba/F3-FL- EGFR(del19-S752-I759), Ba/F3-FL-EGFR(del19-E746-A750/T790M/C797S), Ba/F3-FL-EGFR(L858R/T790M), Ba/F3-FL-EGFR(del19 -E746-A750/T790M), Ba/F3-TEL-EGFR(L858R/C797S), Ba/F3-FL-EGFR(del19-E746-A750/C797S) stably transfected cell lines.
- Cell lines were cultured in an incubator with culture conditions of 37 °C, 5% CO2 . Passage regularly, and take cells in logarithmic growth phase for plating.
- the cell viability rate should be over 90%.
- Inhibition Rate (Inh%) 100-(RLUDrug-RLUMin)/(RLUMax-RLUMin)*100%.
- the compound of the present invention exhibits extremely strong inhibitory activity on cell proliferation to cell lines carrying triple mutations of EGFR (L858R/T790M/C797S) and EGFR (del19-E746-A750/T790M/C797S), T790M), EGFR(del19-E746-A750/T790M), EGFR(del19-E746-A750/C797S) and EGFR(L858R/C797S) dual mutant cell lines also exhibited higher cell proliferation inhibitory activity; in addition, It has weaker inhibition on EGFR (WT) cell line and better selectivity.
- WT EGFR
- Experimental example 3 Phosphorylation inhibition experiment of compounds on Ba/F3-FL-EGFR (L858R/T790M/C797S) and Ba/F3-FL-EGFR (del19-E746-A750/T790M/C797S) cells
- the cell viability must be over 90%. Inoculate the cells into a sterile 6 -well plate with 2 ⁇ 106 cells per well. Make up 1640 complete medium to 1998 ⁇ L. The 6-well plate was placed in a constant temperature incubator at 37°C and 5% CO 2 for static culture.
- the medium was collected and centrifuged at 8000rpm for 3 minutes, and the cells were collected in a 1.5mL EP tube. After the supernatant was discarded, the total protein was extracted;
- the PVDF membrane was put into the blocking solution of 5% skimmed milk, shaken slowly on a shaker, and blocked at room temperature for 1 hour. The blocked PVDF membrane was slowly washed 3 times in TBST, 10 min each time. After washing, put the PVDF membrane into the antibody box of the primary antibody.
- the primary antibody was diluted with the primary antibody diluent at a ratio of 1:1000, and the antibody box was incubated at 4°C on a gentle shaker (10-16h).
- PVDF membrane Remove the overnight incubated PVDF membrane from the antibody box and recover the primary antibody.
- the PVDF membrane was slowly washed 3 times in TBST, 10 min each time. Put the washed PVDF membrane into the corresponding species of secondary antibody (1:3000) dilution solution (containing 5% skimmed milk), and incubate for 1 h at room temperature on a gentle shaker. After the secondary antibody incubation, the PVDF membrane was taken out and washed slowly in TBST three times, 10 min each time.
- Mix medium volumes of solution A and solution B in the ECL kit add evenly on the surface of the membrane (protein surface), put it into a Tanon 5200 luminescence imager (turn on pre-cooling 5 minutes in advance) for exposure and development, take pictures and save the pictures.
- the aim of this study was to determine the inhibitory effect of test compounds on the activity of human liver microsomal cytochrome P450 isozymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4).
- the test compound (10.0mM) was serially diluted to prepare a working solution (100 ⁇ final concentration), and the concentrations of the working solution were: 5.00, 1.50, 0.500, 0.150, 0.0500, 0.0150 and 0.00500mM.
- Enzyme CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 working solution of each positive inhibitor and its specific substrate mixture; thaw human liver microsomes stored in a refrigerator below -60°C on ice, and treat human liver microsomes
- the body was completely dissolved and diluted with Potassium phosphate buffer (PB) to prepare a certain concentration of working solution (0.253mg/ml).
- PB Potassium phosphate buffer
- each CYP isoenzyme was reflected by the generation rate of each probe substrate metabolite.
- the generation rate of the metabolites of the control sample was compared and multiplied by 100% to be the remaining activity percentage of each isoenzyme.
- With the remaining activity percentage as the ordinate and the inhibitor concentration as the abscissa use XL fit software for three-parameter or four-parameter nonlinear regression analysis to calculate the IC 50 value of the test product and each positive inhibitor.
- the IC 50 value is marked as “>50 ⁇ M”.
- the experimental results are shown in Table 6.
- mice 7-9 weeks old male ICR mice were used as the experimental animals, and the drug concentration of the compound in plasma at different times was determined by LC/MS/MS method after a single intravenous injection (IV) and intragastric administration (PO) of the compound , to study the pharmacokinetic behavior of the compound of the present invention in mice, and evaluate its pharmacokinetic characteristics.
- IV intravenous injection
- PO intragastric administration
- Drug preparation the compounds were formulated into solutions with corresponding solvents for administration in IV (intravenous injection) and PO (gastric administration) groups.
- the dosage of each compound was as follows: IV dose was 3 mg/kg; PO dose was 10 mg/kg, and the vehicle was 10% DMSO+10% solutol+80% (10% HP- ⁇ -CD).
- the results of pharmacokinetic parameters are shown in Table 7:
- Ba/F3-FL-EGFR (del19-T790M-C797S) cell line was used in RPMI1640 medium (Viva Cell) + 10% fetal bovine serum (Viva Cell) + 1% double antibody (Penicillin Streptomycin solution, Gibco, USA), 37 °C, 5% CO 2 culture, 2-3 subcultures a week. When the cell saturation is 80%-90%, the cells are collected, counted, and inoculated.
- mice After the inoculation, the growth status of the tumor was observed daily, and when the average volume of the tumor reached about 100-150 mm 3 , the mice were randomly divided into groups according to the tumor volume.
- Dosing according to mouse body weight 10 ⁇ L/g, if the weight loss exceeds 20%, the dosing regimen is adjusted accordingly.
- Statistical analysis included mean (Mean) and standard error (SEM) of tumor volume at each time point for each group. Statistical analysis was performed based on the data at day 10 after administration to evaluate differences between groups. One-way ANOVA (one way ANOVA) post hoc test Tamhane test method was used to compare the tumor volume of the treatment group compared with the tumor volume of the control group whether there was a significant difference. p ⁇ 0.05 means significant difference.
- Drug efficacy evaluation indicators include tumor volume and tumor weight to investigate whether tumor growth is delayed, inhibited or cured. The antitumor efficacy of the compound is evaluated by relative tumor proliferation rate T/C (%) or tumor growth inhibition rate TGI (%).
- the evaluation criteria are: T/C(%)>40% or TGI(%) ⁇ 40% is invalid; T/C(%) ⁇ 40%, and p ⁇ 0.05 or TGI(%) ⁇ 40% and p ⁇ 0.05 is valid.
- the body weight of the experimental animals is used as a reference index for indirect determination of drug toxicity, and the results are shown in Table 8.
- Table 10 shows the results of antitumor drug efficacy evaluation indexes.
- the tumor inhibition rates of the 10mg/kg and 25mg/kg dose groups of WX-027A were 94% and 102%, respectively, and the P value was ⁇ 0.01; the tumor inhibition rates of the 10mg/kg and 25mg/kg dose groups of WX-019 were respectively 101%, 103%, and P value ⁇ 0.01.
- the compound of the present invention significantly inhibits the growth of transplanted tumors.
Abstract
一系列大环酰胺类化合物及其应用,具体公开了式(V)所示化合物或其药学上可接受的盐及其应用。
Description
本发明主张如下优先权:
CN202110839425.1,申请日:2021年07月23日;
CN202110960699.6,申请日:2021年08月20日;
CN202111127366.1,申请日:2021年09月18日;
CN202111187955.9,申请日:2021年10月12日;
CN202210093818.7,申请日:2022年01月26日;
CN202210731479.0,申请日:2022年06月24日。
本发明涉及一系列大环酰胺类化合物及其应用,具体涉及式(V)所示化合物及其药学上可接受的盐。
表皮生长因子受体(EGFR,epidermal growth factor receptor)是一种转导有丝分裂信号的受体酪氨酸激酶,在正常组织中广泛表达。同时,EGFR的异常激活突变存在于10-15%的白种人和高达50%的东亚非小细胞肺癌患者中。这些激活突变促进了肿瘤细胞的存活、增殖和转移。其中,外显子19缺失(del 19)和外显子21的L858R点突变是最常见的突变。因此,靶向EGFR的酪氨酸激酶抑制剂(TKI,tyrosine kinase inhibitor)被研发用于竞争性地与内源性配体结合EGFR,抑制其异常活化,阻断EGFR信号通路以治疗肺癌。
第一代EGFR抑制剂如吉非替尼(gefitinib)、厄洛替尼(erlotinib),首先被研发出并在患者身上表现出了良好的疗效。然而,治疗一段时间后,患者出现了多种耐药突变,特别是T790M突变。于是,第二代EGFR抑制剂阿法替尼(afatinib)和达克替尼(dacomitinib)被研发出,以缓解T790M相关突变产生的耐药性。随后,第三代EGFR抑制剂奥西替尼(osimertinib)解决了T790M的耐药性问题,并且对野生型EGFR具有很大的选择性。
然而,最近的数据表明,使用奥希替尼复发的二线患者中有20-40%在共价抑制剂结合所需的半胱氨酸残基(C797S)处获得了新的EGFR突变。更为重要的是,在接受奥希替尼治疗后进展的二线患者中出现的EGFR del19/L858R T790M C797S cis突变的激酶变体不再能被任何已批准的第一、第二或第三代EGFR TKI抑制。因此,针对C797S突变开发更加安全有效的第四代EGFR抑制剂具有重要的研究意义和强烈的临床需求。
在2019年《J.Med.Chem.2019,62,22,10272–10293》中,德国勃林格殷格翰制药公司报道了一种新一代的EGFR TKI——BI-4020。BI-4020是一种非共价大环TKI,它不仅抑制EGFR del19/T790M/C797S三重突变体,还抑制双突变EGFR del19/T790M和单突变EGFR del19,同时对EGFR野生型具有良好的选择性。此外,BI-4020还显示出对EGFR突变细胞良好的抑制活性、优越的激酶选择性和体内的药代特性。在PC-9(EGFR del19/T790M/C797S)NSCLC异种移植模型中,BI-4020同样表现出良好的抗肿瘤疗效,但BI-4020最终未进入临床研究。
发明内容
本发明提供了式(V)所示化合物或其药学上可接受的盐,
其中,
T
1和T
2分别独立地选自N和CH;
T
3选自N和CR
e;
T
4选自N和CR
f;
L
1选自-O-和-NH-;
L
2选自-CH
2-和-C(=O)-;
L
3选自-O-、-NH-和-CH
2-;
L
4选自-C
1-3烷基-、-P(=O)(R
a)-、-S(=O)
2-、-S(=O)(=NR
c)-和-N=S(=O)(R
b)-;
L
5选自
-C
3-5环烷基-、-4-5元杂环烷基-、-CH
2-C
5-6环烷基-、-CH
2-C
5-6环烷基-CH
2-、-CH
2-5-6元杂环烷基-和-CH
2-5-6元杂环烷基-CH
2-;
R
1不存在,R
2选自CH
3和环丙基;
或者,R
1和R
2与相连的原子形成五元杂芳基;
R
3选自C
1-3烷基、C
3-5环烷基和-哌嗪基-甲基;
R
4选自C
1-3烷基,所述C
1-3烷基任选被1、2或3个R
d取代;
R
5选自CH
3,所述CH
3任选被1、2或3个卤素取代;
R
6选自H和CH
3,所述CH
3任选被1、2或3个卤素取代;
R
7选自H和CH
3,所述CH
3任选被1、2或3个卤素取代;
或者R
5和R
6与相连的原子形成环丙基;
R
a选自C
1-3烷基和C
3-5环烷基;
R
b选自C
1-3烷基;
R
c选自H和C
1-3烷基;
R
d选自卤素和C
1-3烷氨基;
或者R
a和R
3与相连的原子形成5-6元杂环烷基,所述5-6元杂环烷基任选被1或2个CH
3取代;
或者R
b和R
3与相连的原子形成5-11元杂环烷基,所述5-11元杂环烷基任选被1或2个R
g取代;
或者R
c和R
3与相连的原子形成5-6元杂环烷基,所述5-6元杂环烷基任选被1或2个CH
3取代;
R
e选自H、F、Cl、Br、I和CN;
R
f选自H、F、Cl、Br、I和CN;
R
g选自CH
3和4-6元杂环烷基,所述4-6元杂环烷基任选被1或2个CH
3取代;
条件是,当L
1选自-O-,L
2选自-CH
2-,L
3选自-CH
2-,L
4选自-CH
2-,R
3选自-哌嗪基-甲基时,T
1和T
2至少一个选自N,或者R
1和R
2与相连的原子形成五元杂芳基。
在本发明的一些方案中,所述T
1选自N,其他变量如本发明所定义。
在本发明的一些方案中,所述T
1选自CH,其他变量如本发明所定义。
在本发明的一些方案中,所述T
2选自N,其他变量如本发明所定义。
在本发明的一些方案中,所述T
2选自CH,其他变量如本发明所定义。
在本发明的一些方案中,所述R
g选自CH
3、氧杂环丁基、氮杂环丁基、四氢吡喃基、吗啉基、哌啶基、哌嗪基和N-甲基哌啶基,其他变量如本发明所定义。
在本发明的一些方案中,所述R
a选自CH
3、CH
2CH
3、CH(CH
3)
2和环丙基,其他变量如本发明所定义。
在本发明的一些方案中,所述R
b选自CH
3、CH
2CH
3和CH(CH
3)
2,其他变量如本发明所定义。
在本发明的一些方案中,所述R
b和R
3与相连的原子形成5-6元单环杂环烷基和7-11元双环杂环烷基,所述5-6元单环杂环烷基和7-11元双环杂环烷基任选被1或2个R
g取代,其他变量如本发明所定义。
在本发明的一些方案中,所述L
4选自-CH
2-、-P(=O)(CH
3)-、-P(=O)(CH
2CH
3)-、
-S(=O)
2-、-S(=O)(=NH)-、-S(=O)(=NCH
3)-、-S(=O)(=NCH
2CH
3)-、-N=S(=O)(CH
3)-、-N=S(=O)(CH
2CH
3)-,其他变量如本发明所定义。
在本发明的一些方案中,所述R
4选自CH
3、CH
2CH
2N(CH
3)
2和CH
2CH
2NHCH(CH
3)
2,其他变量如本发明所定义。
在本发明的一些方案中,所述L
5选自-CH
2CH(CH
3)CH
2CH
2-、-CH
2CH(CH
3)OCH
2-、-CH
2C(CH
3)
2CH
2CH
2-、-CH(CH
3)CH(CH
3)CH
2CH
2-、-CH
2CH(CF
3)CH
2CH
2-、环戊基、吡咯烷基、-CH
2-环戊基-、-CH
2-环戊基-CH
2-、-CH
2-环己基-、-CH
2-吡咯烷基-、-CH
2-四氢呋喃基-和
其他变量如本发明所定义。
本发明提供了式(V)所示化合物或其药学上可接受的盐,
其中,
T
1和T
2分别独立地选自N和CH;
T
3选自N和CR
e;
T
4选自N和CR
f;
L
1选自-O-和-NH-;
L
2选自-CH
2-和-C(=O)-;
L
3选自-O-、-NH-和-CH
2-;
L
4选自-C
1-3烷基-、-P(=O)(R
a)-、-S(=O)
2-、-S(=O)(=NH)-和-N=S(=O)(R
b)-;
R
1不存在;
R
2选自CH
3;
或者,R
1和R
2与相连的原子形成五元杂芳基;
R
3选自C
1-3烷基、C
3-5环烷基和-哌嗪基-甲基;
R
4选自C
1-3烷基,所述C
1-3烷基任选被1、2或3个R
d取代;
R
5选自CH
3,所述CH
3任选被1、2或3个卤素取代;
R
6选自H和CH
3,所述CH
3任选被1、2或3个卤素取代;
R
7选自H和CH
3,所述CH
3任选被1、2或3个卤素取代;或者R
5和R
6与相连的原子形成环丙基;
R
a选自C
1-3烷基和C
3-5环烷基;
R
b选自C
1-3烷基;
R
c选自H和C
1-3烷基;
R
d选自卤素和C
1-3烷氨基;
或者R
a和R
3与相连的原子形成5-6元杂环烷基,所述5-6元杂环烷基任选被1或2个CH
3取代;
或者R
b和R
3与相连的原子形成5-11元杂环烷基,所述5-11元杂环烷基任选被1或2个R
g取代;
或者R
c和R
3与相连的原子形成5-6元杂环烷基,所述5-6元杂环烷基任选被1或2个CH
3取代;
R
e选自H、F、Cl、Br、I和CN;
R
f选自H、F、Cl、Br、I和CN;
R
g选自CH
3、哌啶基、哌嗪基和N-甲基哌啶基;
条件是,当L
1选自-O-,L
2选自-CH
2-,L
3选自-CH
2-,L
4选自-CH
2-,R
3选自-哌嗪基-甲基时,T
2和T
3至少一个选自N,或者R
1和R
2与相连的原子形成五元杂芳基。
在本发明的一些方案中,所述R
a选自CH
3、CH
2CH
3、CH(CH
3)
2和环丙基,其他变量如本发明所定义。
在本发明的一些方案中,所述R
b选自CH
3、CH
2CH
3和CH(CH
3)
2,其他变量如本发明所定义。
在本发明的一些方案中,所述L
4选自-CH
2-、-P(=O)(CH
3)-、-P(=O)(CH
2CH
3)-、
-S(=O)
2-、-S(=O)(=NH)-、-S(=O)(=NCH
3)-、-S(=O)(=NCH
2CH
3)-、-N=S(=O)(CH
3)-、-N=S(=O)(CH
2CH
3)-,其他变量如本发明所定义。
在本发明的一些方案中,所述R
4选自CH
3、CH
2CH
2N(CH
3)
2和CH
2CH
2NHCH(CH
3)
2,其他变量如本发明所定义。
在本发明的一些方案中,所述L
5选自-CH
2CH(CH
3)CH
2CH
2-、-CH
2CH(CH
3)OCH
2-、-CH
2C(CH
3)
2CH
2CH
2-、-CH(CH
3)CH(CH
3)CH
2CH
2-、-CH
2CH(CF
3)CH
2CH
2-、环戊基、吡咯烷基和
其他变量如本发明所定义。
本发明提供了式(IV)所示化合物或其药学上可接受的盐,
其中,
T
1和T
2分别独立地选自N和CH;
T
3选自N、CF和CH;
T
4选自N和CH;
L
1选自-O-和-NH-;
L
2选自-CH
2-和-C(=O)-;
L
3选自-O-、-NH-和-CH
2-;
L
4选自-C
1-3烷基-、-P(=O)(R
a)-、-S(=O)
2-、-S(=O)(=NH)-和-N=S(=O)(R
b)-;
R
1不存在;
R
2选自CH
3;
或者,R
1和R
2与相连的原子形成五元杂芳基;
R
3选自C
1-3烷基、C
3-5环烷基和-哌嗪基-甲基;
R
4选自C
1-3烷基,所述C
1-3烷基任选被1、2或3个R
d取代;
R
5选自CH
3;
R
6选自H和CH
3;
或者R
5和R
6与相连的原子形成环丙基;
R
a选自C
1-3烷基和C
3-5环烷基;
R
b选自C
1-3烷基;
R
c选自H和C
1-3烷基;
R
d选自卤素和C
1-3烷氨基;
或者R
a和R
3与相连的原子形成5-6元杂环烷基,所述5-6元杂环烷基任选被1或2个CH
3取代;
或者R
b和R
3与相连的原子形成5-6元杂环烷基,所述5-6元杂环烷基任选被1或2个CH
3取代;
或者R
c和R
3与相连的原子形成5-6元杂环烷基,所述5-6元杂环烷基任选被1或2个CH
3取代;
条件是,当L
1选自-O-,L
2选自-CH
2-,L
3选自-CH
2-,L
4选自-CH
2-,R
3选自-哌嗪基-甲基时,T
2和T
3至少一个选自N,或者R
1和R
2与相连的原子形成五元杂芳基。
在本发明的一些方案中,所述R
a选自CH
3、CH
2CH
3、CH(CH
3)
2和环丙基,其他变量如本发明所定义。
在本发明的一些方案中,所述R
b选自CH
3、CH
2CH
3和CH(CH
3)
2,其他变量如本发明所定义。
在本发明的一些方案中,所述L
4选自-CH
2-、-P(=O)(CH
3)-、-P(=O)(CH
2CH
3)-、
-S(=O)
2-、-S(=O)(=NH)-、-S(=O)(=NCH
3)-、-S(=O)(=NCH
2CH
3)-、-N=S(=O)(CH
3)-、-N=S(=O)(CH
2CH
3)-, 其他变量如本发明所定义。
在本发明的一些方案中,所述R
4选自CH
3、CH
2CH
2N(CH
3)
2和CH
2CH
2NHCH(CH
3)
2,其他变量如本发明所定义。
在本发明的一些方案中,所述结构单元-L
3-CH
2-L
2-L
1-选自-(CH
2)
3-O-#、-(CH
2)
3-NH-#、-O-CH
2CH
2-NH-#、-O-CH
2-C(=O)-NH-#和-O-CH
2CH
2-O-#,“#”端连接于吡唑基,其他变量如本发明所定义。
本发明提供了式(I)所示化合物或其药学上可接受的盐,
其中,
T
1和T
2分别独立地选自N和CH;
L
1选自-O-和-NH-;
L
2选自-CH
2-和-C(=O)-;
L
3选自-O-、-NH-和-CH
2-;
L
4选自-C
1-3烷基-、-P(=O)(R
a)-、-S(=O)
2-、-S(=O)(=NH)-和-N=S(=O)(R
b)-;
R
1不存在;
R
2选自CH
3;
或者,R
1和R
2与相连的原子形成五元杂芳基;
R
3选自C
1-3烷基、C
3-5环烷基和-哌嗪基-甲基;
R
a选自C
1-3烷基和C
3-5环烷基;
R
b选自C
1-3烷基;
R
c选自H和C
1-3烷基;
或者R
a和R
3与相连的原子形成5-6元杂环烷基,所述5-6元杂环烷基任选被1或2个CH
3取代;
或者R
b和R
3与相连的原子形成5-6元杂环烷基,所述5-6元杂环烷基任选被1或2个CH
3取代;
或者R
c和R
3与相连的原子形成5-6元杂环烷基,所述5-6元杂环烷基任选被1或2个CH
3取代;
条件是,当L
1选自-O-,L
2选自-CH
2-,L
3选自-CH
2-,L
4选自-CH
2-,R
3选自-哌嗪基-甲基时,T
2和T
3至少一个选自N,或者R
1和R
2与相连的原子形成五元杂芳基。
在本发明的一些方案中,所述化合物或其药学上可接受的盐,其选自,
其中,
T
1、T
2、L
1、L
2、L
3、L
4、R
1、R
2和R
3如本发明所定义。
在本发明的一些方案中,所述R
a选自CH
3、CH
2CH
3、CH(CH
3)
2和环丙基,其他变量如本发明所定义。
在本发明的一些方案中,所述R
b选自CH
3、CH
2CH
3和CH(CH
3)
2,其他变量如本发明所定义。
在本发明的一些方案中,所述L
4选自-CH
2-、-P(=O)(CH
3)-、-P(=O)(CH
2CH
3)-、
-S(=O)
2-、-S(=O)(=NH)-、-S(=O)(=NCH
3)-、-S(=O)(=NCH
2CH
3)-、-N=S(=O)(CH
3)-、-N=S(=O)(CH
2CH
3)-,其他变量如本发明所定义。
在本发明的一些方案中,所述结构单元-L
3-CH
2-L
2-L
1-选自-(CH
2)
3-O-#、-(CH
2)
3-NH-#、-O-CH
2CH
2-NH-#、-O-CH
2-C(=O)-NH-#和-O-CH
2CH
2-O-#,“#”端连接于吡唑基,其他变量如本发明所定义。
本发明提供了式(I)所示化合物或其药学上可接受的盐,
其中,
T
1和T
2分别独立地选自N和CH;
L
1选自-O-和-NH-;
L
2选自-CH
2-和-C(=O)-;
L
3选自-O-、-NH-和-CH
2-;
L
4选自-C
1-3烷基-、-P(=O)(R
a)-、-S(=O)
2-、-S(=O)(=NH)-和-N=S(=O)(R
b)-;
R
1不存在;
R
2选自CH
3;
或者,R
1和R
2与相连的原子形成五元杂芳基;
R
3选自C
1-3烷基、C
3-5环烷基和-哌嗪基-甲基;
R
a选自C
1-3烷基和C
3-5环烷基;
R
b选自C
1-3烷基;
R
c选自H和C
1-3烷基;
或者R
a和R
3与相连的原子形成5-6元杂环烷基,所述5-6元杂环烷基任选被1个CH
3取代;
或者R
b和R
3与相连的原子形成5-6元杂环烷基,所述5-6元杂环烷基任选被1个CH
3取代;
条件是,当L
1选自-O-,L
2选自-CH
2-,L
3选自-CH
2-,L
4选自-CH
2-,R
3选自-哌嗪基-甲基时,T
2和T
3至少一个选自N,或者R
1和R
2与相连的原子形成五元杂芳基。
在本发明的一些方案中,所述化合物或其药学上可接受的盐,其选自,
其中,
T
1、T
2、L
1、L
2、L
3、L
4、R
1、R
2和R
3如本发明所定义。
在本发明的一些方案中,所述R
a选自CH
3、CH
2CH
3、CH(CH
3)
2和环丙基,其他变量如本发明所定义。
在本发明的一些方案中,所述R
b选自CH
3、CH
2CH
3和CH(CH
3)
2,其他变量如本发明所定义。
在本发明的一些方案中,所述L
4选自-CH
2-、-P(=O)(CH
3)-、-P(=O)(CH
2CH
3)-、
-S(=O)
2-、-S(=O)(=NH)-、-S(=O)(=NCH
3)-、-S(=O)(=NCH
2CH
3)-、-N=S(=O)(CH
3)-、-N=S(=O)(CH
2CH
3)-,其他变量如本发明所定义。
在本发明的一些方案中,所述R
3选自CH
3、CH
2CH
3、CH(CH
3)
2、环丙基和
其他变量如本发明所定义。在本发明的一些方案中,所述结构单元-L
4-R
3选自
其他变量如本发明所定义。
在本发明的一些方案中,所述结构单元-L
3-CH
2-L
2-L
1-选自-(CH
2)
3-O-#、-(CH
2)
3-NH-#、-O-CH
2CH
2-NH-#和-O-CH
2-C(=O)-NH-#,“#”端连接于吡唑基,其他变量如本发明所定义。
本发明提供了式(I)所示化合物或其药学上可接受的盐,
其中,
T
1和T
2分别独立地选自N和CH;
L
1选自-O-和-NH-;
L
2选自-CH
2-和-C(=O)-;
L
3选自-O-、-NH-和-CH
2-;
L
4选自-C
1-3烷基-、-P(=O)(R
a)-、-S(=O)
2-、-S(=O)(=NH)-和-N=S(=O)(R
b)-;
R
1不存在;
R
2选自CH
3;
或者,R
1和R
2与相连的原子形成五元杂芳基;
R
3选自C
1-3烷基、C
3-5环烷基和-哌嗪基-甲基;
R
a选自C
1-3烷基和C
3-5环烷基;
R
b选自C
1-3烷基;
条件是,当L
1选自-O-,L
2选自-CH
2-,L
3选自-CH
2-,L
4选自-CH
2-,R
3选自-哌嗪基-甲基时,T
2和T
3至少一个选自N,或者R
1和R
2与相连的原子形成五元杂芳基。
在本发明的一些方案中,所述化合物或其药学上可接受的盐,其选自,
其中,
T
1、T
2、L
1、L
2、L
3、L
4、R
1、R
2和R
3如本发明所定义。
在本发明的一些方案中,所述R
a选自CH
3、CH
2CH
3、CH(CH
3)
2和环丙基,其他变量如本发明所定义。
在本发明的一些方案中,所述R
b选自CH
3、CH
2CH
3和CH(CH
3)
2,其他变量如本发明所定义。
在本发明的一些方案中,所述L
4选自-CH
2-、-P(=O)(CH
3)-、-P(=O)(CH
2CH
3)-、
-S(=O)
2-、-S(=O)(=NH)-和-N=S(=O)(CH
3)-,其他变量如本发明所定义。
在本发明的一些方案中,所述R
3选自CH
3、CH
2CH
3、CH(CH
3)
2、环丙基和-哌嗪基-甲基,其他变量如本发明所定义。在本发明的一些方案中,所述结构单元-L
4-R
3选自
其他变量如本发明所定义。
在本发明的一些方案中,所述结构单元-L
3-CH
2-L
2-L
1-选自-(CH
2)
3-O-#、-(CH
2)
3-NH
2-#、-O-CH
2CH
2-NH-#和-O-CH
2-C(=O)-NH-#,“#”端连接于吡唑基,其他变量如本发明所定义。
本发明还有一些方案是由上述变量任意组合而来。
在本发明的一些方案中,所述化合物或其药学上可接受的盐,其化合物选自
其中,T
3、L
5、R
2、R
3、R
4、R
b和R
f如本发明所定义。
本发明还提供了下列化合物或其药学上可接受的盐,
相关定义
除非另有说明,本文所用的下列术语和短语旨在具有下列含义。一个特定的术语或短语在没有特别定义的情况下不应该被认为是不确定的或不清楚的,而应该按照普通的含义去理解。当本文中出现商品名时,意在指代其对应的商品或其活性成分。
这里所采用的术语“药学上可接受的”,是针对那些化合物、材料、组合物和/或剂型而言,它们在可靠的医学判断的范围之内,适用于与人类和动物的组织接触使用,而没有过多的毒性、刺激性、过敏性反应或其它问题或并发症,与合理的利益/风险比相称。
术语“药学上可接受的盐”是指本发明化合物的盐,由本发明发现的具有特定取代基的化合物与相对无毒的酸或碱制备。当本发明的化合物中含有相对酸性的功能团时,可以通过在纯的溶液或合适的惰性溶 剂中用足够量的碱与这类化合物接触的方式获得碱加成盐。当本发明的化合物中含有相对碱性的官能团时,可以通过在纯的溶液或合适的惰性溶剂中用足够量的酸与这类化合物接触的方式获得酸加成盐。本发明的某些特定的化合物含有碱性和酸性的官能团,从而可以被转换成任一碱或酸加成盐。
本发明的药学上可接受的盐可由含有酸根或碱基的母体化合物通过常规化学方法合成。一般情况下,这样的盐的制备方法是:在水或有机溶剂或两者的混合物中,经由游离酸或碱形式的这些化合物与化学计量的适当的碱或酸反应来制备。
本发明的化合物可以存在特定的几何或立体异构体形式。本发明设想所有的这类化合物,包括顺式和反式异构体、(-)-和(+)-对映体、(R)-和(S)-对映体、非对映异构体、(D)-异构体、(L)-异构体,及其外消旋混合物和其他混合物,例如对映异构体或非对映体富集的混合物,所有这些混合物都属于本发明的范围之内。烷基等取代基中可存在另外的不对称碳原子。所有这些异构体以及它们的混合物,均包括在本发明的范围之内。
除非另有说明,术语“对映异构体”或者“旋光异构体”是指互为镜像关系的立体异构体。
除非另有说明,术语“顺反异构体”或者“几何异构体”系由因双键或者成环碳原子单键不能自由旋转而引起。
除非另有说明,术语“非对映异构体”是指分子具有两个或多个手性中心,并且分子间为非镜像的关系的立体异构体。
除非另有说明,“(+)”表示右旋,“(-)”表示左旋,“(±)”表示外消旋。
除非另有说明,用楔形实线键
和楔形虚线键
表示一个立体中心的绝对构型,用直形实线键
和直形虚线键
表示立体中心的相对构型,用波浪线
表示楔形实线键
或楔形虚线键
或用波浪线
表示直形实线键
和直形虚线键
除非另有说明,术语“互变异构体”或“互变异构体形式”是指在室温下,不同官能团异构体处于动态平衡,并能很快的相互转化。若互变异构体是可能的(如在溶液中),则可以达到互变异构体的化学平衡。例如,质子互变异构体(proton tautomer)(也称质子转移互变异构体(prototropic tautomer))包括通过质子迁移来进行的互相转化,如酮-烯醇异构化和亚胺-烯胺异构化。价键异构体(valence tautomer)包括一些成键电子的重组来进行的相互转化。其中酮-烯醇互变异构化的具体实例是戊烷-2,4-二酮与4-羟基戊-3-烯-2-酮两个互变异构体之间的互变。
为互变异构体。
除非另有说明,术语“富含一种异构体”、“异构体富集”、“富含一种对映体”或者“对映体富集”指其中一种异构体或对映体的含量小于100%,并且,该异构体或对映体的含量大于等于60%,或者大于等于70%, 或者大于等于80%,或者大于等于90%,或者大于等于95%,或者大于等于96%,或者大于等于97%,或者大于等于98%,或者大于等于99%,或者大于等于99.5%,或者大于等于99.6%,或者大于等于99.7%,或者大于等于99.8%,或者大于等于99.9%。
除非另有说明,术语“异构体过量”或“对映体过量”指两种异构体或两种对映体相对百分数之间的差值。例如,其中一种异构体或对映体的含量为90%,另一种异构体或对映体的含量为10%,则异构体或对映体过量(ee值)为80%。
本发明的化合物可以在一个或多个构成该化合物的原子上包含非天然比例的原子同位素。例如,可用放射性同位素标记化合物,比如氚(
3H),碘-125(
125I)或C-14(
14C)。又例如,可用重氢取代氢形成氘代药物,氘与碳构成的键比普通氢与碳构成的键更坚固,相比于未氘化药物,氘代药物有降低毒副作用、增加药物稳定性、增强疗效、延长药物生物半衰期等优势。本发明的化合物的所有同位素组成的变换,无论放射性与否,都包括在本发明的范围之内。
术语“任选”或“任选地”指的是随后描述的事件或状况可能但不是必需出现的,并且该描述包括其中所述事件或状况发生的情况以及所述事件或状况不发生的情况。
术语“被取代的”是指特定原子上的任意一个或多个氢原子被取代基取代,取代基可以包括重氢和氢的变体,只要特定原子的价态是正常的并且取代后的化合物是稳定的。当取代基为氧(即=O)时,意味着两个氢原子被取代。氧取代不会发生在芳香基上。
术语“任选被取代的”是指可以被取代,也可以不被取代,除非另有规定,取代基的种类和数目在化学上可以实现的基础上可以是任意的。
当任何变量(例如R)在化合物的组成或结构中出现一次以上时,其在每一种情况下的定义都是独立的。因此,例如,如果一个基团被0-2个R所取代,则所述基团可以任选地至多被两个R所取代,并且每种情况下的R都有独立的选项。此外,取代基和/或其变体的组合只有在这样的组合会产生稳定的化合物的情况下才是被允许的。
当一个连接基团的数量为0时,比如-(CRR)
0-,表示该连接基团为单键。
当其中一个变量选自单键时,表示其连接的两个基团直接相连,比如A-L-Z中L代表单键时表示该结构实际上是A-Z。
当所列举的连接基团没有指明其连接方向,其连接方向是任意的,例如,
中连接基团L为-M-W-,此时-M-W-既可以按与从左往右的读取顺序相同的方向连接环A和环B构成
也可以按照与从左往右的读取顺序相反的方向连接环A和环B构成
所述连接基团、取代基和/或其变体的组合只有在这样的组合会产生稳定的化合物的情况下才是被允许的。
除非另有规定,当某一基团具有一个或多个可连接位点时,该基团的任意一个或多个位点可以通过化学键与其他基团相连。当该化学键的连接方式是不定位的,且可连接位点存在H原子时,则连接化学键时,该位点的H原子的个数会随所连接化学键的个数而对应减少变成相应价数的基团。所述位点与其他基团连接的化学键可以用直形实线键
直形虚线键
或波浪线
表示。例如-OCH
3中的直形实线键表示通过该基团中的氧原子与其他基团相连;
中的直形虚线键表示通过该基团中的氮原子的两端与其他基团相连;
中的波浪线表示通过该苯基基团中的1和2位碳原子与其他基团相连;
表示该哌啶基上的任意可连接位点可以通过1个化学键与其他基团相连,至少包括
这4种连接方式,即使-N-上画出了H原子,但是
仍包括
这种连接方式的基团,只是在连接1个化学键时,该位点的H会对应减少1个变成相应的一价哌啶基;
表示R可以任意连接在双键的两端,即表示
除非另有规定,术语“卤代素”或“卤素”本身或作为另一取代基的一部分表示氟(F)、氯(Cl)、溴(Br)或碘(I)原子。
除非另有规定,术语“C
1-3烷基”用于表示直链或支链的由1至3个碳原子组成的饱和碳氢基团。所述C
1-3烷基包括C
1-2和C
2-3烷基等;其可以是一价(如甲基)、二价(如亚甲基)或者多价(如次甲基)。C
1-
3烷基的实例包括但不限于甲基(Me)、乙基(Et)、丙基(包括n-丙基和异丙基)等。
除非另有规定,术语“C
1-3烷氨基”表示通过氨基连接到分子的其余部分的那些包含1至3个碳原子的烷基基团。所述C
1-3烷氨基包括C
1-2、C
3和C
2烷氨基等。C
1-3烷氨基的实例包括但不限于-NHCH
3、-N(CH
3)
2、-NHCH
2CH
3、-N(CH
3)CH
2CH
3、-NHCH
2CH
2CH
3、-NHCH
2(CH
3)
2等。
除非另有规定,“C
3-5环烷基”表示由3至5个碳原子组成的饱和环状碳氢基团,其为单环体系,所述C
3-5环烷基包括C
3-4和C
4-5环烷基等;其可以是一价、二价或者多价。C
3-5环烷基的实例包括,但不限于,环丙基、环丁基、环戊基等。
除非另有规定,“C
5-6环烷基”表示由5至6个碳原子组成的饱和环状碳氢基团,其为单环和双环体系,所述C
5-6环烷基包括C
5和C
6环烷基等;其可以是一价、二价或者多价。C
5-6环烷基的实例包括,但不限于,环戊基、环己基等。
除非另有规定,本发明术语“5元杂芳环”和“5元杂芳基”可以互换使用,术语“5元杂芳基”表示由5个环原子组成的具有共轭π电子体系的单环基团,其1、2、3或4个环原子为独立选自O、S和N的杂原子,其余为碳原子。其中氮原子任选地被季铵化,氮和硫杂原子可任选被氧化(即NO和S(O)
p,p是1或2)。5元杂芳基可通过杂原子或碳原子连接到分子的其余部分。所述5元杂芳基实例包括但不限于吡咯基(包 括N-吡咯基、2-吡咯基和3-吡咯基等)、吡唑基(包括2-吡唑基和3-吡唑基等)、咪唑基(包括N-咪唑基、2-咪唑基、4-咪唑基和5-咪唑基等)、噁唑基(包括2-噁唑基、4-噁唑基和5-噁唑基等)、三唑基(1H-1,2,3-三唑基、2H-1,2,3-三唑基、1H-1,2,4-三唑基和4H-1,2,4-三唑基等)、四唑基、异噁唑基(3-异噁唑基、4-异噁唑基和5-异噁唑基等)、噻唑基(包括2-噻唑基、4-噻唑基和5-噻唑基等)、呋喃基(包括2-呋喃基和3-呋喃基等)、噻吩基(包括2-噻吩基和3-噻吩基等)。
除非另有规定,术语“4-5元杂环烷基”本身或者与其他术语联合分别表示由4至5个环原子组成的饱和单环基团,其1、2、3或4个环原子为独立选自O、S和N的杂原子,其余为碳原子,其中氮原子任选地被季铵化,氮和硫杂原子可任选被氧化(即NO和S(O)
p,p是1或2)。此外,就该“4-5元杂环烷基”而言,杂原子可以占据杂环烷基与分子其余部分的连接位置。所述4-5元杂环烷基包括4元和5元杂环烷基。4-5元杂环烷基的实例包括但不限于氮杂环丁基、氧杂环丁基、硫杂环丁基、吡咯烷基、吡唑烷基、咪唑烷基、四氢噻吩基(包括四氢噻吩-2-基和四氢噻吩-3-基等)或四氢呋喃基(包括四氢呋喃-2-基等)等。
除非另有规定,术语“4-6元杂环烷基”本身或者与其他术语联合分别表示由4至6个环原子组成的饱和环状基团,其1、2、3或4个环原子为独立选自O、S和N的杂原子,其余为碳原子,其中氮原子任选地被季铵化,氮和硫杂原子可任选被氧化(即NO和S(O)
p,p是1或2)。其包括单环和双环体系,其中双环体系包括螺环、并环和桥环。此外,就该“4-6元杂环烷基”而言,杂原子可以占据杂环烷基与分子其余部分的连接位置。所述4-6元杂环烷基包括5-6元、4元、5元和6元杂环烷基等。4-6元杂环烷基的实例包括但不限于氮杂环丁基、氧杂环丁基、硫杂环丁基、吡咯烷基、吡唑烷基、咪唑烷基、四氢噻吩基(包括四氢噻吩-2-基和四氢噻吩-3-基等)、四氢呋喃基(包括四氢呋喃-2-基等)、四氢吡喃基、哌啶基(包括1-哌啶基、2-哌啶基和3-哌啶基等)、哌嗪基(包括1-哌嗪基和2-哌嗪基等)、吗啉基(包括3-吗啉基和4-吗啉基等)、二噁烷基、二噻烷基、异噁唑烷基、异噻唑烷基、1,2-噁嗪基、1,2-噻嗪基或六氢哒嗪基等。
除非另有规定,术语“5-6元杂环烷基”本身或者与其他术语联合分别表示由5至6个环原子组成的饱和或部分不饱和环状基团,其1、2、3或4个环原子为独立选自O、S和N的杂原子,其余为碳原子,其中氮原子任选地被季铵化,氮和硫杂原子可任选被氧化(即NO和S(O)
p,p是1或2)。其包括单环和双环体系,其中双环体系包括螺环、并环和桥环。此外,就该“5-6元杂环烷基”而言,杂原子可以占据杂环烷基与分子其余部分的连接位置。所述5-6元杂环烷基包括5元和6元杂环烷基。5-6元杂环烷基的实例包括但不限于吡咯烷基、吡唑烷基、咪唑烷基、四氢噻吩基(包括四氢噻吩-2-基和四氢噻吩-3-基等)、四氢呋喃基(包括四氢呋喃-2-基等)、四氢吡喃基、哌啶基(包括1-哌啶基、2-哌啶基和3-哌啶基等)、哌嗪基(包括1-哌嗪基和2-哌嗪基等)、吗啉基(包括3-吗啉基和4-吗啉基等)、二噁烷基、二噻烷基、异噁唑烷基、异噻唑烷基、1,2-噁嗪基、1,2-噻嗪基、六氢哒嗪基、高哌嗪基或高哌啶基等。
除非另有规定,术语“5-6元单环杂环烷基”本身或者与其他术语联合分别表示由5至6个环原子组成的饱和或部分不饱和环状基团,其1、2、3或4个环原子为独立选自O、S和N的杂原子,其余为碳原子,其中氮原子任选地被季铵化,氮和硫杂原子可任选被氧化(即NO和S(O)
p,p是1或2),其仅为单环。
除非另有规定,术语“7-11元杂环烷基”本身或者与其他术语联合分别表示由7至11个环原子组成的 饱和环状基团,其1、2、3或4个环原子为独立选自O、S和N的杂原子,其余为碳原子,其中氮原子任选地被季铵化,氮和硫杂原子可任选被氧化(即NO和S(O)
p,p是1或2)。所述其包括单环、双环和三环体系,其中双环和三环体系包括螺环、并环和桥环。此外,就该“7-11元杂环烷基”而言,杂原子可以占据杂环烷基与分子其余部分的连接位置。所述7-11元杂环烷基包括7元、8元、9元、10和11元杂环烷基等。7-11元杂环烷基的实例包括但不限于高哌嗪基、高哌啶基或二氧杂环庚烷基等。
除非另有规定,术语“7-11元双环杂环烷基”本身或者与其他术语联合分别表示由7至11个环原子组成的饱和环状基团,其1、2、3或4个环原子为独立选自O、S和N的杂原子,其余为碳原子,其中氮原子任选地被季铵化,氮和硫杂原子可任选被氧化(即NO和S(O)
p,p是1或2),所述双环体系包括螺环、并环和桥环。
除非另有规定,术语“5-11元杂环烷基”本身或者与其他术语联合分别表示由5至11个环原子组成的饱和环状基团,其1、2、3或4个环原子为独立选自O、S和N的杂原子,其余为碳原子,其中氮原子任选地被季铵化,氮和硫杂原子可任选被氧化(即NO和S(O)
p,p是1或2)。所述其包括单环、双环和三环体系,其中双环和三环体系包括螺环、并环和桥环。此外,就该“5-11元杂环烷基”而言,杂原子可以占据杂环烷基与分子其余部分的连接位置。所述5-11元杂环烷基包括5-10元、5-9元、5-8元、5-7元、5-6元、5元、6元、7元、8元、9元、10和11元杂环烷基等。5-11元杂环烷基的实例包括但不限于吡咯烷基、吡唑烷基、咪唑烷基、四氢噻吩基(包括四氢噻吩-2-基和四氢噻吩-3-基等)、四氢呋喃基(包括四氢呋喃-2-基等)、四氢吡喃基、哌啶基(包括1-哌啶基、2-哌啶基和3-哌啶基等)、哌嗪基(包括1-哌嗪基和2-哌嗪基等)、吗啉基(包括3-吗啉基和4-吗啉基等)、二噁烷基、二噻烷基、异噁唑烷基、异噻唑烷基、1,2-噁嗪基、1,2-噻嗪基、六氢哒嗪基、高哌嗪基、高哌啶基或二氧杂环庚烷基等。
除非另有规定,C
n-n+m或C
n-C
n+m包括n至n+m个碳的任何一种具体情况,例如C
1-12包括C
1、C
2、C
3、C
4、C
5、C
6、C
7、C
8、C
9、C
10、C
11、和C
12,也包括n至n+m中的任何一个范围,例如C
1-12包括C
1-
3、C
1-6、C
1-9、C
3-6、C
3-9、C
3-12、C
6-9、C
6-12、和C
9-12等;同理,n元至n+m元表示环上原子数为n至n+m个,例如3-12元环包括3元环、4元环、5元环、6元环、7元环、8元环、9元环、10元环、11元环、和12元环,也包括n至n+m中的任何一个范围,例如3-12元环包括3-6元环、3-9元环、5-6元环、5-7元环、6-7元环、6-8元环、和6-10元环等。
本发明的化合物可以通过本领域技术人员所熟知的多种合成方法来制备,包括下面列举的具体实施方式、其与其他化学合成方法的结合所形成的实施方式以及本领域技术上人员所熟知的等同替换方式,优选的实施方式包括但不限于本发明的实施例。
本发明的化合物可以通过本领域技术人员所熟知的常规方法来确认结构,如果本发明涉及化合物的绝对构型,则该绝对构型可以通过本领域常规技术手段予以确证。例如单晶X射线衍射法(SXRD),把培养出的单晶用Bruker D8 venture衍射仪收集衍射强度数据,光源为CuKα辐射,扫描方式:φ/ω扫描,收集相关数据后,进一步采用直接法(Shelxs97)解析晶体结构,便可以确证绝对构型。
本发明所使用的溶剂可经市售获得。
本发明化合物对携带EGFR(L858R/T790M/C797S)、EGFR(del19-E746-A750/T790M/C797S)三突变的激酶展现了较高的抑制活性;对携带EGFR(L858R/T790M/C797S)、EGFR(del19-E746-A750/T790M/C797S)三突变的细胞株表现出极强的细胞增殖抑制活性,对携带EGFR(L858R/T790M)、EGFR(del19-E746-A750/T790M)、EGFR(del19-E746-A750/C797S)和EGFR(L858R/C797S)二突变的细胞株也都展现了较高的细胞增殖抑制活性;对携带EGFR(L858R/T790M/C797S)、EGFR(del19/T790M/C797S)三突变的细胞株的EGFR磷酸化有着良好的抑制作用。并且,对EGFR(WT)激酶和细胞株抑制较弱,具有很好的选择性。本发明化合物对P450同工酶抑制作用弱。本发明化合物还具有优异的药代动力学特性,优异的肿瘤抑制作用。
下面通过实施例对本发明进行详细描述,但并不意味着对本发明任何不利限制。本文已经详细地描述了本发明,其中也公开了其具体实施例方式,对本领域的技术人员而言,在不脱离本发明精神和范围的情况下针对本发明具体实施方式进行各种变化和改进将是显而易见的。
参考例1
步骤1:化合物A-1的合成
将A-1-1(2.11g,21.55mmol,2eq),碳酸氢钠(3.43g,32.33mmol,3eq)以及[1,1'-双(二苯基膦)二茂铁]二氯化钯二氯甲烷络合物(8.80g,10.78mmol,1eq)加入到苯甲醚(40mL)中,反应液在130℃下搅拌反应16小时。反应结束后,反应液经硅藻土过滤得滤液,滤饼再用甲苯(30mL)洗3次,合并得到黑色滤液。向黑色滤液中加入20mL甲醇,搅拌下滴加4M氯化氢/1,4-二氧六环(30mL),滴加完成后继续室温搅拌1小时,有固体析出。随后过滤得滤饼,滤饼依次用甲苯(60mL)和正庚烷(60mL)洗,再将滤饼真空旋干,得A-1。LCMS m/z=248.0[M+H]
+。
参考例2
步骤1:化合物B-1的合成
将B-1-1(1.38g,10.00mmol,1.29mL,1eq)溶于THF(30mL),冷却至-70℃,滴加异丙基氯化镁的THF溶液(2M,3.09g,30mmol,15mL,3eq)搅拌2小时,然后缓慢升温至25℃搅拌3小时。随后冷却至0℃,加0.5M盐酸水溶液(40mL)淬灭反应,用乙酸乙酯30mL萃取3次,合并有机相,饱和氯化钠溶液(20mL)洗一次,无水硫酸钠干燥,过滤,减压浓缩。
1H NMR(400MHz,CDCl
3)δ=6.27(dt,1H,J=432,3.0 Hz),2.02-1.83(m,2H),1.24-1.08(m,12H)。
参考例3
步骤1:化合物C-1的合成
将B-1-1(1.38g,10.00mmol,1.29mL,1eq)溶于THF(30mL),冷却至-70℃,滴加环丙基溴化镁的THF溶液(0.5M,3.09g,30mmol,60mL,3eq)搅拌2小时,然后缓慢升温至25℃搅拌3小时。随后冷却至0℃,加0.5M盐酸水溶液(40mL)淬灭反应,用乙酸乙酯30mL萃取三次,合并有机相,饱和氯化钠溶液(20mL)洗一次,无水硫酸钠干燥,过滤,减压浓缩得到化合物C-1。LCMS m/z=131.2[M+H]
+。
参考例4
步骤1:化合物D-1的合成
将D-1-1(200mg,1.96mmol,1eq)溶于甲醇(20mL),加入醋酸碘苯(1.89g,5.87mmol,3eq)和乙酸铵(603.40mg,7.83mmol,4eq),25℃搅拌4小时。反应液真空浓缩得粗品。粗品经硅胶柱层析分离纯化(梯度淋洗:二氯甲烷/甲醇=100:0~100:5),得到D-1。
1H NMR(400MHz,CDCl
3)δ=3.04-2.96(m,4H),2.06-1.95(m,4H),1.63-1.52(m,2H);LCMS m/z=134.1[M+H]
+。
参考例5
步骤1:化合物E-1的合成
将E-1-1(200mg,2.22mmol,1eq)溶于甲醇(20mL),加入醋酸碘苯(2.14g,6.65mmol,3eq)和乙酸铵(683.76mg,8.87mmol,4eq),25℃搅拌4小时。反应液真空浓缩得粗品。粗品经硅胶柱层析分离纯化(梯度淋洗:二氯甲烷/甲醇=100:0~100:5),得到E-1。
1H NMR(400MHz,CDCl
3)δ=3.09-2.94(m,4H),1.34(t,J=7.5Hz,6H);LCMS m/z=122.1[M+H]
+。
参考例6
步骤1:化合物F-1的合成
将F-1-1(200mg,1.92mmol,1eq)溶于甲醇(10mL),加入醋酸碘苯(1.86g,5.76mmol,3eq)和乙酸铵(591.97mg,7.68mmol,4eq),25℃搅拌4小时。反应液真空浓缩得粗品。粗品经硅胶柱层析分离纯化(梯度淋洗:二氯甲烷/甲醇=100:0~100:5),得到F-1。
1H NMR(400MHz,CDCl
3)δ=4.05(br s,4H),3.09(br s,4H),1.97(s,1H);LCMS m/z=136.2[M+H]
+。
参考例7
步骤1:化合物G-1-2的合成
将G-1-1(200mg,1.94mmol,1eq)溶于二氯甲烷(10mL),加入二碳酸二叔丁酯(846mg,3.88mmol,2eq),三乙胺(0.81mL,5.81mmol,3eq)和二甲氨基吡啶(118mg,0.97mmol,0.5eq),25℃搅拌16小时。反应液减压浓缩得粗品。粗品经硅胶柱层析分离纯化(梯度淋洗:二氯甲烷/甲醇=100:0~100:10),得到G-1-2。
1H NMR(400MHz,CDCl
3)δ=3.51-3.72(m,4H),2.41-2.63(m,4H),1.39(s,9H)。
步骤2:化合物G-1的合成
将G-1-2(400mg,1.97mmol,1eq)溶于甲醇(5mL),加入醋酸碘苯((1.90g,5.90mmol,3eq)和乙酸铵(606.65mg,7.87mmol,4eq),25℃搅拌2小时。反应液真空浓缩得粗品。粗品经硅胶柱层析分离纯化(梯度淋洗:二氯甲烷/甲醇=100:0~100:3),得到G-1。
1H NMR(400MHz,CDCl
3)δ=3.56-4.08(m,4H),2.93-3.09(m,4H),1.31-1.53(s,9H)。
参考例8
步骤1:化合物H-1-2的合成
将氰乙酸乙酯(1.78g,15.77mmol,3eq)溶于甲醇(5mL)中,加入醋酸铵(40.51mg,525.59μmol,0.1eq),然后滴加H-1-1(994.70mg,5.26mmol,974.24μL,1eq),最后加入氨水(0.75mL),25℃搅拌24小时。反应结束后,加入1mL浓盐酸,析出固体,抽滤,用乙酸乙酯洗涤滤饼,得到H-1-2。LCMS m/z=323.1[M+1]
+。
步骤2:化合物H-1-3的合成
将硫酸(60mL)与水(40mL)混合,分批加入H-1-2(10g,31.02mmol,1eq),逐渐升温至130℃搅拌24小时。反应结束后,减压浓缩。随后溶于乙醇(110mL)中,120℃反应20小时。再次反应完全后,冷却。随后在冰浴下加入碳酸氢钠(40g),再加入水(100mL)和二氯甲烷(200mL)萃取,有机相用无水硫酸钠干燥,过滤浓缩得到H-1-3。LCMS m/z=348.3[M+1]
+。
步骤3:化合物H-1-4的合成
将化合物H-1-3(3.1g,8.92mmol,1eq)溶于四氢呋喃(3mL)中,氮气保护,0℃下分批加入氢化锂铝(677.27mg,17.84mmol,2eq),25℃搅拌过夜。搅拌下缓慢加入十水硫酸钠淬灭,过滤,四氢呋喃洗涤,浓缩得到化合物H-1-4。LCMS m/z=264.2[M+1]
+。
步骤4:化合物H-1-5的合成
将化合物H-1-4(3.98g,15.13mmol,1eq)溶于甲醇(70mL)中,加入二碳酸二叔丁酯(3.30g,15.13mmol,3.48mL,1eq),加入氢氧化钯(640mg,4.56mmol,0.301eq),在氢气下40℃搅拌12小时。随后反应液经硅藻土过滤,滤液减压浓缩,得到化合物H-1-5。
1H NMR(400MHz,CDCl
3)δ=3.77(t,J=6.7Hz,4H),3.50(s,2H),3.44-3.38(m,4H),1.72(t,J=6.7Hz,4H),1.49-1.42(m,13H).
步骤5:化合物H-1-6的合成
将化合物H-1-5(1.76g,6.45mmol,1eq)溶于二氯甲烷(25mL)中,冷却至-20℃加入甲基磺酰氯(2.43g,21.21mmol,3.29eq),三乙胺(2.61g,25.82mmol,4eq),搅拌30分钟。向反应液中缓慢加入30mL水淬灭,加入40mL二氯甲烷萃取,有机相收集干燥后浓缩,粗品经硅胶柱层析分离纯化,得到化合物H-1-6。
1H NMR(400MHz,CDCl
3)δ=4.25(t,J=6.9Hz,4H),3.38-3.32(m,4H),2.97(s,6H),1.82(t,J=7.0Hz,4H),1.41(br d,J=5.8Hz,4H),1.38(s,9H)。
步骤6:化合物H-1-7的合成
将化合物H-1-6(0.5g,1.16mmol,1eq)溶于N,N-二甲基甲酰胺(4mL)中,加入九水合硫化钠(335.49mg,1.40mmol 1.2eq),50℃搅拌12小时。加入50mL乙酸乙酯和20mL水萃取,收集有机相干燥后浓缩。粗品经硅胶柱层析分离纯化,得到化合物H-1-7。
1H NMR(400MHz,CDCl
3)δ=3.44-3.36(m,4H),2.66-2.59(m,4H),1.78-1.72(m,4H),1.49-1.42(m,13H)。
步骤7:化合物H-1的合成
将H-1-7(0.25g,921.09μmol,1eq)溶于甲醇(5mL),加入醋酸碘苯(890.04mg,2.76mmol,3eq)和乙酸铵(284.00mg,3.68mmol,4eq),25℃搅拌2小时。反应液真空浓缩得粗品。粗品经硅胶柱层析分离纯化,得到化合物H-1。
1H NMR(400MHz,CDCl
3)δ=3.42(br d,J=4.1Hz,4H),3.12-3.03(m,4H),2.01(br t,J=5.9Hz,4H),1.55-1.51(m,4H),1.47(s,9H).
参考例9
步骤1:化合物I-1-2的合成
将化合物I-1-1(5.93g,24.98mmol,1.2eq),顺丁烯二酸二甲酯(3g,20.82mmol,1eq)溶于二氯甲烷(20mL)中,加入三氟乙酸(237.34mg,2.08mmol,0.1eq),25℃搅拌12小时。加入20mL水,50mL二氯甲烷萃取,有机相用饱和食盐水洗,无水硫酸钠干燥,过滤,浓缩。粗品经硅胶柱层析分离纯化,得到I-1-2。
1H NMR(400MHz,CDCl
3)δ=7.31-7.16(m,5H),3.67-3.56(m,8H),3.29-3.21(m,2H),3.13-3.03(m,2H),2.72-2.61(m,2H)。
步骤2:化合物I-1-3的合成
将I-1-2溶于甲醇(100mL),加入二碳酸二叔丁酯(4.72g,21.64mmol,2eq),氢氧化钯(1.52g,2.16mmol,0.2eq),在氢气下25℃搅拌48小时。反应液经硅藻土过滤,浓缩得到I-1-3。
1H NMR(400MHz,CDCl
3)δ=3.73-3.62(m,8H),3.62-3.54(m,2H),3.29-3.15(m,2H),1.46-1.36(m,9H)。
步骤3:化合物I-1-4的合成
将I-1-3(1.6g,5.57mmol,1eq)溶于四氢呋喃(20mL),-5℃下加入氢化锂铝(634.02mg,16.71mmol,3eq),-5℃搅拌2小时。随后,缓慢加入十水硫酸钠淬灭,搅拌10分钟,过滤,浓缩得到I-1-4。
1H NMR(400MHz,CDCl
3)δ=4.19-3.86(m,2H),3.70-3.55(m,4H),3.45-3.29(m,2H),3.18-2.97(m,2H),2.44(br d,J=3.6Hz,2H),1.37(s,9H).
步骤4:化合物I-1-5的合成
将化合物I-1-4(580mg,2.51mmol,1eq)溶于二氯甲烷(12mL)中,降温至0℃,加入三乙胺(1.27g,12.54mmol,5eq),甲基磺酰氯(890mg,7.77mmol,3.10eq),0℃下搅拌4小时。检测原料反应完全,停止搅拌。向反应液中缓慢加入水10mL和二氯甲烷15mL分液萃取,收集有机相,无水硫酸钠干燥后过滤,浓缩。粗品经硅胶柱层析分离纯化,得到化合物I-1-5。
1H NMR(400MHz,CDCl
3)δ=4.25(br dd,J=5.8,12.8Hz,2H),4.21-4.15(m,2H),3.54-3.46(m,2H),3.30-3.22(m,2H),2.99(s,6H),2.76-2.68(m,2H),1.40(s,9H)。
步骤5:化合物I-1-6的合成
将化合物I-1-5(500mg,1.29mmol,1eq)溶于N,N-二甲基甲酰胺(5mL)中,加入九水合硫化钠(371.92mg,1.55mmol,1.2eq),氮气保护,50℃搅拌16小时。反应液中加入15mL水和30mL乙酸乙酯萃取,有机相经饱和氯化钠溶液洗1次,无水硫酸钠干燥。粗品经硅胶柱层析分离纯化,得到化合物I-1-6。
1H NMR (400MHz,CDCl
3)δ=3.56(br d,J=6.9Hz,2H),3.32-3.11(m,2H),3.07-2.98(m,2H),2.98-2.95(m,2H),2.71(br dd,J=3.8,10.8Hz,2H),1.43(s,9H)。
步骤6:化合物I-1的合成
将化合物I-1-6(300mg,1.31mmol,1eq),乙酸铵(403.33mg,5.23mmol,4eq),醋酸碘苯(1.26g,3.92mmol,3eq)溶于乙醇(6mL)中,25℃搅拌2小时。原料反应完全后将反应液浓缩,粗品经硅胶柱层析分离纯化,得到化合物I-1。
1H NMR(400MHz,CDCl
3)δ=3.77-3.70(m,2H),3.50-3.38(m,4H),3.20-3.10(m,4H),1.49(s,9H)。
参考例10
步骤1:化合物J-1-2的合成
将J-1-1溶于N,N-二甲基甲酰胺(25mL),分批加入九水合硫化钠(1.62g,6.76mmol,1.1eq),50℃反应7小时。加入50mL水,100mL乙酸乙酯萃取,饱和氯化钠溶液洗,无水硫酸钠干燥,过滤,浓缩。硅胶柱层析得到化合物J-1-2。
1H NMR(400MHz,CDCl
3)δ=4.81-4.62(m,4H),3.50-3.27(m,4H)。
步骤2:化合物J-1的合成
将J-1-2(0.2g,1.72mmol,1eq),乙酸铵(530.77mg,6.89mmol,4eq),醋酸碘苯(1.66g,5.16mmol,3eq)溶于甲醇(5mL),25℃搅拌2小时。浓缩反应液,硅胶柱层析得到化合物J-1。
1H NMR(400MHz,CDCl
3)δ=4.24(s,4H),3.62(d,J=3.0Hz,4H)。
参考例11
步骤1:化合物K-1-2的合成
将1-叔丁氧羰基哌嗪(961.86mg,5.16mmol,1.2eq),K-1-1(500mg,4.30mmol,1eq)溶于乙醇(9mL),加入乙酸(0.3mL),三乙酰氧基硼氢化钠(1.82g,8.61mmol,2eq),25℃搅拌16小时。随后加入10mL水淬灭,50mL乙酸乙酯萃取,饱和氯化钠溶液洗,无水硫酸钠干燥,过滤,浓缩。粗品经硅胶柱层析分离,得到化合物K-1-2。
1H NMR(400MHz,CDCl
3)δ=3.50-3.35(m,4H),2.75-2.67(m,4H),2.58-2.47(m,4H),2.43-2.32(m,1H),2.12(br dd,J=2.9,12.7Hz,2H),1.78-1.64(m,2H),1.51-1.41(m,9H)。
步骤2:化合物K-1的合成
将K-1-2(90mg,314.21μmol,1eq)溶于甲醇(2mL),加入乙酸铵(96.88mg,1.26mmol,4eq)和醋酸碘苯(303.62mg,942.63μmol,3eq),25℃搅拌2小时。反应液直接浓缩,经经硅胶柱层析分离,得到化合物K-1。
1H NMR(400MHz,CDCl
3)δ=3.40-3.32(m,4H),3.20(ddd,J=3.0,7.3,11.0Hz,2H),3.02-2.90(m,2H),2.54-2.47(m,1H),2.45-2.37(m,4H),2.23-2.01(m,4H),1.42-1.36(m,9H)。
参考例12
步骤1:化合物L-1-2的合成
将L-1-1(21.00g,132.78mmol,1eq)溶于甲醇(200mL)中,加入浓硫酸(13.02g,132.78mmol,7.08mL,1eq),80℃搅拌16小时。浓缩反应液,用200mL乙酸乙酯溶解,加入200mL水,有机相用100mL饱和氯化钠水溶液洗涤,无水硫酸钠干燥,过滤,滤液浓缩得到化合物L-1-2。LCMS m/z:187.1[M+H]
+。
步骤2:化合物L-1-3的合成
将L-1-2(24.67g,132.49mmol,1eq)和氢氧化钠(5.30g,132.49mmol,1eq)加入MeOH(200mL)中,25℃反应12小时。反应液过滤,滤液浓缩后加200mL水溶解,调pH至2,加入200mL乙酸乙酯萃取,有机相用100mL饱和氯化钠水溶液洗涤,无水硫酸钠干燥,过滤,滤液浓缩得到L-1-3。
1H NMR(400MHz,DMSO-d
6)δ=12.12(br s,1H),3.59(s,3H),2.94-2.62(m,2H),2.03-1.64(m,6H)。LCMS m/z:173.1[M+H]
+。
步骤3:化合物L-1-4的合成
将L-1-3溶于氨水(136.50g,1.09mol,9.48eq),25℃搅拌16小时。反应液直接浓缩得到L-1-4。
1H NMR(400MHz,DMSO-d
6)δ=7.53(br s,1H),6.68(br s,1H),2.66-2.55(m,1H),1.98-1.83(m,1H),1.83-1.49(m,6H)。LCMS m/z=158.1[M+1]
+。
步骤5:化合物L-1-5的合成
将化合物L-1-4(19g,120.89mmol,1eq)溶于四氢呋喃(100mL),冷却降至0℃,氮气保护,滴加硼烷二甲硫醚(10M,54.40mL,4.5eq),控制内温小于20℃,滴加完后缓慢升温至室温20℃,搅拌2小时。然后升温至80℃反应16小时。将反应冷却到0℃缓慢向反应液里滴加甲醇(50mL)的四氢呋喃溶液(100mL)淬灭反应,检测内温,保持小于25℃,搅拌2小时,之后直接浓缩得到L-1。LCMS m/z=130.2[M+1]
+
参考例13
步骤1:化合物M-1-2的合成
将氰乙酸乙酯(33.90g,299.65mmol,31.98mL,3eq)溶于甲醇(40mL),加入氨水(15.38mL),再加入化合物M-1-1(10g,99.88mmol 1eq),最后加入乙酸铵(769.94mg,9.99mmol,0.1eq),25℃搅拌16小时。反应结束后,加入15mL浓盐酸,析出固体,抽滤,用乙醇洗涤滤饼,得到化合物M-1-2。
1H NMR(400MHz,DMSO-d
6)δ=12.28(s,1H),5.09(s,2H),3.75-3.60(m,4H),1.86-1.63(m,4H).
步骤2:化合物M-1-3的合成
将M-1-2(14g,60.03mmol,1eq)加入硫酸(60mL)与水(40mL)的混合溶液中,升温至130℃搅拌16小时。反应结束后,减压浓缩。随后加入乙醇(60mL)中,120℃反应12小时。反应完全后,冷却。随后在冰浴下加入碳酸氢钠(50g),再加入乙酸乙酯(300mL)萃取,饱和食盐水洗一次,有机相用无水硫酸钠干燥,过滤浓缩得到M-1-3。
1H NMR(400MHz,CDCl
3)δ=4.14-4.00(m,4H),3.68-3.59(m,4H),2.57-2.50(m,4H),1.67-1.56(m,4H),1.23-1.14(m,6H).
步骤3:化合物M-1-4的合成
将化合物M-1-3(200mg,774.26μmol,1eq)溶于四氢呋喃(5mL)中,氮气保护,0℃下分批加入氢化锂铝(705.28mg,18.58mmol,3eq),25℃搅拌过夜。搅拌下缓慢加入十水硫酸钠淬灭,过滤,四氢呋喃洗涤,浓缩得到化合物M-1-4。
1H NMR(400MHz,CDCl
3)δ=3.81-3.73(m,4H),3.72-3.64(m,4H),1.77(t,J=6.7Hz,4H),1.56-1.48(m,4H).
步骤5:化合物M-1-5的合成
将化合物M-1-4(115mg,660.02μmol,1eq)溶于二氯甲烷(5mL)中,冷却至0℃加入甲基磺酰氯(260mg,2.27mmol,3.44eq),三乙胺(267.15mg,2.64mmol,4eq),搅拌30分钟。向反应液中缓慢加入30mL水淬灭,加入40mL二氯甲烷萃取,饱和食盐水洗一次,有机相收集干燥后浓缩,得到化合物M-1-5。
1H NMR(400MHz,CDCl
3)δ=4.25(t,J=6.9Hz,4H),3.38-3.32(m,4H),2.97(s,6H),1.82(t,J=7.0Hz,4H),1.47(t,J=5.3Hz,4H)。
步骤6:化合物M-1-6的合成
将化合物M-1-5(210mg,635.56μmol,1eq)溶于N,N-二甲基甲酰胺(4mL)中,加入硫化钠(59.52mg,762.67μmol,1.2eq),50℃搅拌12小时。加入50mL乙酸乙酯和20mL水萃取,收集有机相干燥后浓 缩。粗品经硅胶柱层析分离纯化,得到化合物M-1-6。
1H NMR(400MHz,CDCl
3)δ=3.71-3.64(m,4H),2.68-2.59(m,4H),1.86-1.77(m,4H),1.55-1.47(m,4H)。
步骤7:化合物M-1的合成
将M-1-6(250mg,1.45mmol,1eq)溶于甲醇(5mL),加入醋酸碘苯(1.40g,4.35mmol,3eq)和乙酸铵(447.41mg,5.80mmol,4eq),25℃搅拌2小时。反应液真空浓缩得粗品。粗品经硅胶柱层析分离纯化,得到化合物M-1。
1H NMR(400MHz,CDCl
3)δ=3.88-3.71(m,1H),3.67-3.57(m,4H),3.02(br d,J=5.0Hz,4H),1.99(br d,J=4.3Hz,4H),1.53(br d,J=4.3Hz,4H).
参考例14
步骤1:化合物N-1-2的合成
称取氢化钠(844.09mg,21.10mmol,3eq)于反应瓶中,置换氮气,0℃下缓慢加入四氢呋喃(8mL),搅拌10分钟,缓慢滴加丙二酸二乙酯(3.94g,24.62mmol,3.5eq),升温至25℃搅拌20分钟,加入四丁基溴化铵(907.10mg,2.81mmol,0.4eq)以及化合物N-1-1(1g,7.03mmol,1eq)的四氢呋喃(1.65mL)溶液,于25℃搅拌16小时。随后,加入乙酸(1.5mL)淬灭反应,加入40mL乙酸乙酯,有机相用饱和氯化钠水溶液洗三次,无水硫酸钠干燥,过滤,浓缩。粗品经硅胶柱层析分离,得到化合物N-1-2。
1H NMR(400MHz,CDCl
3)δ=4.70(d,J=7.0Hz,2H),4.52(d,J=7.0Hz,2H),4.16(q,J=7.0Hz,4H),4.07(q,J=7.3Hz,2H),3.90(s,1H),2.92(s,2H),1.28-1.17(m,9H).
步骤2:化合物N-1-3的合成
将化合物N-1-2(0.5g,1.65mmol,1eq)溶于二甲基亚砜(5mL)中,加入氯化钠(193.31mg,3.31mmol,2eq)和水(0.1mL),逐渐升温至160℃搅拌3.5小时。随后冷却至室温,加入40mL乙酸乙酯,用20mL饱和食盐水洗一次,水层再用20mL乙酸乙酯洗一次,合并两次有机相,用20mL饱和食盐水再洗两次,有机相用无水硫酸钠干燥,浓缩。粗品经硅胶柱层析分离,得到化合物N-1-3。
1H NMR(400MHz,CDCl
3)δ=4.56(s,4H),4.14(q,J=7.1Hz,4H),2.92(s,4H),1.26(t,J=7.1Hz,6H).
步骤3:化合物N-1-4的合成
称取四氢锂铝(219.21mg,5.78mmol,3.8eq)于反应瓶中,置换氮气,0℃下缓慢加入四氢呋喃(10mL),搅拌10分钟,再缓慢滴加N-1-3(0.35g,1.52mmol,1eq)的四氢呋喃(0.5mL)溶液,搅拌2小时,氮气流保护下缓慢加入1mL水和1.5mL的15%氢氧化钠水溶液,再加入20mL四氢呋喃,用无水硫酸钠干燥,过 滤。用四氢呋喃洗两次滤饼,合并滤液与洗液,减压浓缩,得到化合物N-1-4。
1H NMR(400MHz,CDCl
3)δ=4.51-4.37(m,4H),3.81-3.63(m,4H),2.05-1.95(m,4H).
步骤4:化合物N-1-5的合成
将化合物N-1-4(0.2g,1.37mmol,1eq)溶于二氯甲烷(8mL)中,降温至0℃,加入甲基磺酰氯(0.510g,4.45mmol,3.25eq),三乙胺(692.20mg,6.84mmol,5eq),0℃下搅拌4小时。随后,向反应液中缓慢加入10mL冰水淬灭,加入20mL二氯甲烷萃取两次,有机相合并,干燥,浓缩,得到化合物N-1-5。
1H NMR(400MHz,CDCl
3)δ=4.42(s,4H),4.28(t,J=6.4Hz,4H),2.96(s,6H),2.20(t,J=6.4Hz,4H).
步骤5:化合物N-1-6的合成
将化合物N-1-5(0.35g,1.16mmol,1eq)溶于N,N-二甲基甲酰胺(5mL),加入硫化钠(333.63mg,1.39mmol,1.2eq),50℃搅拌12小时。加入10mL水,用20mL乙酸乙酯萃取3次,收集有机相,用20mL饱和食盐水洗两次,无水硫酸钠干燥后浓缩。硅胶柱层析分离,得到化合物N-1-6。
1H NMR(400MHz,CDCl
3)δ=4.30(s,4H),2.53-2.43(m,4H),2.08-1.98(m,4H).
步骤6:化合物N-1的合成
将化合物N-1-6(0.1g,693.32μmol,1eq),乙酸铵(213.76mg,2.77mmol,4eq),醋酸碘苯(669.95mg,2.08mmol,3eq)溶于甲醇(4mL),25℃搅拌2小时。随后浓缩反应液,粗品经硅胶柱层析分离纯化,得到化合物N-1。
1H NMR(400MHz,CDCl
3)δ=4.46-4.29(m,4H),2.96(br d,J=4.3Hz,4H),2.33(br s,4H).
参考例15
步骤1:化合物O-1-2的合成
称取氢化钠(497.34mg,12.43mmol,3eq)于反应瓶中,置换氮气,0℃下缓慢加入四氢呋喃(8mL),搅拌10分钟,缓慢滴加丙二酸二乙酯(2.32g,14.51mmol,3.5eq),升温至25℃搅拌20分钟,加入四丁基溴化铵(534.42mg,1.66mmol,0.4eq)以及化合物O-1-1(1g,4.14mmol,1eq)的四氢呋喃(1.65mL)溶液,于25℃搅拌18小时。随后,加入乙酸(1.5mL)淬灭反应,加入40mL乙酸乙酯,有机相用饱和氯化钠水溶液洗三次,无水硫酸钠干燥,过滤,浓缩。粗品经硅胶柱层析分离,得到化合物O-1-2。
1H NMR(400MHz,CDCl
3)δ=4.26-4.18(m,4H),4.17-4.07(m,4H),3.91(s,1H),3.84(d,J=9.5Hz,2H),2.88(s,2H),1.43(s,9H),1.27(q,J=7.1Hz,9H).
步骤2:化合物O-1-3的合成
将化合物O-1-2(6.5g,16.19mmol,1eq)溶于二甲基亚砜(65mL)中,加入氯化钠(1.89g,32.38mmol,2eq)和水(0.9mL),逐渐升温至160℃搅拌3.5小时。随后冷却至室温,加入300mL乙酸乙酯,用150mL饱和食盐水洗一次,水层再用200mL乙酸乙酯洗一次,合并两次有机相,用200mL饱和食盐水再洗两次,有机相用无水硫酸钠干燥,浓缩。粗品经硅胶柱层析分离,得到化合物O-1-3。
1H NMR(400MHz,CDCl
3)δ=4.18-4.13(m,4H),3.85-3.82(m,4H),2.82(s,4H),1.49-1.41(m,9H),1.30-1.26(m,6H).
步骤3:化合物O-1-4的合成
称取四氢锂铝(831.84mg,21.92mmol,3.8eq)于反应瓶中,置换氮气,0℃下缓慢加入四氢呋喃(20mL),搅拌10分钟,再缓慢滴加O-1-3(1.9g,5.77mmol,1eq)的四氢呋喃(4mL)溶液,搅拌2小时,氮气流保护下缓慢加入2mL水和3mL的15%氢氧化钠水溶液,再加入40mL四氢呋喃,用无水硫酸钠干燥,过滤。用四氢呋喃洗两次滤饼,合并滤液与洗液,减压浓缩,得到化合物O-1-4。
1H NMR(400MHz,CDCl
3)δ=3.79-3.73(m,4H),3.68(s,4H),2.55(br s,2H),1.96(t,J=6.3Hz,4H),1.44(s,9H).
步骤4:化合物O-1-5的合成
将化合物O-1-4(1.11g,4.52mmol,1eq)溶于二氯甲烷(25mL)中,降温至0℃,加入甲基磺酰氯(1.750g,15.28mmol,3.25eq),三乙胺(2.29g,22.62mmol,5eq),0℃下搅拌4小时。随后,向反应液中缓慢加入20ml冰水淬灭,加入40mL二氯甲烷萃取两次,有机相合并,干燥,浓缩,得到化合物O-1-5。
1H NMR(400MHz,CDCl
3)δ=4.25(t,J=6.5Hz,4H),3.66(s,4H),2.97(s,6H),2.09(t,J=6.4Hz,4H),1.37(s,9H).
步骤5:化合物O-1-6的合成
将化合物O-1-5(1.62g,4.03mmol,1eq)溶于N,N-二甲基甲酰胺(20mL),加入硫化钠(1.16g,4.84mmol,1.2eq),50℃搅拌12小时。加入20mL水,用50mL乙酸乙酯萃取3次,收集有机相,用30mL饱和食盐水洗两次,无水硫酸钠干燥后浓缩。硅胶柱层析分离,得到化合物O-1-6。
1H NMR(400MHz,CDCl
3)δ=3.50(s,4H),2.53-2.44(m,4H),1.94-1.86(m,4H),1.37(s,9H).
步骤6:化合物O-1的合成
将化合物O-1-6(0.3g,1.23mmol,1eq),乙酸铵(380.07mg,4.93mmol,4eq),醋酸碘苯(1.19g,3.70mmol,3eq)溶于甲醇(4mL),25℃搅拌2小时。随后浓缩反应液,粗品经硅胶柱层析分离纯化,得到化合物O-1。
1H NMR(400MHz,CDCl
3)δ=3.73(d,J=4.5Hz,4H),3.13-2.96(m,4H),2.40-2.21(m,4H),1.47(s,9H).
实施例1
步骤1:化合物1-2的合成
在2-氟-4-溴硝基苯(5g,22.73mmol,1eq),化合物1-1(盐酸盐)(3.49g,22.73mmol,1eq)的乙醇(50mL)溶液中加入三乙胺(9.20g,90.91mmol,12.65mL,4eq),80℃搅拌16小时。向反应液中缓慢加入水(200mL),再加入150mL乙酸乙酯萃取3次,合并有机相并用无水硫酸钠干燥,加水(200mL),饱和食盐水(200mL)洗涤,有机相用无水硫酸钠干燥后减压浓缩得1-2粗品。LCMS m/z=316.7/318.7[M+H]
+。
步骤2:化合物1-3的合成
将1-2(2.50g,7.88mmol,1eq)溶于二氯甲烷(20mL)中,冷却至0℃,加入三乙胺(957.10mg,9.46mmol,1.32mL,1.2eq),甲磺酰氯(1.36g,11.90mmol,921.19μL,1.51eq)。然后,升温25℃搅拌反应3小时。反应完成后,向反应液中加入50mL二氯甲烷,再用饱和碳酸氢钠水溶液(50mL)洗2次,分液收集有机相,有机层用无水硫酸钠干燥,真空浓缩得粗品。粗品使用硅胶柱层析(石油醚:乙酸乙酯=10:1~3:1)分离纯化,得到化合物1-3。LCMS m/z=394.8/396.8[M+H]
+。
步骤3:化合物1-4的合成
将1-3(9.00g,22.77mmol,1eq)和A-1(7.32g,29.60mmol,1.3eq),碳酸钾(9.44g,68.31mmol,3eq)溶于N,N-二甲基甲酰胺(100mL)中,加热至60℃搅拌反应16小时。随后反应液直接真空浓缩得到粗品, 再通过硅胶柱层析分离纯化得到产物1-4。
1H NMR(400MHz,CD
3OD)δ=7.97(dd,J=2.4,9.2Hz,1H),7.90(s,1H),7.87(d,J=1.0Hz,1H),7.49(s,1H),7.13(s,1H),6.74(td,J=1.9,9.2Hz,1H),5.49(s,1H),4.12(d,J=2.3Hz,1H),3.91(s,3H),3.73(s,3H),3.30-3.23(m,1H),3.22-3.14(m,1H),2.56(s,3H),2.00-1.79(m,3H),1.79-1.65(m,1H),1.54-1.40(m,1H),1.06(d,J=6.8Hz,3H);LCMS m/z=546.1/548.1[M+H]
+。
步骤4:化合物1-5的合成
将1-4(8.50g,15.56mmol,1eq),六水三氯化铁(630.71mg,2.33mmol,0.15eq),活性炭(1.12g,93.34mmol,6eq)溶于四氢呋喃(100mL),加入50%水合肼(46.72g,466.68mmol,45.36mL,30eq),65℃搅拌反应6小时。反应液使用硅藻土抽滤得滤液,滤饼中加入乙酸乙酯30mL洗涤2次,滤液真空浓缩得粗品。再经硅胶柱层析(二氯甲烷:甲醇=20:1)纯化得到化合物1-5。
1H NMR(400MHz,CD
3OD)δ=7.87(s,1H),7.79(s,1H),7.37(s,1H),6.58(s,3H),3.92(s,1H),3.73(br s,1H),3.72(s,3H),3.05-2.97(m,1H),2.92(br d,J=6.5Hz,1H),2.58(br s,1H),2.57(s,3H),2.10(s,3H),2.00(s,1H),1.70(br d,J=5.3Hz,1H),1.44-1.30(m,2H),1.00(d,J=6.5Hz,3H);LCMS m/z=516.2/518.2[M+H]
+。
步骤5:化合物1-6的合成
将1-5(8g,15.49mmol,1eq)溶于二氯甲烷(150mL)和叔丁醇(30mL),然后加入溴化氰(13.42g,126.72mmol,9.32mL,8.18eq),在25℃下搅拌反应18小时。向反应液中加入30mL饱和碳酸氢钠水溶液搅拌10分钟,分取有机层,再依次用饱和碳酸氢钠(30mL)洗2次,饱和食盐水(30mL)洗1次,有机层用无水硫酸钠干燥,真空浓缩得粗品。粗品使用硅胶柱层析(二氯甲烷:甲醇=20:1)分离纯化得到化合物1-6。
1H NMR(400MHz,CD
3OD)δ=7.89(s,1H),7.87(s,1H),7.53(s,1H),7.27(d,J=1.5Hz,1H),7.25-7.20(m,1H),7.08(d,J=8.3Hz,1H),4.09-4.01(m,1H),3.94(s,3H),3.72(d,J=3.5Hz,1H),3.70(s,3H),3.65(s,1H),2.58(s,3H),2.57(br s,1H),2.18-2.10(m,1H),2.02-1.96(m,1H),1.84-1.78(m,1H),1.68-1.59(m,1H),1.50-1.43(m,1H),0.99(d,J=6.5Hz,3H);LCMS m/z=541.1/543.1[M+H]
+。
步骤6:化合物1-7的合成
将1-6(4g,7.39mmol,1eq)溶于四氢呋喃(50mL)中,加入氢氧化钠(1.18g,29.55mmol,4eq),室温25℃搅拌反应1小时。反应完毕,反应液真空浓缩,再加入3M盐酸水溶液调节pH至4-5,再真空浓缩除去溶剂。再溶于二氯甲烷(30mL)和甲醇(5mL)的混合溶剂中,用无水硫酸钠干燥,过滤后滤液真空浓缩得粗品1-7。
1H NMR(400MHz,DMSO-d
6)δ=7.86-7.85(m,1H),7.87-7.82(m,1H),7.44(s,1H),7.39-7.30(m,1H),7.05(s,1H),6.72(br s,1H),4.08(br t,J=6.3Hz,2H),3.96-3.85(m,2H),3.84-3.77(m,1H),3.62(s,1H),3.63-3.60(m,1H),3.64(br d,J=4.3Hz,1H),3.17(s,3H),2.52(br s,3H),2.03(br s,1H),1.98-1.88(m,1H),1.79-1.68(m,1H),1.64-1.51(m,1H),0.83(d,J=6.5Hz,3H);LCMS m/z=527.1/529.1[M+H]
+。
步骤7:化合物1-8的合成
将1-7(4g,6.45mmol,1eq)溶于二氯甲烷(50mL)中,加入三乙胺(3.26g,32.23mmol,4.49mL,5eq)和O-苯并三氮唑-N,N,N',N'-四甲基脲四氟硼酸酯(6.21g,19.34mmol,3eq),25℃搅拌反应16小时。向反应液中加入二氯甲烷(30mL),饱和食盐水(30mL)洗3次,有机层用无水硫酸钠干燥,过滤,真空浓缩得粗品。经柱层析(EA:PE=10:1-1:1)分离后得到化合物1-8。
1H NMR(400MHz,CDCl
3)δ=12.28-11.75(m,1H),8.54(s,1H),8.42-8.22(m,1H),7.69(s,1H),7.44(d,J=1.5Hz,1H),7.39(d,J=8.6Hz,1H),7.24(d,J=8.5Hz, 1H),4.46(br d,J=4.8Hz,1H),4.35(dd,J=3.1,13.7Hz,1H),3.96-3.88(m,1H),3.80(s,3H),3.71-3.63(m,1H),2.83(br d,J=14.3Hz,1H),2.72(br s,3H),2.34-2.22(m,1H),2.19-2.09(m,1H),2.02-1.92(m,1H),1.54(br d,J=6.8Hz,1H),0.94(d,J=6.5Hz,3H);LCMS m/z=509.1/511.1[M+H]
+。
步骤8:化合物WX-001三氟乙酸盐的合成
将1-8(50mg,98.16μmol,1eq),二甲基氧化膦(76.61mg,981.55μmol,10eq)的1,4-二氧六环(3mL)溶液中加入4,5-双二苯基膦-9,9-二甲基氧杂蒽(34.08mg,58.89μmol,0.6eq),N,N-二异丙基乙胺(63.43mg,490.78μmol,85.48μL,5eq),氮气置换后加入三(二亚苄基丙酮)二钯(26.96mg,29.45μmol,0.3eq),氮气保护下120℃搅拌36小时。反应液减压浓缩得粗品。粗品经制备HPLC分离,色谱柱:Welch Xtimate C18 100*40mm*3μm;流动相:[水(三氟乙酸)-乙腈];梯度:乙腈%:15%-45%,8分钟,得WX-001的三氟乙酸盐。
1H NMR(400MHz,CD
3OD)δ=8.82(s,1H),8.19(s,1H),8.02(s,1H),7.94(br d,J=12.3Hz,1H),7.72-7.57(m,2H),4.50(td,J=4.7,9.2Hz,1H),4.37(br dd,J=2.4,13.7Hz,1H),4.10(br d,J=3.5Hz,1H),4.00(br dd,J=10.7,13.4Hz,1H),3.80(s,3H),2.80(s,4H),2.32(br d,J=7.0Hz,1H),2.16-1.96(m,2H),1.87(dd,J=3.3,13.3Hz,6H),1.66-1.49(m,1H),0.89(br d,J=6.5Hz,3H);LCMS m/z=507.3[M+H]
+。
实施例2
步骤1:化合物2-1的合成
将化合物1-8(150.00mg,294.47μmol,1eq),三(二亚苄基丙酮)二钯(80.89mg,88.34μmol,0.3eq),4,5-双二苯基膦-9,9-二甲基氧杂蒽(102.23mg,176.68μmol,0.6eq)和N,N-二异丙基乙胺(114.17mg,883.40μmol,153.87μsL,3eq)加入到二氧六环(13mL)中,再加入乙硫醇(2.71g,43.62mmol,3.23mL,148.12eq),氮气保护120℃下搅拌反应2.5小时。然后,在反应液中加入50mL二氯甲烷,再用饱和食盐水(50mL)洗3次,水层加入50mL次氯酸钠水溶液搅拌5min,有机层过滤得滤液,滤液用无水硫酸钠干燥,真空浓缩得粗品。粗品经硅胶柱层析分离纯化(梯度淋洗:二氯甲烷/甲醇=100:0~100:10),得到化合物2-1。
1H NMR(400MHz,CDCl
3)δ=8.52(br s,1H),8.22(br s,1H),7.69(br s,1H),7.33(d,J=9.8Hz,2H),7.10-6.98(m,1H),4.55-4.44(m,1H),4.41-4.32(m,1H),3.97-3.88(m,1H),3.81(s,3H),3.71(br dd,J=9.9,13.8Hz,1H),3.03-2.81(m,3H),2.69(br s,3H),2.28(br s,1H),2.20-2.12(m,1H),1.98(dt,J=4.9,9.3Hz,1H),1.55(br d,J=6.6Hz,1H),1.34(t,J=7.3Hz,3H),0.95(br d,J=6.5Hz,3H);LCMS m/z=491.2[M+H]
+。
步骤2:化合物WX-002甲酸盐的合成
将化合物2-1(20mg,40.76μmol,1eq)溶于水(1mL)和甲醇(1mL)的混合溶剂,加入单过硫酸氢钾(75.18mg,122.29μmol,3eq),30℃搅拌1小时。随后,加水(20mL)淬灭,乙酸乙酯10mL萃取3次,饱和氯化钠溶液(10mL)洗涤,无水硫酸钠干燥,过滤,浓缩有机相得粗品。粗品经制备HPLC分离,色谱柱: Phenomenex C18 150*40mm*5μm;流动相:[水(甲酸)-乙腈];梯度:乙腈%:15%-45%,10分钟,纯化后冷冻干燥,减压浓缩得WX-002的甲酸盐。
1H NMR(400MHz,CDCl
3)δ=8.46(br s,1H),7.87-7.72(m,2H),7.61(br s,1H),7.46(br d,J=8.5Hz,1H),7.22-7.14(m,1H),4.48-4.27(m,3H),3.85(br s,1H),3.77-3.68(m,3H),3.12(q,J=7.4Hz,2H),2.86-2.52(m,4H),2.27-1.86(m,4H),1.25(t,J=7.3Hz,3H),0.86(d,J=6.5Hz,3H);LCMS m/z=523.2[M+H]
+。
实施例3
步骤1:化合物WX-003甲酸盐的合成
将化合物2-1(20mg,40.76μmol,1eq)加入到甲醇(0.5mL)中,然后加入碘苯二乙酸(39.39mg,122.29μmol,3eq)和乙酸铵(12.57mg,163.06μmol,4eq),在30℃下反应2小时。反应液经滤膜过滤,经制备HPLC分离,色谱柱:Phenomenex C18 150*40mm*5μm;流动相:[水(甲酸)-乙腈];梯度:乙腈%:10%-40%,10分钟,纯化后得WX-003的甲酸盐。
1H NMR(400MHz,CDCl
3)δ=8.51(s,1H),8.22(br s,1H),8.08(s,1H),7.96(s,1H),7.92(d,J=8.5Hz,1H),7.68(s,1H),7.53(d,J=8.5Hz,1H),4.52-4.37(m,3H),3.98-3.77(m,5H),3.33-3.21(m,2H),2.90(br s,1H),2.69(s,3H),2.36-2.12(m,2H),2.07-2.02(m,1H),1.32(t,J=7.5Hz,3H),0.95(br d,J=6.5Hz,3H);LCMS m/z=522.3[M+H]
+。
实施例4
步骤1:化合物WX-004三氟乙酸盐的合成
在化合物1-8(50mg,98.16μmol,1eq),二乙基氧化膦(104.15mg,981.55μmol,10eq)的1,4-二氧六环(3mL)溶液中加入4,5-双二苯基膦-9,9-二甲基氧杂蒽(34.08mg,58.89μmol,0.6eq),N,N-二异丙基乙胺(63.43mg,490.78μmol,85.48μL,5eq),氮气置换后加入三(二亚苄基丙酮)二钯(26.96mg,29.45μmol,0.3eq),氮气保护下120℃搅拌20小时。反应液减压浓缩得粗品。粗品经制备HPLC分离,色谱柱:Welch Xtimate C18 100*40mm*3μm;流动相:[水(三氟乙酸)-乙腈];梯度:乙腈%:20%-50%,8分钟,得WX-004的三氟乙酸盐。
1H NMR(400MHz,CD
3OD)δ=9.02-8.84(m,1H),8.38-8.23(m,1H),8.15-8.03(m,1H),8.04-7.89(m,1H),7.79-7.58(m,2H),4.64-4.49(m,1H),4.47-4.37(m,1H),4.23-4.01(m,2H),3.91-3.77 (m,3H),2.98-2.75(m,4H),2.47-2.30(m,1H),2.28-1.98(m,6H),1.70-1.52(m,1H),1.18-1.03(m,6H),0.98-0.85(m,3H);LCMS m/z=535.3[M+H]
+。
实施例5
步骤1:化合物WX-005三氟乙酸盐的合成
化合物1-8(50mg,98.16μmol,1eq),B-1(131.69mg,981.55μmol,10eq)的1,4-二氧六环(3mL)溶液中加入4,5-双二苯基膦-9,9-二甲基氧杂蒽(34.08mg,58.89μmol,0.6eq),N,N-二异丙基乙胺(63.43mg,490.78μmol,85.48μL,5eq),氮气置换后加入三(二亚苄基丙酮)二钯(26.96mg,29.45μmol,0.3eq),氮气保护下120℃搅拌20小时。反应液减压浓缩得粗品。粗品经制备HPLC分离,色谱柱:Welch Xtimate C18100*40mm*3μm;流动相:[水(三氟乙酸)-乙腈];梯度:乙腈%:20%-50%,8分钟,得WX-005的三氟乙酸盐。
1H NMR(400MHz,CD
3OD)δ=8.97(s,1H),8.28(s,1H),8.10(s,1H),7.92(br d,J=10.4Hz,1H),7.84-7.60(m,2H),4.66-4.55(m,1H),4.41(br d,J=13.4Hz,1H),4.28-4.01(m,2H),3.85(s,3H),2.84(s,4H),2.68-2.00(m,5H),1.62(br s,1H),1.21(br dd,J=6.9,15.1Hz,6H),1.15-1.03(m,6H),0.92(br d,J=6.3Hz,3H);LCMS m/z=563.1[M+H]
+。
实施例6
合成路线1
步骤1:化合物WX006三氟乙酸盐的合成
在化合物1-8(30mg,58.89μmol,1eq),二甲基亚磺酰亚胺(6.86mg,73.62μmol,1.25eq)的1,4-二氧六环(3mL)溶液中加入2-(二叔丁基膦)联苯(5.27mg,17.67μmol,0.3eq),叔丁醇钠(8.49mg,88.34μmol,1.5eq),氮气置换后加入三(二亚苄基丙酮)二钯(16.18mg,17.67μmol,0.3eq),氮气保护下100℃搅拌5小时。反应液减压浓缩得粗品。粗品经制备HPLC分离,色谱柱:Welch Xtimate C18 100*40mm*3μm;流动相:[水(三氟乙酸)-乙腈];梯度:乙腈%:20%-50%,8分钟,减压浓缩得WX-006的三氟乙酸盐。LCMS m/z=522.1[M+H]
+。
合成路线2
步骤1:化合物WX-006的合成
在化合物1-8(30mg,58.89μmol,1eq),二甲基亚磺酰亚胺(6.86mg,73.62μmol,1.25eq)的1,4-二氧六环(3mL)溶液中加入2-(二叔丁基膦)联苯(5.27mg,17.67μmol,0.3eq),叔丁醇钠的四氢呋喃溶液(2M,88.34μmol,44.17μL,1.5eq),氮气置换后加入三(二亚苄基丙酮)二钯(16.18mg,17.67μmol,0.3eq),氮气保护下80℃搅拌12小时。冷却至室温,加入10mL水,再用50mL二氯甲烷萃取,随后用10mL饱和氯化钠溶液洗涤1次,有机相用无水硫酸钠干燥,过滤,真空浓缩得粗品。粗品经硅胶柱层析分离纯化(梯度淋洗:二氯甲烷/甲醇=100:0~100:3),得到WX-006。
1H NMR(400MHz,CDCl
3)δ=11.85(br s,1H),8.40(s,1H),8.08(s,1H),7.59(s,1H),7.14(d,J=8.5Hz,1H),6.98(d,J=1.5Hz,1H),6.94-6.90(m,1H),4.40(dt,J=4.9,9.1Hz,1H),4.25(dd,J=3.0,13.8Hz,1H),3.86-3.78(m,1H),3.71(s,3H),3.59(dd,J=9.8,13.6Hz,1H),3.11(d,J=1.0Hz,6H),2.77(br s,1H),2.57(s,3H),2.24-2.12(m,1H),2.10-1.99(m,1H),1.92–1.82(m,1H),1.48-1.38(m,1H),0.84(d,J=6.5Hz,3H);LCMS m/z=522.1[M+H]
+。
实施例7
步骤1:化合物WX-007三氟乙酸盐的合成
在化合物1-8(40mg,78.52μmol,1eq),C-1(102.18mg,785.24μmol,10eq)的1,4-二氧六环(3mL)溶液中加入4,5-双二苯基膦-9,9-二甲基氧杂蒽(27.26mg,47.11μmol,0.6eq),N,N-二异丙基乙胺(50.74mg,392.62μmol,5eq),氮气置换后加入三(二亚苄基丙酮)二钯(21.57mg,23.56μmol,0.3eq),氮气保护下120℃搅拌20小时。反应液减压浓缩得粗品。粗品经制备HPLC分离,色谱柱:Welch Xtimate C18 100*40mm*3μm;流动相:[水(三氟乙酸)-乙腈];梯度:乙腈%:16%-46%,8分钟,得WX-007的三氟乙酸盐。
1H NMR(400MHz,CD
3OD)δ=8.80(s,1H),8.23(s,1H),8.05-7.94(m,2H),7.76(dd,J=8.7,10.7Hz,1H),7.61(dd,J=2.0,8.0Hz,1H),4.51(td,J=4.7,9.0Hz,1H),4.40(br d,J=12.0Hz,1H),4.11(br s,1H),4.01(br dd,J=10.8,13.3Hz,1H),3.81(s,3H),2.78(s,4H),2.33(br d,J=7.0Hz,1H),2.11-1.97(m,2H),1.66-1.53(m,1H),1.49-1.27(m,2H),1.17-0.78(m,11H);LCMS m/z=559.1[M+H]
+。
实施例8
步骤1:化合物WX-008三氟乙酸盐的合成
在WX-003(20.00mg,38.34μmol,1eq)溶于的1,4-二氧六环(3mL)溶液中加入乙酸铜(10.45mg,57.51μmol,1.5eq),吡啶(7.28mg,92.02μmol,7.43μL,2.4eq)和乙基硼酸(8.50mg,115.02μmol,3eq),氮气保护下100℃搅拌4小时。反应液减压浓缩得粗品。粗品经制备HPLC分离,色谱柱:Welch Xtimate C18 100*40mm*3μm;流动相:[水(三氟乙酸)-乙腈];梯度:乙腈%:17%-47%,8分钟,得WX-008的三氟乙酸盐。
1H NMR(400MHz,CD
3OD)δ=9.01-8.91(m,1H),8.38-8.22(m,2H),8.14-8.07(m,1H),8.01-7.86(m,2H),4.60-4.52(m,1H),4.48-4.39(m,1H),4.22-4.07(m,2H),4.05-3.92(m,2H),3.91-3.81(m,3H),3.78-3.60(m,2H),2.98-2.79(m,4H),2.43-2.34(m,1H),2.14-2.02(m,2H),1.68-1.59(m,1H),1.39-1.30(m,6H),1.00-0.91(m,3H);LCMS m/z=550.1[M+H]
+。
实施例9
步骤1:化合物WX-009三氟乙酸盐的合成
在WX-003(30.00mg,57.51μmol,1eq)溶于的1,4-二氧六环(3mL)溶液中加入乙酸铜(15.67mg,86.27μmol,1.5eq),吡啶(10.92mg,138.03μmol,11.14μL,2.4eq)和甲基硼酸(10.33mg,172.54μmol,3eq),氮气保护下100℃搅拌4小时。反应液减压浓缩得粗品。粗品经制备HPLC分离,色谱柱:Welch Xtimate C18 100*40mm*3μm;流动相:[水(三氟乙酸)-乙腈];梯度:乙腈%:9%-39%,10分钟,得WX-009的三氟乙酸盐。
1H NMR(400MHz,CD
3OD)δ=8.91(br s,1H),8.28(br s,1H),8.17(s,1H),8.06(br s,1H),7.94-7.84(m,2H),4.56(br s,1H),4.43(br d,J=9.5Hz,1H),4.16(br s,1H),4.24-4.03(m,1H),3.92-3.76(m,5H),2.91(br s,1H),2.86-2.78(m,1H),2.78(br s,1H),2.97-2.77(m,3H),2.94-2.75(m,1H),2.43-2.32(m,1H),2.17-2.01(m,2H),1.68-1.58(m,1H),1.36-1.33(m,3H),0.95(d,J=6.5Hz,3H);LCMS m/z=536.1[M+H]
+。
实施例10
步骤1:化合物WX-010三氟乙酸盐的合成
在化合物1-8(50.00mg,98.16μmol,1eq),10-1(23.40mg,196.31μmol,2eq)的1,4-二氧六环(3mL)溶液中加入2-(二叔丁基膦)联苯(8.79mg,29.45μmol,0.3eq),叔丁醇钠的四氢呋喃溶液(2M,196.31μmol,98.16μl,2eq),氮气置换后加入三(二亚苄基丙酮)二钯(26.96mg,29.45μmol,0.3eq),氮气保护下80℃搅拌12小时。反应液减压浓缩得粗品。粗品经制备HPLC分离,色谱柱:Welch Xtimate C18 100*40mm*3μm;流动相:[水(三氟乙酸)-乙腈];梯度:乙腈%:26%-56%,8分钟,得WX-010的三氟乙酸盐。
1H NMR(400MHz,CD
3OD)δ=8.75(s,1H),8.24(s,1H),7.87(s,1H),7.31(br d,J=8.3Hz,1H),7.03-6.90(m,2H),4.53-4.41(m,1H),4.30(br d,J=13.3Hz,1H),4.08(br s,1H),3.82(s,3H),3.73(br t,J=11.8Hz,1H),3.50-3.37(m,2H),3.32-3.20(m,2H),2.87-2.64(m,4H),2.46-2.20(m,5H),2.04(br s,2H),1.62-1.48(m,1H),0.87(br d,J=6.5Hz,3H);LCMS m/z=548.1[M+H]
+。
实施例11
步骤1:化合物WX-011的合成
在化合物1-8(50mg,98.16μmol,1eq),D-1(26.15mg,196.32μmol,2eq)的1,4-二氧六环(3mL)溶液中加入2-(二叔丁基膦)联苯(17.57mg,58.90μmol,0.6eq),叔丁醇钠的四氢呋喃溶液(2M,147.24μmol,73.62μl,1.5eq),氮气置换后加入三(二亚苄基丙酮)二钯(26.96mg,29.45umol,0.3eq),氮气保护下80℃搅拌12小时。冷却至室温,加入10mL水,再用50mL二氯甲烷萃取,随后用10mL饱和氯化钠溶液洗涤1次,有机相用无水硫酸钠干燥,过滤,真空浓缩得粗品。粗品经硅胶柱层析分离纯化(梯度淋洗:二氯甲烷/甲醇=100:0~100:3),得到WX-011。
1H NMR(400MHz,CDCl
3)δ=11.89(br s,1H),8.50(s,1H),8.18(s,1H),7.68(s,1H),7.22(d,J=8.4Hz,1H),7.11(d,J=1.6Hz,1H),7.06(dd,J=1.8,8.4Hz,1H),4.81(br s,1H),4.54-4.45(m,1H),4.34(dd,J=3.0,14.1Hz,1H),3.96-3.86(m,1H),3.81(s,3H),3.74-3.63(m,1H),3.38(br s,2H),3.20-3.07(m,2H),2.86(br s,1H),2.67(s,3H),2.28(br s,2H),2.18-2.03(m,5H),1.97(br d,J=5.0Hz,1H),1.82(br d,J=14.6Hz,1H),0.94(d,J=6.6Hz,3H);LCMS m/z=562.1[M+H]
+。
实施例12
步骤1:化合物WX-012盐酸盐的合成
在化合物1-8(30.00mg,58.89μmol,1eq),E-1(14.28mg,117.79μmol,2eq)的1,4-二氧六环(3mL)溶液中加入2-(二叔丁基膦)联苯(5.27mg,17.67μmol,0.3eq),叔丁醇钠的四氢呋喃溶液(2M,88.34μmol,44.17μl,1.5eq),氮气置换后加入三(二亚苄基丙酮)二钯(16.18mg,17.67μmol,0.3eq),氮气保护下80℃搅拌12小时。反应液减压浓缩得粗品。粗品经制备HPLC分离,色谱柱:Welch Xtimate C18 150*40mm*5μm;流动相:[水(盐酸)-乙腈];梯度:乙腈%:10%-40%,10分钟,得WX-012的盐酸盐。
1H NMR(400MHz,CD
3OD)δ=8.85(s,1H),8.32(s,1H),7.99(s,1H),7.35(d,J=8.5Hz,1H),7.16(d,J=1.8Hz,1H),7.05(dd,J=1.8,8.5Hz,1H),4.57-4.47(m,1H),4.32(dd,J=2.6,13.7Hz,1H),4.18-4.10(m,1H),3.86-3.76(m,4H),3.41(quin,J=7.2Hz,4H),2.86(s,3H),2.80-2.70(m,1H),2.43-2.27(m,1H),2.13-2.00(m,2H),1.64-1.51(m,1H),1.43(q,J=7.3Hz,6H),0.94-0.84(m,3H);LCMS m/z=550.2[M+H]
+。
实施例13
步骤1:化合物WX-013的合成
在化合物1-8(50mg,98.16μmol,1,1eq),F-1(26.54mg,196.31μmol,2eq)的1,4-二氧六环(3mL)溶液中加入2-(二叔丁基膦)联苯(17.57mg,58.89μmol,0.6eq),叔丁醇钠的四氢呋喃溶液(2M,147.24μmol,73.62μl,1.5eq),氮气置换后加入三(二亚苄基丙酮)二钯(26.96mg,29.45μmol,0.3eq),氮气保护下80℃搅拌12小时。冷却至室温,加入10mL水,再用50mL二氯甲烷萃取,随后用10mL饱和氯化钠溶液洗涤1次,有机相用无水硫酸钠干燥,过滤,真空浓缩得粗品。粗品经硅胶柱层析分离纯化(梯度淋洗:二氯甲烷/甲醇=100:0~100:3),得到WX-013。
1H NMR(400MHz,CDCl
3)δ=11.84(br s,1H),8.40(s,1H),8.08(s,1H),7.59(s,1H),7.14(d,J=8.3Hz,1H),7.01(d,J=1.5Hz,1H),6.95(dd,J=1.8,8.3Hz,1H),4.40(dt,J=5.1,9.1Hz,1H),4.25(dd,J=2.8,13.6Hz,1H),4.18-4.10(m,2H),4.09-4.01(m,2H),3.87-3.78(m,1H),3.71(s,3H),3.60(dd,J=9.8,13.6Hz,1H),3.39-3.30(m,2H),3.27-3.17(m,2H),2.77(br s,1H),2.57(s,3H),2.26-2.11(m,1H),2.05(dt,J=4.9,9.5Hz,1H),1.92–1.82(m,1H),1.49-1.39(m,1H),0.84(d,J=6.5Hz,3H); LCMS m/z=564.1[M+H]
+。
实施例14
步骤1:化合物14-1的合成
在化合物1-8(100.00mg,196.31μmol,1eq),G-1(92.00mg,392.62μmol,2eq)的1,4-二氧六环(5mL)溶液中加入2-(二叔丁基膦)联苯(70.30mg,235.57μmol,1.2eq),叔丁醇钠的四氢呋喃溶液(2M,500μmol,250μl,1.5eq),氮气置换后加入三(二亚苄基丙酮)二钯(71.91mg,78.52μmol,0.4eq),氮气保护下80℃搅拌16小时。冷却至室温,加入10mL水,再用50mL二氯甲烷萃取,随后用10mL饱和氯化钠溶液洗涤1次,有机相用无水硫酸钠干燥,过滤,真空浓缩得粗品。粗品经硅胶柱层析分离纯化(梯度淋洗:二氯甲烷/甲醇=100:0~100:3),得到化合物14-1。LCMS m/z=663.2[M+H]
+。
步骤2:化合物WX-014的合成
将化合物14-1(40.00mg,60.35μmol,1eq)溶于乙酸乙酯(1mL),加入盐酸/乙酸乙酯溶液(4M,1mL,66.28eq),25℃搅拌1小时。反应液浓缩,加10mL水溶解后,用饱和碳酸氢钠水溶液调节pH至8,用二氯甲烷15mL萃取3次,分离有机相后经无水硫酸钠干燥,过滤,真空浓缩得到化合物WX-014。
1H NMR(400MHz,CDCl
3)δ=11.86(br s,1H),8.40(s,1H),8.08(s,1H),7.59(s,1H),7.12(d,J=8.53Hz,1H),7.01(d,J=1.51Hz,1H),6.95(dd,J=8.41,1.63Hz,1H),4.40(td,J=9.16,5.02Hz,1H),4.24(dd,J=13.55,3.01Hz,1H),3.78-3.84(m,1H),3.71(s,3H),3.59(dd,J=13.55,9.79Hz,1H),3.23-3.34(m,6H),3.05-3.15(m,2H),2.72-2.83(m,1H),2.56(s,3H),2.13-2.21(m,1H),2.01-2.09(m,1H),1.90-1.80(m,1H),1.37-1.48(m,1H),0.83(s,3H);LCMS m/z=563.2[M+H]
+。
实施例15
步骤1:化合物WX-015的合成
将WX-014(20mg,35.54μmol,1eq)溶于无水甲醇(2mL),加入乙酸(0.06mL),甲醛水溶液(5.77mg,71.09μmol,37%,2eq)和氰基硼氢化钠(5.58mg,88.86μmol,2.5eq),25℃搅拌3小时。反应液经制备HPLC 分离,色谱柱:Welch Xtimate C18 150*40mm*5μm;流动相:[水(碳酸氢铵)-乙腈];梯度:乙腈%:25%-55%,10分钟,得WX-015。
1H NMR(400MHz,CD
3OD)δ=8.99(s,1H),8.34(s,1H),8.12(s,1H),7.45(d,J=8.5Hz,1H),7.30(s,1H),7.14(br d,J=7.0Hz,1H),4.57(d,J=4.8Hz,1H),4.35(br d,J=11.0Hz,1H),4.19(br s,1H),3.98-3.80(m,12H),3.10(s,3H),2.89(s,4H),2.42-2.29(m,1H),2.15-2.05(m,2H),1.62(br s,1H),0.99-0.92(m,3H);LCMS m/z=577.2[M+H]
+。
实施例16
步骤1:化合物16-1的合成
将化合物1-溴-2-氯-5-氟-4-硝基苯(4g,15.72mmol,1eq)溶于无水乙醇(40mL)中,25℃加入化合物1-1(2.42g,15.72mmol,1eq),N,N-二异丙基乙胺(6.10g,47.16mmol,3eq),60℃下搅拌12小时。将反应液减压浓缩,随后用二氯甲烷60mL溶解,饱和食盐水洗两次,收集有机相,无水硫酸钠干燥,过滤,浓缩得到化合物16-1。LCMS m/z=350.9/352.9[M+1]
+。
步骤2:化合物16-2的合成
将化合物16-1(5.68g,16.15mmol,1eq)溶于二氯甲烷(60mL)中,0℃下加入三乙胺(4.90g,48.46mmol,3eq)和对甲苯磺酰氯(2.28g,32.31mmol,2eq),25℃搅拌16小时。向反应液中加入30mL饱和食 盐水洗一次,有机相无水硫酸钠干燥,浓缩。加入30mL甲醇,搅拌1小时,析出固体,过滤得化合物16-2。LCMS m/z=504.9/506.9[M+1]
+。
步骤3:化合物16-3的合成
将化合物16-2(5.7g,11.27mmol,1eq),化合物A-1(3.62g,14.65mmol,1.3eq)溶于N,N-二甲基甲酰胺(60mL)中,加入碳酸钾(4.67g,33.81mmol,3eq),于60℃搅拌12小时。随后向反应液中加入100mL水和100mL乙酸乙酯萃取,水层用60mL乙酸乙酯再萃取一次,合并有机相,用饱和食盐水洗两次,无水硫酸钠干燥,过滤,浓缩。粗品经硅胶柱层析分离得到化合物16-3。LCMS m/z=580.0/582.0[M+1]
+。
步骤4:化合物16-4的合成
将化合物16-3(3g,5.16mmol,1eq)和六水三氯化铁(209.40mg,774.72μmol,0.15eq),活性炭(371.86mg,30.99mmol,6eq)溶于THF(30mL),加入水合肼(6.58g,131.44mmol,25.45eq),氮气保护,50℃搅拌2.5小时。随后加入60mL乙酸乙酯经硅藻土过滤,收集滤液。滤液用饱和食盐水洗一次,无水硫酸钠干燥,过滤,浓缩。粗品经硅胶柱层析分离得到化合物16-4。LCMS m/z=550.0/552.0[M+1]
+。
步骤5:化合物16-5的合成
将化合物16-4(4.42g,8.02mmol,1eq)溶于二氯甲烷(45mL)和叔丁醇(9mL)的混合溶液中,加入溴化氰(4.94g,46.64mmol,5.81eq),室温25℃搅拌16小时。向反应液中加入60mL二氯甲烷,用40mL饱和碳酸氢钠水溶液洗一次,再用饱和食盐水洗一次,有机相用无水硫酸钠干燥,过滤,浓缩得到化合物16-5。LCMS m/z=575.0/577.0[M+1]
+。
步骤6:化合物16-6的合成
将化合物16-5(744.53mg,1.29mmol,1eq)溶于四氢呋喃(7mL)和甲醇(5mL)的混合溶液,加入氢氧化钠(1M,5.17mL,4eq)的水溶液,于25℃搅拌2小时。将反应液浓缩,加入5mL水,6M盐酸调pH至5-6,有固体析出,过滤,得化合物16-6。LCMS m/z=561.0/563.0[M+1]
+。
步骤7:化合物16-7的合成
将化合物16-6(0.6g,1.07mmol,1eq)溶于N,N-二甲基甲酰胺(20mL),加入三乙胺(540.30mg,5.34mmol,743.19μL,5eq),O-苯并三氮唑-N,N,N',N'-四甲基脲四氟硼酸酯(1.03g,3.20mmol,3eq),25℃搅拌1.5小时。向反应液中加入15mL饱和食盐水和20mL乙酸乙酯萃取,随后用饱和食盐水洗3次,无水硫酸钠干燥,过滤,浓缩得粗品。经硅胶柱层析分离得到化合物16-7。LCMS m/z=543.0/545.0[M+1]
+。
步骤8:化合物WX-016的合成
将化合物16-7(0.1g,183.88μmol,1eq),二甲基亚磺酰亚胺(17.13mg,183.88μmol,1.0eq)溶于1,4-二氧六环(2.5mL)和二氯甲烷(1mL)的混合溶液中,加入2-(二叔丁基膦)联苯(16.46mg,55.16μmol,0.3eq),叔丁醇钠的四氢呋喃溶液(2M,183.88μL,2eq),三(二亚苄基丙酮)二钯(25.26mg,27.58μmol,0.15eq),80℃搅拌14小时。反应液经制备HPLC分离,色谱柱:Welch Xtimate C18 100*40mm*3μm;流动相:[水(三氟乙酸)-乙腈];乙腈%:12%-42%,8分钟纯化。随后加入30mL二氯甲烷,用饱和碳酸氢钠溶液洗1次,饱和氯化钠溶液洗一次,无水硫酸钠干燥,浓缩得到化合物WX-016。
1H NMR(400MHz,CDCl
3)δ=12.09-11.62(m,1H),8.39(br s,1H),8.08(br s,1H),7.58(br s,1H),7.30(br s,1H),7.14(s,1H),4.39(br d,J=3.8Hz,1H), 4.23(br d,J=12.3Hz,1H),3.81(br s,1H),3.71(s,3H),3.63-3.55(m,1H),3.12(br d,J=17.3Hz,6H),2.84-2.67(m,1H),2.56(br s,3H),2.25-2.10(m,1H),2.09-1.96(m,1H),1.92-1.81(m,1H),1.43-1.36(m,1H),0.83(br d,J=6.1Hz,3H)。LCMS m/z:556.0[M+H]
+。
实施例17
步骤1:化合物WX-017的合成
将化合物16-7(0.05g,91.94μmol,1eq),化合物10-1(10.96mg,91.94μmol,1eq)溶于1,4-二氧六环(3mL),加入2-(二叔丁基膦)联苯(8.23mg,27.58μmol,0.3eq),叔丁醇钠的四氢呋喃溶液(2M,137.91μL,3eq),三(二亚苄基丙酮)二钯(12.63mg,13.79μmol,0.15eq),80℃搅拌14小时。反应液经制备HPLC分离,色谱柱:Welch Xtimate C18 100*40mm*3μm;流动相:[水(三氟乙酸)-乙腈];乙腈%:18%-48%,8分钟纯化。随后加入30mL二氯甲烷,用饱和碳酸氢钠溶液洗1次,饱和氯化钠溶液洗一次,无水硫酸钠干燥,浓缩得到化合物WX-017。
1H NMR(400MHz,CDCl
3)δ=12.23-11.60(m,1H),8.38(s,1H),8.07(s,1H),7.57(s,1H),7.29(s,1H),7.14(s,1H),4.42-4.32(m,1H),4.22(br dd,J=2.6,13.4Hz,1H),3.85-3.77(m,1H),3.71(s,3H),3.57(br dd,J=9.9,13.4Hz,1H),3.39-3.29(m,2H),3.16-2.99(m,2H),2.80-2.65(m,1H),2.54(s,3H),2.32-2.22(m,4H),2.20-2.11(m,1H),2.07-1.95(m,1H),1.86(ddd,J=4.4,9.5,13.9Hz,1H),1.49-1.37(m,1H),0.82(d,J=6.5Hz,3H)。LCMS m/z:582.0[M+H]
+。
实施例18
步骤1:化合物WX-018的合成
将化合物16-7(0.05g,91.94μmol,1eq),化合物F-1(12.43mg,91.94μmol,1eq)溶于1,4-二氧六环(3mL),加入2-(二叔丁基膦)联苯(8.23mg,27.58μmol,0.3eq),叔丁醇钠的四氢呋喃溶液(2M,183.88μL,4eq),三(二亚苄基丙酮)二钯(12.63mg,13.79μmol,0.15eq),80℃搅拌14小时。反应液经硅藻土过滤,浓缩,硅胶柱层析纯化得化合物WX-018。
1H NMR(400MHz,CDCl
3)δ=12.31-11.31(m,1H),8.39(s,1H),8.08(s,1H),7.57(s,1H),7.30(s,1H),7.20(s,1H),4.39(dt,J=5.1,9.1Hz,1H),4.29-4.06(m,5H),3.85-3.75(m,1H),3.71(s,3H),3.69-3.54(m,2H),3.36(br s,1H),3.26-3.12(m,2H),2.75(br d,J=3.4Hz,1H),2.56(s, 3H),2.29-2.11(m,1H),2.08-1.97(m,1H),1.87(ddd,J=4.4,9.5,14.1Hz,1H),1.47-1.35(m,1H),0.82(d,J=6.5Hz,3H)。LCMS m/z:598.1[M+H]
+。
实施例19
步骤1:化合物19-2的合成
将化合物19-1(1g,4.46mmol,1eq)溶于甲苯(15mL),加入间氯过氧苯甲酸(3.08g,17.82mmol,4eq),50℃搅拌12小时。随后加入20mL乙酸乙酯,过滤,滤液用20mL得10%硫代硫酸钠水溶液洗一次,饱和食盐水洗两次,浓缩。粗品经硅胶柱层析(乙酸乙酯:石油醚=0~30%)纯化,得化合物19-2。
1H NMR(400MHz,CDCl
3)δ=7.81(dd,J=7.2,8.9Hz,1H),7.55(dd,J=2.0,9.0Hz,1H)。
步骤2:化合物19-3的合成
将化合物19-2(1.6g,6.29mmol,1eq)溶于无水乙醇(30mL)中,25℃加入化合物1-1(1.16g,7.55mmol,1.2eq),N,N-二异丙基乙胺(2.44g,18.86mmol,3.29mL,3eq),60℃下搅拌12小时。将反应液减压浓缩,随后用二氯甲烷40mL溶解,饱和食盐水洗两次,收集有机相,无水硫酸钠干燥,过滤,浓缩得到化合物19-3。LCMS m/z=350.9/352.9[M+1]
+。
步骤3:化合物19-4的合成
将化合物19-3(0.82g,2.33mmol,1eq)溶于二氯甲烷(10mL)中,0℃下加入三乙胺(707.94mg,7.00mmol,3eq)和对甲苯磺酰氯(411.20mg,5.83mmol,2.5eq),25℃搅拌16小时。反应液中用饱和食盐水洗一 次,有机相无水硫酸钠干燥。粗品经硅胶柱层析纯化(乙酸乙酯:石油醚=10~50%),得化合物19-4。LCMS m/z=504.9/506.9[M+1]
+。
步骤4:化合物19-5的合成
将化合物19-4(0.8g,1.58mmol,1eq),化合物A-1(508.37mg,2.06mmol,1.3eq)溶于N,N-二甲基甲酰胺(15mL)中,加入碳酸钾(655.79mg,4.74mmol,3eq),于60℃搅拌12小时。向反应液中加入20mL水和20mL乙酸乙酯萃取,有机相用饱和食盐水洗1次,无水硫酸钠干燥,过滤,浓缩。粗品经硅胶柱层析分离纯化(乙酸乙酯:石油醚=0~50%),得到化合物19-5。LCMS m/z=580.0/582.0[M+1]
+。
步骤5:化合物19-6的合成
将化合物19-5(1.6g,2.75mmol,1eq)和六水三氯化铁(111.68mg,413.18μmol,0.15eq),活性炭(397.01mg,33.05mmol,12eq)溶于四氢呋喃(25mL),加入水合肼(8.24g,164.60mmol,59.76eq),氮气保护,50℃搅拌2.5小时。随后加入40mL乙酸乙酯,经硅藻土过滤,收集滤液。滤液用饱和食盐水洗三次,无水硫酸钠干燥,浓缩。粗品经硅胶柱层析分离纯化(乙酸乙酯:石油醚=0~70%),得到化合物19-6。LCMS m/z=550.0/552.0[M+1]
+。
步骤6:化合物19-7的合成
将化合物19-6(1.5g,2.72mmol,1eq)溶于二氯甲烷(15mL)和叔丁醇(3mL)的混合溶液中,25℃搅拌,加入溴化氰(1.29g,12.18mmol,4.47eq),25℃搅拌16小时。向反应液中加入30mL二氯甲烷和20mL饱和碳酸氢钠水溶液萃取,再用饱和食盐水洗一次,无水硫酸钠干燥,过滤,浓缩得到化合物19-7。LCMS m/z=575.0/577.0[M+1]
+。
步骤7:化合物19-8的合成
将化合物19-7(0.6g,1.04mmol,1eq)溶于四氢呋喃(7mL)和甲醇(5mL)的混合溶液,加入氢氧化钠(1M,4.17mL,4eq)的水溶液,25℃搅拌2小时。将反应液浓缩,加入5mL水,6M盐酸调pH至5-6,有固体析出,过滤,得化合物19-8。LCMS m/z=561.0/563.0[M+1]
+。
步骤8:化合物19-9的合成
将化合物19-8(160.10mg,284.94μmol,1eq)溶于二氯甲烷(20mL),加入N,N-二异丙基乙胺(184.13mg,1.42mmol,5eq),O-苯并三氮唑-N,N,N',N'-四甲基脲四氟硼酸酯(274.47mg,854.82μmol,3eq),25℃搅拌1.5小时。向反应液中加入15mL饱和食盐水和20mL二氯甲烷萃取,随后用饱和食盐水洗3次,无水硫酸钠干燥,过滤,浓缩得粗品。经硅胶柱层析分离(甲醇:二氯甲烷=0~3%)得到化合物19-9。LCMS m/z=543.0/545.0[M+1]
+。
步骤9:化合物WX-019的合成
将化合物19-9(42.79mg,78.68μmol,1eq),化合物二甲基亚磺酰亚胺(10.99mg,118.01μmol,1.5eq)溶于1,4-二氧六环(2.5mL)和二氯甲烷(1mL)的混合溶液中,加入2-(二叔丁基膦)联苯(7.04mg,23.60μmol,0.3eq),叔丁醇钠的四氢呋喃溶液(2M,183.88μL,2eq),三(二亚苄基丙酮)二钯(10.81mg,11.80μmol,0.15eq),80℃搅拌14小时。反应液经硅藻土过滤,浓缩。粗品经硅胶柱层析分离纯化(甲醇:二氯甲烷=0~3%),得到化合物WX-019。
1H NMR(400MHz,DMSO-d
6)δ=12.31-11.90(m,1H),8.38(s,1H),8.09(s,1H),7.58 (s,1H),7.18-7.13(m,1H),7.11-7.05(m,1H),4.76(dd,J=10.3,13.6Hz,1H),4.38(dt,J=4.0,9.8Hz,1H),4.28(dd,J=3.8,13.6Hz,1H),3.83-3.77(m,1H),3.71(s,3H),3.13(d,J=10.3Hz,6H),2.89-2.78(m,1H),2.56(s,3H),2.28-2.17(m,1H),2.10-1.99(m,1H),1.84-1.76(m,1H),1.51-1.41(m,1H),0.89(d,J=6.5Hz,3H)。LCMS m/z:556.0[M+H]
+。SFC(柱子:Chiralpak AS-3,3μm,0.46cm id×10cm L;流动相:A(CO
2)和B(乙醇,含0.05%二乙胺);梯度:B%=5~40%;流速:2.8mL/分钟;柱温:35℃;波长:220nm;压力:1500psi),保留时间=3.956分钟,手性异构体过量98.8%。
实施例20
步骤1:化合物WX-020的合成
将化合物19-9(0.06g,110.33μmol,1eq),化合物10-1(19.72mg,165.49μmol,1.5eq)溶于1,4-二氧六环(3mL)和二氯甲烷(3mL)的混合溶液中,加入2-(二叔丁基膦)联苯(15.15mg,16.55μmol,0.15eq),叔丁醇钠的四氢呋喃溶液(2M,165.49μL,3eq),三(二亚苄基丙酮)二钯(9.88mg,33.10μmol,0.3eq),80℃搅拌14小时。反应液经制备HPLC分离,色谱柱:Welch Xtimate C18 100*40mm*3μm;流动相:[水(三氟乙酸)-乙腈];乙腈%:17%-47%,8分钟纯化。随后加入30mL二氯甲烷,用饱和碳酸氢钠溶液洗1次,饱和氯化钠溶液洗一次,无水硫酸钠干燥,浓缩得到化合物WX-020。
1H NMR(400MHz,CDCl
3)δ=12.13(br s,1H),8.37(s,1H),8.07(s,1H),7.57(s,1H),7.17-6.96(m,2H),4.75(br dd,J=10.4,13.4Hz,1H),4.37(dt,J=3.4,9.5Hz,1H),4.26(br dd,J=3.4,13.6Hz,1H),3.84-3.75(m,1H),3.70(s,3H),3.45-3.25(m,2H),3.18-3.02(m,2H),2.81(br d,J=5.8Hz,1H),2.55(s,3H),2.35-2.12(m,5H),2.11-1.97(m,1H),1.86-1.70(m,1H),1.44(br d,J=3.8Hz,1H),0.88(br d,J=6.5Hz,3H)。LCMS m/z:582.2[M+H]
+。
实施例21
步骤1:化合物WX-021的合成
将化合物19-9(60.00mg,110.33μmol,1eq),化合物F-1(22.37mg,165.49μmol,1.5eq)溶于1,4-二氧六环(4mL)和二氯甲烷(4mL)的混合溶液中,加入2-(二叔丁基膦)联苯(9.88mg,33.10μmol,0.3eq),叔丁醇钠的四氢呋喃溶液(2M,220.65μL,4eq),三(二亚苄基丙酮)二钯(15.15mg,16.55μmol,0.15eq),80℃搅拌14小时。反应液经制备HPLC分离,色谱柱:Welch Xtimate C18 100*40mm*3μm;流动相:[水(三氟乙酸)-乙腈];乙腈%:17%-47%,8分钟纯化。随后加入30mL二氯甲烷,用饱和碳酸氢钠溶液洗1次,饱和氯化钠溶液洗一次,无水硫酸钠干燥,浓缩得到化合物WX-021。
1H NMR(400MHz,CDCl
3)δ=12.46-11.77(m,1H),8.37(s,1H),8.06(s,1H),7.57(s,1H),7.23-7.16(m,1H),7.05(d,J=8.4Hz,1H),4.76(br dd,J=10.2,13.6Hz,1H),4.38(dt,J=3.9,9.8Hz,1H),4.27(br dd,J=3.6,13.6Hz,1H),4.20-4.08(m,4H),3.86-3.77(m,1H),3.70(s,3H),3.36(br dd,J=2.7,13.8Hz,2H),3.29-3.17(m,2H),2.82(br dd,J=3.1,6.3Hz,1H),2.55(s,3H),2.28-2.13(m,1H),2.11-1.97(m,1H),1.80(ddd,J=3.5,10.6,14.1Hz,1H),1.52-1.39(m,1H),0.90(d,J=6.6Hz,3H)。LCMS m/z:598.1[M+H]
+。
实施例22
步骤1:化合物WX-022的合成
将WX-014(87.13mg,154.84μmol,1eq)溶于甲醇(2mL),加入乙酸(0.065mL),氰基硼氢化钠(29.19mg,464.53μmol,3eq),1-甲基-4-哌啶酮(52.56mg,464.53μmol,54.02μL,3eq),25℃搅拌2小时。加入10mL水,再用50mL二氯甲烷萃取,随后用10mL饱和氯化钠溶液洗涤1次,有机相用无水硫酸钠干燥,过滤,真空浓缩得粗品。粗品经硅胶柱层析分离纯化,得到WX-022。LCMS m/z:660.3[M+H]
+。
实施例23
步骤1:化合物23-1的合成
将化合物H-1(106.66mg,352.66μmol,1.5eq),1-8(119.76mg,235.11μmol,1eq)溶于1,4-二氧六环(3mL)和二氯甲烷(2mL)中,加入三(二亚苄基丙酮)二钯(32.29mg,35.27μmol,0.15eq),2-(二叔丁基膦)联苯(21.05mg,70.53μmol,0.3eq),叔丁醇钠的四氢呋喃溶液(2M,352.66μL,3eq),氮气保护,80℃反应12小时。反应液硅藻土过滤,收集滤液,粗品经硅胶柱层析分离纯化,得到化合物23-1。LCMS m/z=731.2[M+1]
+。
步骤2:化合物23-2的合成
将化合物23-1(70mg,95.77μmol,1eq)溶于二氯甲烷(3mL)中,加入三氟乙酸(1mL),25℃搅拌2小时。反应完全后,浓缩反应液。反应液经制备HPLC分离,色谱柱:Welch Xtimate C18 100*40mm*3μm;流动相:[水(三氟乙酸)-乙腈];梯度:乙腈%:4%-34%,8分钟纯化。随后加入30mL二氯甲烷,用饱和碳酸氢钠溶液洗1次,饱和氯化钠溶液洗一次,无水硫酸钠干燥,浓缩得化合物23-2。LCMS m/z=631.1[M+1]
+。
步骤3:化合物WX-023的合成
将化合物23-2(30mg,47.56μmol,1eq)溶于甲醇(2mL)和乙酸(0.065mL)混合溶液中,加入甲醛水溶液(7.14mg,95.12μmol,2eq),氰基硼氢化钠(7.47mg,118.90μmol,2.5eq),25℃搅拌12小时。反应液经制备HPLC分离,色谱柱:Welch Xtimate C18 100*40mm*3μm;流动相:[水(三氟乙酸)-乙腈];乙腈%:3%-33%,8分钟纯化。随后加入30mL二氯甲烷,用饱和碳酸氢钠溶液洗1次,饱和氯化钠溶液洗一次,无水硫酸钠干燥,浓缩得到化合物WX-023。
1H NMR(400MHz,CDCl
3)δ=12.19-11.60(m,1H),8.40(s,1H),8.08(s,1H),7.58(s,1H),7.12(d,J=8.5Hz,1H),6.99(d,J=1.5Hz,1H),6.93(dd,J=1.6,8.4Hz,1H),4.39(td,J=4.5,9.0Hz,1H),4.24(br dd,J=2.8,13.6Hz,1H),3.88-3.77(m,1H),3.71(s,3H),3.59(br dd,J=9.8,13.6Hz,1H),3.28-3.15(m,2H),3.12-3.03(m,2H),2.83-2.69(m,1H),2.56(s,3H),2.36(br s,4H),2.28-2.14(m,4H),2.11-1.99(m,1H),1.96-1.81(m,5H),1.69-1.51(m,4H),1.49-1.38(m,1H),0.83(d,J=6.5Hz,3H)。LCMS m/z=645.1[M+1]
+。
实施例24
步骤1:化合物24-1的合成
将化合物I-1(115mg,441.70μmol,1.5eq),1-8(150mg,294.47μmol,1eq)溶于1,4-二氧六环(3mL)中,加入三(二亚苄基丙酮)二钯(40.45mg,44.17μmol,0.15eq),2-(二叔丁基膦)联苯(26.36mg,88.34μmol,0.3eq),叔丁醇钠的四氢呋喃溶液(2M,441.70μL,3eq),氮气保护,80℃反应12小时。反应液硅藻土过滤,收集滤液,粗品经硅胶柱层析分离纯化,得到化合物24-1。LCMS m/z=689.1[M+1]
+。
步骤2:化合物24-2的合成
将化合物24-1(120mg,174.21μmol,1eq)溶于二氯甲烷(3mL)中,加入三氟乙酸(1mL),25℃搅拌2小时。反应完全后,浓缩反应液。反应液经制备HPLC分离,色谱柱:Welch Xtimate C18 100*40mm*3μm;流动相:[水(三氟乙酸)-乙腈];梯度:乙腈%:2%-32%,8分钟纯化,随后加入30mL二氯甲烷,用饱和碳酸氢钠溶液洗1次,饱和氯化钠溶液洗一次,无水硫酸钠干燥,浓缩化合物24-2。LCMS m/z=589.1[M+1]
+。
步骤3:化合物WX-024的合成
将化合物24-2(40mg,67.94μmol,1eq)溶于甲醇(2mL)和乙酸(0.065mL)混合溶液中,加入甲醛水溶液(10.2mg,135.89μmol,2eq),氰基硼氢化钠(10.67mg,169.86μmol,2.5eq),25℃搅拌12小时。反应液经制备HPLC分离,色谱柱:column:Welch Xtimate C18 100*40mm*3μm;流动相:[水(三氟乙酸)-乙腈];乙腈%:3%-33%,8分钟纯化。随后加入30mL二氯甲烷,用饱和碳酸氢钠溶液洗1次,饱和氯化钠溶液洗一次,无水硫酸钠干燥,浓缩得到WX-024。LCMS m/z=603.1[M+1]
+。
实施例25
步骤1:化合物WX-025的合成
在化合物1-8(50mg,98.16μmol,1eq),J-1(28.9mg,196.31μmol,2eq)的1,4-二氧六环(3mL)中,加入2-(二叔丁基膦)联苯(8.79mg,29.45μmol,0.3eq),叔丁醇钠的四氢呋喃溶液(2M,147.24μmol,73.62μl,1.5eq),氮气置换后加入三(二亚苄基丙酮)二钯(26.96mg,29.45μmol,0.3eq),氮气保护下100℃搅拌12小时。冷却至室温,加入50mL乙酸乙酯和20mL水萃取,用饱和氯化钠水溶液洗,无水硫酸钠干燥,过滤,浓缩。粗品经硅胶柱层析分离纯化,得到WX-025。
1H NMR(400MHz,CDCl
3)δ=11.85(br s,1H),8.40(s,1H),8.09(s,1H),7.59(s,1H),7.14(br d,J=8.3Hz,1H),6.87(s,1H),6.82(br d,J=8.4Hz,1H),4.82(d,J=12.5Hz,4H),4.51-4.20(m,6H),3.87-3.80(m,1H),3.72(s,3H),3.58(br dd,J=9.9,13.5Hz,1H),2.75(br d,J=13.9Hz,1H),2.57(s,3H),2.25-2.04(m,2H),1.95-1.80(m,1H),1.46-1.35(m,1H),0.84(br d,J=6.6Hz,3H)。LCMS m/z=576.2[M+1]
+。
实施例26
步骤1:化合物WX-026的合成
在化合物1-8(10mg,19.63μmol,1eq),K-1(7.48mg,23.56μmol,1.2eq)的1,4-二氧六环(3mL)溶液中加入2-(二叔丁基膦)联苯(2.34mg,7.85μmol,0.4eq),叔丁醇钠的四氢呋喃溶液(2M,29.45μmol,73.62μl,1.5eq),氮气置换后加入三(二亚苄基丙酮)二钯(3.6mg,3.93μmol,0.2eq),氮气保护下100℃搅拌12小时。冷却至室温,加入30mL乙酸乙酯和10mL水萃取,用饱和氯化钠水溶液洗,无水硫酸钠干燥,过滤,浓缩。粗品经硅胶柱层析分离纯化,得到WX-026。
1H NMR(400MHz,CDCl
3)δ=11.83(br s,1H),8.41(s,1H),8.09(s,1H),7.65-7.57(m,1H),7.13(d,J=8.3Hz,1H),7.04-6.93(m,2H),4.40(br d,J=5.0Hz,1H),4.25 (br d,J=11.0Hz,1H),3.88-3.78(m,1H),3.76-3.69(m,3H),3.61(br dd,J=9.9,13.4Hz,1H),3.44(br s,2H),3.03(br t,J=11.7Hz,2H),2.76(br s,1H),2.67-2.45(m,11H),2.31(br s,3H),2.24-1.98(m,7H),1.87(br s,1H),1.44(br s,1H),0.84(br d,J=6.3Hz,3H)。LCMS m/z:660.3[M+1]
+。
实施例27
步骤1:化合物27-1的合成
将化合物L-1(16.5g,127.71mmol,1eq),2-氟-4-溴硝基苯(28.10g,127.71mmol,1eq)溶于乙醇(200mL),加入N,N-二异丙基乙胺(49.52g,383.13mmol,3eq),60℃搅拌12小时。浓缩反应液,加入300mL乙酸乙酯溶解,用饱和食盐水洗一次,无水硫酸钠干燥,浓缩。粗品经硅胶柱层析纯化(乙酸乙酯:石油醚=0~50%),得到化合物27-1。LCMS m/z:328.9/330.9[M+1]
+。
步骤2:化合物27-2的合成
将化合物27-1(9.66g,29.34mmol,1eq),三乙胺(8.91g,88.03mmol,12.25mL,3eq)溶于二氯甲烷(200mL),冷却至0℃后加入对甲苯磺酰氯(16.78g,88.03mmol,3eq),然后在25℃下搅拌16小时。反应液倒入100mL水中淬灭,分离有机相。水相用二氯甲烷(100mL x 3)萃取,合并后的有机相用100mL饱和食盐水洗涤一次,无水硫酸钠干燥,过滤,浓缩得到化合物27-2。LCMS m/z=483.0/485.0[M+1]
+。
步骤3:化合物27-3的合成
将化合物27-2(23.36g,29.00mmol,1eq)和化合物A-1(10.75g,43.49mmol,1.5eq)溶于N,N-二甲基甲酰胺(200mL),加入碳酸钾(12.02g,86.99mmol,3eq),80℃搅拌反应16小时。冷却至室温后,加入水(400mL)淬灭,用乙酸乙酯(400mL*3)萃取,有机相经饱和食盐水(400mL*3)洗后浓缩。粗品经硅胶柱层析分离纯化(乙酸乙酯:石油醚=0~50%),得到化合物27-3。LCMS m/z=558.1/560.1[M+1]
+。
步骤4:化合物27-4的合成
将化合物27-3(6.6g,11.82mmol,1eq)溶解于四氢呋喃(50mL)和N,N-二甲基甲酰胺(5mL)的混合溶液中,加入六水三氯化铁(3.19g,11.82mmol,1eq),活性炭(2.84g,236.38mmol,20eq),然后加入水合肼(18.340g,366.36mmol,31.00eq),55℃搅拌3小时。反应液经硅藻土过滤,滤饼用乙酸乙酯洗,收集滤液,用饱和食盐水洗一次,随后无水硫酸钠干燥,浓缩。粗品经硅胶柱层析(甲醇:二氯甲烷=0~10%)得到化合物27-4。
1H NMR(400MHz,CDCl
3)δ=7.89(d,J=1.3Hz,2H),7.48(s,1H),6.84-6.65(m,2H),6.56(d,J=8.0Hz,1H),4.07-3.97(m,2H),3.96-3.88(m,3H),3.75(s,3H),3.05(dq,J=7.2,11.4Hz,2H),2.62(s,3H),2.56-2.42(m,1H),2.38-2.16(m,2H),1.98-1.84(m,2H),1.64-1.51(m,1H),1.51-1.37(m,1H),1.20-1.09(m,1H)。LCMS m/z=528.1/530.1[M+1]
+。
步骤5:化合物27-5的合成
将化合物27-4(10.7g,20.25mmol,1eq)溶于叔丁醇(20mL)和二氯甲烷(200mL)的混合溶剂中,然后加入溴化氰(10.94g,103.28mmol,5.10eq),随后25℃搅拌16小时。加入饱和碳酸氢钠水溶液洗一次,无水硫酸钠干燥。浓缩有机相,硅胶柱层析分离(甲醇:二氯甲烷=0~3%)纯化得到化合物27-5。LCMS m/z=553.0/555.0[M+1]
+。
步骤6:化合物27-6的合成
将化合物27-5(5.36g,9.68mmol,1eq)溶于四氢呋喃(40mL),加入氢氧化钠水溶液(1M,38.74mL,4eq),25℃反应2小时。反应液浓缩,用2M的盐酸水溶液调节pH至6,过滤得到化合物27-6。LCMS m/z=539.0/541.0[M+1]
+。
步骤7:化合物27-7的合成
将化合物27-6(9.44g,17.50mmol,1eq)溶于二氯甲烷(200mL),加入2-(1H-苯并三偶氮L-1-基)-1,1,3,3-四甲基脲四氟硼酸酯(8.43g,26.25mmol,1.5eq)和三乙胺(8.85g,87.50mmol,12.18mL,5eq),25℃反应2小时。反应液过滤,直接得到化合物27-7。LCMS m/z=521.0/523.0[M+1]
+。
步骤8:化合物WX-027A和WX-027B的合成
在化合物27-7(5.1g,9.78mmol,1eq),二甲基亚磺酰亚胺(5.47g,58.69mmol,6eq)的1,4-二氧六环(50mL)溶液中加入2-(二叔丁基膦)联苯(1.17g,3.91mmol,0.4eq),叔丁醇钠的四氢呋喃溶液(2M,29.34mmol,3eq),氮气置换后加入三(二亚苄基丙酮)二钯(1.79g,1.96mmol,0.2eq),氮气保护下80℃搅拌16小时。浓缩反应液,加入150mL二氯甲烷和150mL水,搅拌过程中用6M的盐酸水溶液调节pH至6,分离有机相,用饱和食盐水洗一次,无水硫酸钠干燥,浓缩。硅胶柱层析纯化得到消旋体粗品(甲醇:二氯甲烷=0~3%)。经SFC分离,色谱柱:DAICEL CHIRALCEL OD(250mm*30mm,10um);流动相:A(CO
2)和B(异丙醇,含0.1%氨水);梯度:B%=45%,纯化,得到WX-027A和WX-027B。
WX-027A:
1H NMR(400MHz,CDCl
3)δ=11.68(br s,1H),8.50(s,1H),8.08(br s,1H),7.47(s,1H),7.15(d,J=8.3Hz,1H),7.00-6.89(m,2H),4.41(br t,J=12.8Hz,1H),4.22-4.06(m,1H),3.97(dd,J=3.3,8.5Hz,1H),3.86-3.75(m,1H),3.72(s,3H),3.12(d,J=2.3Hz,6H),2.91-2.69(m,1H),2.65-2.44(m,5H),2.01-1.93(m,1H),1.90-1.80(m,2H),1.75-1.62(m,2H).LCMS m/z=534.2[M+1]
+。SFC(柱子:Chiralcel AD-3,3μm,0.46cm id×15cm L;流动相:A(CO
2)和B(乙醇,含0.05%二乙胺);梯度:B%=50%;流速:2.2mL/分 钟;柱温:35℃;波长:220nm;压力:1500psi),保留时间=2.925分钟,手性异构体过量100.00%
WX-027B:
1H NMR(400MHz,CDCl
3)δ=11.77(br s,1H),8.55(s,1H),8.13(s,1H),7.53(s,1H),7.20(br d,J=8.0Hz,1H),7.07-6.97(m,2H),4.47(br t,J=12.2Hz,1H),4.26-4.17(m,1H),4.03(br d,J=5.0Hz,1H),3.86(br d,J=12.0Hz,1H),3.78(s,3H),3.18(d,J=1.8Hz,6H),2.87(br s,1H),2.62(m,5H),2.09-1.97(m,1H),1.96-1.85(m,2H),1.79-1.71(m,2H).LCMS m/z=534.2[M+1]
+。SFC(柱子:Chiralcel AD-3,3μm,0.46cm id×15cm L;流动相:A(CO
2)和B(乙醇,含0.05%二乙胺);梯度:B%=50%;流速:2.2mL/分钟;柱温:35℃;波长:220nm;压力:1500psi),保留时间=3.474分钟,手性异构体过量99.66%。
实施例28
步骤1:化合物WX-028的合成
在化合物1-8(20mg,39.26μmol,1eq),M-1(15.96mg,78.52μmol,2eq)的1,4-二氧六环(50mL)溶液中加入2-(二叔丁基膦)联苯(1.17g,3.91μmol,0.4eq),叔丁醇钠的四氢呋喃溶液(2M,117.79μmol,3eq),氮气置换后加入三(二亚苄基丙酮)二钯(7.19mg,7.85μmol,0.2eq),氮气保护下100℃搅拌12小时。反应完毕,加入50mL乙酸乙酯和20mL水,分离有机相,用饱和食盐水洗一次,无水硫酸钠干燥,浓缩。硅胶柱层析纯化得到化合物WX-028。
1H NMR(400MHz,CDCl
3)δ=11.88(br s,1H),8.40(s,1H),8.09(s,1H),7.59(s,1H),7.12(br d,J=8.3Hz,1H),6.99(s,1H),6.93(br d,J=8.3Hz,1H),4.45-4.33(m,1H),4.24(br d,J=11.3Hz,1H),3.85-3.77(m,1H),3.71(s,3H),3.61(br s,4H),3.21(br d,J=3.8Hz,2H),3.14-3.05(m,2H),2.98(br s,1H),2.76(br s,1H),2.56(s,3H),2.16(br s,1H),2.02-1.97(m,5H),2.05(br d,J=17.1Hz,1H),1.92-1.86(m,1H),1.63-1.47(m,4H),0.86-0.79(m,3H)。LCMS m/z=632.0[M+1]
+。
实施例29
步骤1:化合物WX-029的合成
在化合物1-8(110mg,215.94μmol,1eq),N-1(56.76mg,323.91μmol,1.5eq)的1,4-二氧六环(2.5mL)和二氯甲烷(1mL)溶液中加入2-(二叔丁基膦)联苯(19.33mg,64.78μmol,0.3eq),叔丁醇钠的四氢呋喃溶液(2M,647.8μmol,323.91μl,3eq),氮气置换后加入三(二亚苄基丙酮)二钯(29.66mg,32.39μmol,0.15eq),氮气保护下80℃搅拌14小时。冷却至室温,反应液过滤,浓缩。粗品经硅胶柱层析分离纯化,得到WX-029。
1H NMR(400MHz,CDCl
3)δ=12.41-11.62(m,1H),8.48(s,1H),8.17(s,1H),7.67(s,1H),7.20(d,J=8.5Hz,1H),7.05(d,J=1.8Hz,1H),6.99(dd,J=1.8,8.5Hz,1H),4.55(s,2H),4.49(s,2H),4.51-4.44(m,1H),4.32(dd,J=3.0,13.6Hz,1H),3.94-3.85(m,1H),3.79(s,3H),3.66(dd,J=9.8,13.6Hz,1H),3.40-3.27(m,2H),3.12(ddd,J=3.9,9.8,13.9Hz,2H),2.93-2.78(m,1H),2.64(s,3H),2.53-2.37(m,4H),2.33-2.20(m,1H),2.18-2.07(m,1H),1.95(ddd,J=4.5,9.7,14.2Hz,1H),1.52-1.46(m,1H),0.92(d,J=6.5Hz,3H)。LCMS m/z:604.2[M+1]
+。
实施例30
步骤1:化合物WX-030的合成
将WX-014(20mg,35.54μmol,1eq)溶于甲醇(2mL),加入乙酸(0.065mL),氰基硼氢化钠(6.70mg,106.63μmol,3eq),3-氧杂环丁酮(5.12mg,71.09μmol,54.02μL,3eq),25℃搅拌2小时。反应液经制备HPLC分离,色谱柱:Welch Xtimate C18 100*40mm*3μm;流动相:[水(三氟乙酸)-乙腈];乙腈%:7%-37%,8分钟纯化。分离物加入10mL饱和碳酸氢钠溶液,用30mL二氯甲烷萃取,有机相用饱和氯化钠溶液洗一次,无水硫酸钠干燥,浓缩得到化合物WX-030。
1H NMR(400MHz,CDCl
3)δ=11.92(br s,1H),8.85(br s, 1H),8.55(s,1H),7.90(br s,1H),7.31(br s,1H),7.20-7.01(m,2H),4.73(br t,J=6.1Hz,2H),4.68-4.57(m,2H),4.45(br d,J=4.0Hz,1H),4.30(br d,J=13.3Hz,1H),3.97(br s,1H),3.81(s,4H),3.76-3.68(m,1H),3.51-3.29(m,4H),3.06-2.66(m,8H),2.28(br s,1H),2.16-1.94(m,2H),1.56(br s,1H),0.94(br d,J=6.0Hz,3H)。LCMS m/z:619.1[M+1]
+。
实施例31
步骤1:化合物31-1的合成
在化合物1-8(0.4g,785.24μmol,1eq),O-1(323.18mg,1.18mmol,1.5eq)的1,4-二氧六环(20mL)和二氯甲烷(5mL)溶液中加入2-(二叔丁基膦)联苯(70.29mg,235.57μmol,0.3eq),叔丁醇钠的四氢呋喃溶液(2M,3.93mmol,1.96mL,5eq),氮气置换后加入三(二亚苄基丙酮)二钯(107.86mg,117.79μmol,0.15eq),氮气保护下80℃搅拌14小时。冷却至室温,反应液过滤,浓缩。粗品经硅胶柱层析分离纯化,得到31-1。LCMS m/z:703.3[M+1]
+。
步骤2:化合物31-2的合成
将化合物31-1(0.35g,497.96μmol,1eq)溶于二氯甲烷(4mL)中,加入三氟乙酸(4mL),25℃搅拌2小时。浓缩反应液,得到化合物31-2的三氟乙酸盐。LCMS m/z=603.2[M+1]
+。
步骤3:化合物WX-031的合成
将化合物31-2的三氟乙酸盐(0.1g)溶于甲醇(3mL)和乙酸(0.1mL)混合溶液中,加入甲醛水溶液(26.9mg),25℃搅拌0.5小时,随后加入氰基硼氢化钠(26.06mg,414.77μmol,2.5eq),25℃搅拌12小时。反应液经硅胶柱层析纯化,得到化合物WX-031。
1H NMR(400MHz,CD
3OD)δ=8.86(s,1H),8.25(s,1H),7.99(s,1H),7.39(d,J=8.5Hz,1H),7.18(d,J=1.8Hz,1H),7.06(dd,J=1.8,8.5Hz,1H),4.53(dt,J=4.1,9.1Hz,1H),4.33(br d,J=11.3Hz,2H),4.28-4.18(m,1H),4.16-4.10(m,1H),4.08-3.94(m,2H),3.88-3.78(m,4H),3.53-3.37 (m,4H),3.00(s,3H),2.81(s,4H),2.52-2.27(m,5H),2.14-1.97(m,2H),1.67-1.51(m,1H),0.91(d,J=6.5Hz,3H)。LCMS m/z=617.3[M+1]
+。
生物测试
实验例1:化合物对EGFR(L858R/T790M/C797S),EGFR(del19-E746-A750/T790M/C797S),
EGFR(WT)激酶的抑制活性
化合物对EGFR(L858R/T790M/C797S),EGFR(del19-E746-A750/T790M/C797S),EGFR(WT)的激酶抑制活性测试在Reaction Biology Corp.公司完成。在反应缓冲液(20mM羟乙基哌嗪乙硫磺酸(Hepes)(pH7.5),10mM氯化镁(MgCl
2),1mM乙二醇双氨乙基醚四乙酸(EGTA),0.02%聚氧乙烯十二烷醚(Brij35),0.02mg/ml BSA,0.1mM钒酸钠(Na
3VO
4),2mM二硫苏糖醇(DTT),1%DMSO)中依次加入一定浓度的底物、辅酶因子、激酶和测试化合物(10个剂量,3倍连续稀释液,2%DMSO最终浓度)并混匀,将混合物在室温下孵育20分钟,向反应混合液中加入一定浓度的
33P-ATP开始反应,随后室温孵育120分钟。最后通过过滤-结合的方法来检测反应物的放射性。最终的激酶活性以测试样品中剩余的激酶活性占DMSO对照组的激酶活性的比例来表示。通过GraphPad软件拟合量效关系曲线并计算IC
50。结果如表1和表2所示:
表1.激酶半数抑制浓度IC
50(nM)
化合物 | ATP(μM) | EGFR(L858R/T790M/C797S) | |
1 | WX-001(三氟乙酸盐) | 10 | 0.159 |
2 | WX-002(甲酸盐) | 10 | 0.468 |
3 | WX-001(三氟乙酸盐) | 100 | 1.17 |
4 | WX-004(三氟乙酸盐) | 100 | 1.75 |
5 | WX-005(三氟乙酸盐) | 100 | 1.63 |
6 | WX-006(三氟乙酸盐) | 100 | 0.831 |
7 | WX-019 | 100 | 3.55 |
8 | WX-027A | 100 | 1.82 |
表2.激酶半数抑制浓度IC
50(nM)
结果表明:本发明化合物对携带EGFR(L858R/T790M/C797S)、EGFR(del19-E746-A750/T790M/C797S)三突变的激酶展现了较高的抑制活性,并且对EGFR(WT)激酶抑制活性较低,表现出良好的选择性。
实验例2:化合物对Ba/F3-EGFR相关突变细胞增殖的抑制活性
三磷酸腺苷(Adenosine Tri-Phosphate,ATP)是自然界中各种生命活动中共用的能量载体,是能量储存和转移的最小单位。CellTiter-Glo
TM活细胞检测试剂盒采用萤光素酶作检测物,发光过程中萤光素酶需要ATP的参与。向细胞培养基中加入CellTiter-Glo
TM试剂,测量发光值,光信号和体系中ATP量成正比,而ATP又和活细胞数正相关。因此通过使用CellTiter-Glo试剂盒检测ATP含量,可以检测出细胞的增殖情况。本测试中,细胞系为Ba/F3-FL-EGFR(L858R/T790M/C797S),Ba/F3-FL-EGFR(WT),Ba/F3-FL-EGFR(L858R),Ba/F3-FL-EGFR(del19-S752-I759),Ba/F3-FL-EGFR(del19-E746-A750/T790M/C797S),Ba/F3-FL-EGFR(L858R/T790M),Ba/F3-FL-EGFR(del19-E746-A750/T790M),Ba/F3-TEL-EGFR(L858R/C797S),Ba/F3-FL-EGFR(del19-E746-A750/C797S)稳转细胞株。
IC
50测定过程:
1)细胞培养
将细胞系在培养条件37℃,5%CO
2的培养箱中进行培养。定期传代,取处于对数生长期的细胞用于铺板。
2)化合物存储板制备
a)用DMSO将待测化合物配置成10mM溶液,再用DMSO将待测化合物稀释至0.3或1mM。
b)制备1000×化合物存储板(管):用DMSO从最高浓度3倍梯度稀释至最低浓度,共9个浓度。
c)20×化合物工作液的配制:在平底的96孔透明药板中加入49μL细胞培养液,从1000×化合物存储板中吸取1μL化合物加入96孔透明药板的细胞培养液中。在溶媒对照中加入1μL DMSO。加入化合物或DMSO后用排枪吹打混匀。
3)细胞铺板与给药
a)用台盼兰进行细胞染色并计数活细胞,要求细胞活率90%以上。
b)在化合物检测细胞板中每孔加入95μL细胞悬液(2000细胞/孔),在Min对照孔中加入不含细胞(含0.1%DMSO)的培养液。
c)化合物检测细胞板加药:取5μL的20×化合物工作液加入到细胞培养板中。在Max对照中加入5μL DMSO-细胞培养液混合液。DMSO终浓度为0.1%。
d)将培养板在37℃,5%CO 2培养箱中培养72小时。
4)CellTiter-Glo发光法细胞活性检测
以下步骤按照Promega CellTiter-Glo发光法细胞活性检测试剂盒(Promega-G7573)的说明书来进行。
a)将CellTiter-Glo缓冲液融化并放置至室温。
b)将CellTiter-Glo底物放置至室温。
c)在一瓶CellTiter-Glo底物中加入CellTiter-Glo缓冲液以溶解底物,从而配制CellTiter-Glo工作液。
d)缓慢涡旋震荡使充分溶解。
e)取出细胞培养板放置10分钟使其平衡至室温。
f)在每孔中加入50μL(等于每孔中细胞培养液一半体积)的CellTiter-Glo工作液。
g)将培养板在轨道摇床上振摇2分钟以诱导细胞裂解。
h)培养板在室温放置10分钟以稳定发光信号。
5)数据处理
细胞增殖抑制率(Inhibition Rate)数据采用下列公式来处理:
Inhibition Rate(Inh%)=100-(RLUDrug-RLUMin)/(RLUMax-RLUMin)*100%。
计算不同浓度化合物对应的抑制率,然后用GraphPad Prism软件作抑制率曲线图并计算IC
50值,数据见表3、表4。
表3.细胞半数抑制浓度IC
50(nM)
化合物 | Ba/F3-FL-EGFR(L858R/T790M/C797S) | |
1 | WX-005(三氟乙酸盐) | 7.2 |
2 | WX-006(三氟乙酸盐) | 2.3 |
3 | WX-010(三氟乙酸盐) | 2.8 |
4 | WX-011 | 4.4 |
5 | WX-012(盐酸盐) | 7.3 |
6 | WX-013 | 4.3 |
7 | WX-014 | 14.3 |
8 | WX-015 | 10.6 |
9 | WX-016 | 13.4 |
10 | WX-017 | 6.4 |
11 | WX-018 | 6.5 |
12 | WX-019 | 5.7 |
13 | WX-020 | 4.6 |
14 | WX-021 | 8.6 |
15 | WX-022 | 12.7 |
16 | WX-023 | 2.7 |
17 | WX-024 | 1.4 |
18 | WX-025 | 5.7 |
19 | WX-026 | 11.6 |
20 | WX-027A | 8.6 |
21 | WX-028 | 3.3 |
22 | WX-029 | 5.5 |
23 | WX-030 | 13 |
24 | WX-031 | 2.1 |
表4.细胞半数抑制浓度IC
50(nM)
“/”:未测试。
结果表明:本发明化合物对携带EGFR(L858R/T790M/C797S)、EGFR(del19-E746-A750/T790M/C797S)三突变的细胞株表现出极强的细胞增殖抑制活性,对携带EGFR(L858R/T790M)、EGFR(del19-E746-A750/T790M)、EGFR(del19-E746-A750/C797S)和EGFR(L858R/C797S)二突变的细胞株也都展现了较高的细胞增殖抑制活性;此外,对EGFR(WT)细胞株抑制较弱,具有较好的选择性。
实验例3:化合物对Ba/F3-FL-EGFR(L858R/T790M/C797S)和Ba/F3-FL-EGFR(del19-E746-A750/T790M/C797S)细胞磷酸化抑制实验
EGFR的自磷酸化可以激活它位于细胞内的激酶通路。本实验通过测定量化EGFR的磷酸化,以检测化合物对Ba/F3-FL-EGFR(L858R/T790M/C797S)和Ba/F3-FL-EGFR(del19-E746-A750/T790M/C797S)磷酸化抑制作用。
IC
50测定过程:
1)细胞铺板
取对数生长期细胞用细胞计数仪进行计数,细胞活率要求>90%以上,将细胞接种到无菌的6孔板,每孔2×10
6个细胞,补足1640完全培养基至1998μL,6孔板放37℃,5%CO
2的恒温培养箱静置培养。
2)化合物给药
将6孔板取出显微镜观察细胞正常,在超净工作台中,各取2μL的配置好的梯度稀释的1000×母液,分别加入到接种有细胞的6孔板中,轻轻晃动6孔板,让化合物均匀分布。
3)孵育
将6孔板在37℃,5%CO
2的恒温培养箱静置培养4h;
4)样品收集
细胞静置培养4h后,将培养基收集后8000rpm离心3min,收集细胞于1.5mL EP管中,弃去上清后,抽提总蛋白;
5)细胞裂解
将各组细胞收集至1.5ml EP管中,再加入一定体积(根据细胞量确定,每2×10
6细胞加入约66μL)的Lysis Buffer(RIPA:蛋白酶/磷酸酶抑制剂=100:1)。加入Lysis Buffer后将EP管迅速置于冰上,使用涡旋仪涡旋EP管,使细胞充分裂解。注意涡旋时间不要过久,迅速将样品管置于冰上裂解,每间隔10min震荡一次,共三次。裂解时间结束后将EP管放入预冷至4℃离心机中12000rpm离心10min。离心后,将上清转移至新的1.5ml EP管中,并做好标记。
6)BCA蛋白浓度测定
使用BCA蛋白浓度测定试剂盒,根据试剂盒说明书,对样品裂解上清进行蛋白定量。完成蛋白浓度测定后,以浓度最低的裂解上清为基准,其余的裂解上清均按照BCA标准曲线计算后使用Lysis Buffer稀释至该浓度。向完成稀释的裂解上清中加入相应体积的5×loading Buffer,95℃温金属浴加热10min,随后放置于冰上冷却,-20度冰箱保存样品。
7)制胶
洗净制胶用的玻璃板,将两块玻璃板底部对齐后放入支架,夹子固定。按照10%分离胶配方先配好分离胶,混匀后加入玻璃板中,加入约3/4玻璃板停止,用75%乙醇压胶。90min后,分离胶凝固,倒出75%乙醇,用滤纸吸干玻璃板上残留的乙醇溶液,配置5%浓缩胶,混匀后加入到玻璃板中,再插上加样梳,待60min后,即制成胶。
8)蛋白上样和电泳
将胶板放在电泳槽中固定,用1×电泳液内槽加满,外槽超过金属丝。拔下加样梳,Ba/F3-FL-EGFR(L858R/T790M/C797S)和Ba/F3-FL-EGFR(del19-E746-A750/T790M/C797S)细胞的蛋白样品上样25μg,然后各胶上样蛋白Protein Ladder。接通电源,用恒压70V电泳30min后,恒压86V继续电泳1h 20min,直至溴酚蓝指示带到达底部,停止电泳。
9)蛋白电转
将PVDF膜在甲醇中浸泡30s醒膜,后与4张滤纸,2块海绵一起放入转膜盒中。转膜盒中倒入提前配置好的1×电转液。将凝胶取出,切割成需要的大小,依次按照海绵,滤纸,凝胶,PVDF膜,滤纸,海绵的顺序在转膜夹中放好,去除气泡,将膜位于阳极面,凝胶位于阴极面(黑胶白膜),插入电泳槽中,倒入转膜缓冲液,放入冰袋,将电泳槽周围也放置冰袋降温。恒压100V电泳转移90min。
10)封闭和孵育一抗
电转完成后,将PVDF膜放入5%脱脂牛奶的封闭液中,置于摇床上缓慢摇动,室温封闭1h。将封闭好的PVDF膜,在TBST中缓慢洗涤3次,每次10min。洗涤结束后,将PVDF膜放入一抗的抗体盒中, 一抗按照1:1000的比例,用一抗稀释液进行稀释,抗体盒放置于4℃温和摇床孵育(10-16h)。
11)孵育二抗及显色
将过夜孵育的PVDF膜从抗体盒中取出,回收一抗。将PVDF膜在TBST中缓慢洗涤3次,每次10min。将洗涤之后的PVDF膜放入相应种属的二抗(1:3000)稀释液(含5%脱脂牛奶)中,室温条件下温和摇床孵育1h。二抗孵育结束后,取出PVDF膜,在TBST中缓慢洗涤3次,每次10min。将ECL试剂盒中等体积的A液和B液混合,均匀加在膜的表面(蛋白面),放入Tanon 5200发光成像仪(提前5min开启预冷)中曝光显影,拍照保存图片。
12)Western Blot条带灰度值分析
使用Image J2X软件对Western Blot结果图中的p-EGFR和GAPDH的条带进行灰度值分析,灰度值的结果以曲线图展示,横坐标为化合物浓度,纵坐标的值为药物浓度抑制率的值。纵坐标的数值用以下公式计算:Inhibition(%)=100%-Gray
compound/Gray
dmso*100%,使用GraphPad Prism软件拟合,拟合方式为log(inhibitor)vs.response--Variable slope(four parameters)。实验结果如表5所示:
表5.细胞半数抑制浓度IC
50(nM)
结果表明:本发明化合物对携带EGFR(L858R/T790M/C797S)、EGFR(del19-E746-A750/T790M/C797S)三突变的细胞株的EGFR磷酸化有着良好的抑制作用。
实验例4:细胞色素P450同工酶抑制性研究测试:
本研究的目的是测定受试化合物对人肝微粒体细胞色素P450同工酶(CYP1A2、CYP2C9、CYP2C19、CYP2D6和CYP3A4)活性的抑制作用。
IC
50测定过程:
首先将受试化合物(10.0mM)进行梯度稀释,制备工作液(100×最终浓度),且工作液浓度分别为:5.00、1.50、0.500、0.150、0.0500、0.0150和0.00500mM,同时准备P450同工酶(CYP1A2、CYP2C9、CYP2C19、CYP2D6和CYP3A4)各阳性抑制剂及其特异性底物混合物的工作液;将保存在低于-60℃冰箱的人肝微粒体置于冰上解冻,待人肝微粒体全部溶解,用Potassium phosphate buffer(PB)进行稀释,制备一定浓度工作液(0.253mg/ml)。
先将20.0μL底物混合液加至反应板中(Blank孔中加入20.0μL PB),然后将158μL人肝微粒体工作液加入反应板中,将反应板置于冰上,待用;此时将2.00μL各个浓度的受试化合物(N=1)及特异性抑制剂(N=2)加入对应孔中,无抑制剂(受试化合物或阳性抑制剂)组加入对应的有机溶剂,作为对照组样品(受试化合物对照样品为1:1DMSO:MeOH,阳性对照样品均为1:9DMSO:MeOH);在37℃水浴预孵育10min后,将20.0μL辅酶因子(NADPH)溶液加入反应板中,置于37℃水浴孵育反应10min;加入 400μL预冷的乙腈溶液(含200ng/mL Tolbutamide和Labetalol的内标)终止反应;将反应板置于摇床,振荡10min混匀;然后在4℃、4000rpm条件下离心20min;取200μL上清加至100μL水中,进行样品稀释;最后封板,振荡10min混匀,进行LC/MS/MS检测。
用各探针底物代谢物的生成速率体现各CYP同工酶的活性。设定不加供试品或阳性抑制剂的溶剂对照孵育体系中各同工酶的活性为100%,将含不同浓度供试品或阳性抑制剂时探针底物代谢产物的生成速率与溶剂对照样品代谢产物的生成速率相比再乘以100%作为各同工酶的剩余活性百分比。以剩余活性百分比为纵坐标,抑制剂浓度为横坐标,使用XL fit软件中三参数或四参数进行非线性回归分析,计算得到供试品及各阳性抑制剂的IC
50值。当XL fit软件拟合得到的IC
50大于最高给药浓度(50μM)或无法拟合得到IC
50时,则IC
50值标记为“>50μM”。实验结果如表6所示。
表6.细胞色素P450同工酶抑制浓度(μM)
化合物 | WX-027A | WX-019 |
CYP1A2 | >50 | >50 |
CYP2C9 | 14 | 31 |
CYP2C19 | 9.8 | 3.4 |
CYP2D6 | >50 | >50 |
CYP3A4 | 20 | >50 |
实验结论:本发明化合物对P450同工酶抑制作用弱。
实验例5:化合物在小鼠体内的药代动力学测试
实验目的:以7-9周雄性ICR小鼠为受试动物,应用LC/MS/MS法测定单次静脉注射(IV)及灌胃(PO)给予化合物后,不同时刻血浆中化合物的药物浓度,研究本发明的化合物在小鼠体内的药代动力学行为,评价其药动学特征。
药物配制:化合物均以相应溶媒配成溶液用于IV(静注)和PO(灌胃)组给药。每个化合物的给药剂量为:IV剂量为3mg/kg;PO剂量为10mg/kg,溶媒为10%DMSO+10%solutol+80%(10%HP-β-CD)。药代动力学参数结果见表7:
表7.小鼠体内药代动力学测试结果
结果表明:本发明化合物的小鼠给药后展现了优异的药代动力学特性。
实验例6:化合物的小鼠体内药效试验
1.实验方法
1.1细胞培养及接种
Ba/F3-FL-EGFR(del19-T790M-C797S)细胞株采用RPMI1640培养基(Viva Cell)+10%胎牛血清(Viva Cell)+1%双抗(Penicillin Streptomycin solution,Gibco,USA),37℃、5%CO
2培养,一周2-3次传代处理。当细胞饱和度为80%~90%时,收取细胞,计数,接种。当处于对数生长期的细胞达到实验所需数量时,收集细胞,1000rpm离心5min去上清,用培养基重悬细胞,使用细胞计数仪计数,根据计数结果将原溶液稀释成活细胞浓度1*10
7个/mL的细胞悬液,细胞存活率为98.77%,P17代。将稀释后的细胞悬液和基质胶按照1:1比例稀释。混匀后放置于冰上,用1mL无菌胰岛素注射器吸取混悬液,每只小鼠右腋皮下接种细胞悬液0.2mL。即每只小鼠接种Ba/F3-FL-EGFR(del19-T790M-C797S)细胞1*10
6个。
1.2分组方法
接种完成后,逐日观察肿瘤生长状态,肿瘤平均体积达到约100~150mm
3时将小鼠按肿瘤体积随机分组。
1.3给药类型
按照小鼠体重给药:10μL/g,如果体重下降超过20%,给药方案做出相应调整。
1.4观察
本实验方案的拟定及任何修改均通过了测试机构实验动物福利伦理委员会的评估核准。每天检测动物的健康状况及死亡情况,例常检查包括动物的肿瘤生长情况,活动能力,饮食,体重,眼睛,毛发和其他异常行为,每周三次(周一、周三和周五)测量肿瘤体积及体重。肿瘤体积通过游标卡尺测量,公式为TV=0.5a×b
2,其中a是肿瘤的长径,b是肿瘤的短径。
1.5数据统计分析
统计分析包括每个组的每个时间点的肿瘤体积的平均值(Mean)和标准误(SEM)。基于给药后第10天数据进行统计学分析评估组间差异。用单因素方差分析(one way ANOVA)事后检验Tamhane检验方法比较治疗组肿瘤体积与对照组肿瘤体积相比有无显著性差异。p<0.05为具有显著性差异。药效评价指标包括肿瘤体积和肿瘤重量,考察肿瘤生长是否被延缓、抑制或治愈。化合物的抑瘤疗效采用相对肿瘤增殖率T/C(%)或肿瘤生长抑制率TGI(%)作为评价指标。肿瘤生长抑制由T/C和TGI(TGI(%)=[1-(T
10-T
0)/(V
10-V
0)]×100%)计算。原则上,评价标准为:T/C(%)>40%或TGI(%)<40%为无效;T/C(%)≤40%,且p<0.05或TGI(%)≥40%且p<0.05为有效。
2.实验结果
2.1体重
实验动物的体重作为间接测定药物毒性的参考指标,结果如表8所示。
表8.各组动物在给药后的平均体重
2.2肿瘤体积
肿瘤体积变化结果如表9所示。
表9.各组动物在给药后的平均肿瘤体积
2.3抗肿瘤药效评价指标
抗肿瘤药效评价指标结果如表10所示。
表10.测试化合物对Ba/F3-FL-EGFR-Del19-T790M-C797S细胞同种移植瘤模型的抑瘤药效评价
3.实验结论
试验结束时,化合物WX-027A和WX-019分别在10mg/kg和25mg/kg给药剂量下连续给药10天后,小鼠体重持续增加,相比对照组均未见显著性差异,动物耐受性良好。
同时,WX-027A的10mg/kg和25mg/kg剂量组肿瘤抑制率分别为94%、102%,且P值<0.01;WX-019的10mg/kg和25mg/kg剂量组肿瘤抑制率分别为101%、103%,且P值<0.01。本发明化合物显著抑制移植瘤生长。
Claims (20)
- 式(V)所示化合物或其药学上可接受的盐,其中,T 1和T 2分别独立地选自N和CH;T 3选自N和CR e;T 4选自N和CR f;L 1选自-O-和-NH-;L 2选自-CH 2-和-C(=O)-;L 3选自-O-、-NH-和-CH 2-;L 4选自-C 1-3烷基-、-P(=O)(R a)-、-S(=O) 2-、-S(=O)(=NR c)-和-N=S(=O)(R b)-;R 1不存在,R 2选自CH 3和环丙基;或者,R 1和R 2与相连的原子形成5元杂芳基;R 3选自C 1-3烷基、C 3-5环烷基和-哌嗪基-甲基;R 4选自C 1-3烷基,所述C 1-3烷基任选被1、2或3个R d取代;R 5选自CH 3,所述CH 3任选被1、2或3个卤素取代;R 6选自H和CH 3,所述CH 3任选被1、2或3个卤素取代;R 7选自H和CH 3,所述CH 3任选被1、2或3个卤素取代;或者R 5和R 6与相连的原子形成环丙基;R a选自C 1-3烷基和C 3-5环烷基;R b选自C 1-3烷基;R c选自H和C 1-3烷基;或者R a和R 3与相连的原子形成5-6元杂环烷基,所述5-6元杂环烷基任选被1或2个CH 3取代;或者R b和R 3与相连的原子形成5-11元杂环烷基,所述5-11元杂环烷基任选被1或2个R g取代;或者R c和R 3与相连的原子形成5-6元杂环烷基,所述5-6元杂环烷基任选被1或2个CH 3取代;R d选自卤素和C 1-3烷氨基;R e选自H、F、Cl、Br、I和CN;R f选自H、F、Cl、Br、I和CN;R g选自CH 3和4-6元杂环烷基,所述4-6元杂环烷基任选被1或2个CH 3取代;条件是,当L 1选自-O-,L 2选自-CH 2-,L 3选自-CH 2-,L 4选自-CH 2-,R 3选自-哌嗪基-甲基时,T 1和T 2至少一个选自N,或者R 1和R 2与相连的原子形成五元杂芳基。
- 根据权利要求1所述化合物或其药学上可接受的盐,其中,R g选自CH 3、氧杂环丁基、氮杂环丁基、四氢吡喃基、吗啉基、哌啶基、哌嗪基和N-甲基哌啶基。
- 根据权利要求1所述化合物或其药学上可接受的盐,其中,R a选自CH 3、CH 2CH 3、CH(CH 3) 2和环丙基。
- 根据权利要求1所述化合物或其药学上可接受的盐,其中,R b和R 3与相连的原子形成5-6元单环杂环烷基和7-11元双环杂环烷基,所述5-6元单环杂环烷基和7-11元双环杂环烷基任选被1或2个R g取代。
- 根据权利要求1所述化合物或其药学上可接受的盐,其中,R b选自CH 3、CH 2CH 3和CH(CH 3) 2。
- 根据权利要求1所述化合物或其药学上可接受的盐,其中,R 4选自CH 3、CH 2CH 2N(CH 3) 2和CH 2CH 2NHCH(CH 3) 2。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202280051571.0A CN117794938A (zh) | 2021-07-23 | 2022-07-15 | 大环酰胺类化合物及其应用 |
Applications Claiming Priority (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110839425.1 | 2021-07-23 | ||
CN202110839425 | 2021-07-23 | ||
CN202110960699 | 2021-08-20 | ||
CN202110960699.6 | 2021-08-20 | ||
CN202111127366.1 | 2021-09-18 | ||
CN202111127366 | 2021-09-18 | ||
CN202111187955 | 2021-10-12 | ||
CN202111187955.9 | 2021-10-12 | ||
CN202210093818 | 2022-01-26 | ||
CN202210093818.7 | 2022-01-26 | ||
CN202210731479 | 2022-06-24 | ||
CN202210731479.0 | 2022-06-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023001069A1 true WO2023001069A1 (zh) | 2023-01-26 |
Family
ID=84978905
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/105959 WO2023001069A1 (zh) | 2021-07-23 | 2022-07-15 | 大环酰胺类化合物及其应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN117794938A (zh) |
WO (1) | WO2023001069A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024046221A1 (en) * | 2022-09-02 | 2024-03-07 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. | Egfr inhibitors and uses thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020260252A1 (en) * | 2019-06-24 | 2020-12-30 | Boehringer Ingelheim International Gmbh | New macrocyclic compounds and derivatives as egfr inhibitors |
WO2021121261A1 (zh) * | 2019-12-16 | 2021-06-24 | 北京泰德制药股份有限公司 | 抑制并诱导降解egfr激酶的化合物 |
CN113527335A (zh) * | 2020-04-15 | 2021-10-22 | 南京圣和药业股份有限公司 | 作为egfr抑制剂的大环类化合物及其应用 |
CN114163454A (zh) * | 2020-09-11 | 2022-03-11 | 上海翰森生物医药科技有限公司 | 含吡啶多环类衍生物抑制剂、其制备方法和应用 |
CN114656482A (zh) * | 2020-12-23 | 2022-06-24 | 南京圣和药业股份有限公司 | 作为egfr抑制剂的大环杂环类化合物及其应用 |
-
2022
- 2022-07-15 CN CN202280051571.0A patent/CN117794938A/zh active Pending
- 2022-07-15 WO PCT/CN2022/105959 patent/WO2023001069A1/zh active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020260252A1 (en) * | 2019-06-24 | 2020-12-30 | Boehringer Ingelheim International Gmbh | New macrocyclic compounds and derivatives as egfr inhibitors |
WO2021121261A1 (zh) * | 2019-12-16 | 2021-06-24 | 北京泰德制药股份有限公司 | 抑制并诱导降解egfr激酶的化合物 |
CN113527335A (zh) * | 2020-04-15 | 2021-10-22 | 南京圣和药业股份有限公司 | 作为egfr抑制剂的大环类化合物及其应用 |
CN114163454A (zh) * | 2020-09-11 | 2022-03-11 | 上海翰森生物医药科技有限公司 | 含吡啶多环类衍生物抑制剂、其制备方法和应用 |
CN114656482A (zh) * | 2020-12-23 | 2022-06-24 | 南京圣和药业股份有限公司 | 作为egfr抑制剂的大环杂环类化合物及其应用 |
Non-Patent Citations (2)
Title |
---|
ENGELHARDT, HARALD ET AL.: "Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors", JOURNAL OF MEDICINAL CHEMISTRY, vol. 62, 5 November 2019 (2019-11-05), XP055821569, DOI: 10.1021/acs.jmedchem.9b01169 * |
J. MED. CHEM., vol. 62, no. 22, 2019, pages 10272 - 10293 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024046221A1 (en) * | 2022-09-02 | 2024-03-07 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. | Egfr inhibitors and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
CN117794938A (zh) | 2024-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111247151B (zh) | 2,3-二氢-1h-吡咯嗪-7-甲酰胺类衍生物及其应用 | |
CN115298174A (zh) | 嘧啶并杂环类化合物及其应用 | |
WO2021259331A1 (zh) | 八元含n杂环类化合物 | |
CN115702156A (zh) | 吡啶酰胺类化合物 | |
CN112654619A (zh) | 三环并呋喃取代哌啶二酮类化合物 | |
WO2019157879A1 (zh) | 作为trk抑制剂的杂环化合物 | |
KR20220059517A (ko) | 소분자 pd-1/pd-l1 억제제로서의 화합물 및 이의 용도 | |
WO2020239076A1 (zh) | 作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用 | |
CN112689638A (zh) | 作为lsd1抑制剂的环丙胺类化合物及其应用 | |
WO2022218442A1 (zh) | 环修饰的脯氨酸短肽化合物及其应用 | |
WO2022063308A1 (zh) | 一类1,7-萘啶类化合物及其应用 | |
WO2022161443A1 (zh) | 嘧啶并吡喃类化合物 | |
WO2023138662A1 (zh) | 苯并嘧啶类化合物及其应用 | |
WO2022247757A1 (zh) | 氟取代的嘧啶并吡啶类化合物及其应用 | |
WO2023001069A1 (zh) | 大环酰胺类化合物及其应用 | |
WO2022199670A1 (zh) | 6-氨基甲酸酯取代的杂芳环衍生物 | |
KR102500569B1 (ko) | 선택적 btk 키나제 억제제로서의 피라졸로피리딘계 화합물 | |
CN115667258A (zh) | 氟代吡咯并吡啶类化合物及其应用 | |
CN114761407A (zh) | 作为高选择性ros1抑制剂的化合物及其应用 | |
WO2020063965A1 (zh) | 作为选择性Trk抑制剂的吡唑并嘧啶衍生物 | |
CN111315750B (zh) | 作为mTORC1/2双激酶抑制剂的吡啶并嘧啶类化合物 | |
WO2023001028A1 (zh) | 杂芳-3-哌啶二酮类化合物及其应用 | |
WO2022262782A1 (zh) | 戊二酰亚胺取代的异噁唑稠环化合物及其应用 | |
TWI814092B (zh) | 稠合的三并環衍生物及其在藥學上的應用 | |
WO2022199635A1 (zh) | 苄氨基喹唑啉类衍生物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22845234 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022845234 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022845234 Country of ref document: EP Effective date: 20240223 |